10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                   to

Commission File Number: 33-17387

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware	59-2262718
(State or other jurisdiction of incorporation or organization)	(I.R.S.  Employer Identification No.)

50 Health Sciences Drive Stony Brook, New York	11790
(Address of principal executive offices)	(Zip Code)

631-240-8800

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

  x  Yes    o  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

   x  Yes    o  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer”, “accelerated filer”, and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):

Large accelerated filer    o	Accelerated filer    o
Non-accelerated filer o	Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

o  Yes    x  No

As of August 8, 2013, the registrant had 744,219,263 shares of common stock outstanding.

Applied DNA Sciences, Inc.

Form 10-Q for the Quarter Ended June 30, 2013

Table of Contents

	Page
PART I - FINANCIAL INFORMATION
Item 1 - Financial Statements (unaudited)	1
Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3 - Quantitative and Qualitative Disclosures About Market Risk	27
Item 4 - Controls and Procedures	27
PART II - OTHER INFORMATION	28
Item 1 – Legal Proceedings	28
Item 6 – Exhibits	29

Part I 

Item 1 - Financial Statements

APPLIED DNA SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
	June 30,			September 30,
	2013			2012
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	1,831,791		$	724,782
Accounts receivable, net of allowance of $70,000 and $0, respectively		587,655			296,994
Prepaid expenses		141,563			80,037
Total current assets		2,561,009			1,101,813
Property, plant and equipment-net of accumulated depreciation of $337,593 and $251,958 respectively		664,106			210,845
Other assets:
Deposits		51,260			36,276
Intangible assets:
Intellectual property, net of accumulated amortization of $19,470 and $0, respectively		564,610			—
Total Assets	$	3,840,985		$	1,348,934
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	1,533,478		$	592,009
Total Liabilities		1,533,478			592,009
Commitments and Contingencies
Stockholders’ Equity
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- issued and outstanding as of June 30, 2013 and September 30, 2012		—			—
Series A Preferred stock, par value $0.001 per share; 5,500 shares designated; -0- issued and outstanding as of June 30, 2013 and September 30, 2012		—			—
Common stock, par value $0.001 per share; 1,350,000,000 shares authorized; 733,524,076 and 646,182,550 shares issued and outstanding as of June 30, 2013 and September 30, 2012, respectively		733,524			646,183
Additional paid in capital		184,549,123			169,117,881
Accumulated deficit		(182,975,140	)		(169,007,139	)
Total stockholders’ equity		2,307,507			756,925
Total Liabilities and Stockholders’ Equity	$	3,840,985		$	1,348,934
See the accompanying notes to the unaudited condensed consolidated financial statements

1

APPLIED DNA SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
	Three Months Ended June 30,						Nine Months Ended June 30,
	2013			2012			2013			2012
Revenues	$	644,842		$	528,574		$	1,307,117		$	1,563,880
Operating expenses:
Selling, general and administrative		3,240,815			1,752,501			8,516,390			5,729,575
Research and development		184,981			99,958			509,132			274,528
Depreciation and amortization		62,280			103,338			105,105			300,419
Total operating expenses		3,488,076			1,955,797			9,130,627			6,304,522
LOSS FROM OPERATIONS		(2,843,234	)		(1,427,223	)		(7,823,510	)		(4,740,642	)
Other income (expense):
Interest, net		333			(2,422	)		738			(642,790	)
Gain (loss) on change in fair value of warrant liability		707,289			—			(6,145,229	)		—
Net loss before provision for income taxes		(2,135,612	)		(1,429,645	)		(13,968,001	)		(5,383,432	)
Income taxes (benefit)		—			—			—			—
NET LOSS	$	(2,135,612	)	$	(1,429,645	)	$	(13,968,001	)	$	(5,383,432	)
Net loss per share-basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.02	)	$	(0.01	)
Weighted average shares outstanding-
Basic and diluted		721,142,161			594,931,878			683,709,950			556,036,906
See the accompanying notes to the unaudited condensed consolidated financial statements

2

APPLIED DNA SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(unaudited)
	Nine months ended June 30,
	2013			2012
Cash flows from operating activities:
Net loss	$	(13,968,001	)	$	(5,383,432	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		105,105			300,419
Fair value of vested options issued to officers, directors and employees		1,334,993			1,564,311
Change in fair value of warrant liability		6,145,229			—
Amortization of capitalized financing costs		—			85,975
Amortization of debt discount attributable to convertible debentures		—			541,120
Fair value change from employee option modification		408,605			—
Fair value of vested warrants issued for service		28,256			58,238
Common stock issued in settlement of interest		—			507,939
Bad debt expense		70,000			—
Change in operating assets and liabilities:
Accounts receivable		(360,661	)		(234,180	)
Prepaid expenses and deposits		(76,510	)		(44,247	)
Accounts payable and accrued liabilities		616,067			(389,151	)
Deferred revenue		—			25,000
Net cash used in operating activities		(5,696,917	)		(2,968,008	)
Cash flows from investing activities:
Purchase of assets under RedWeb asset purchase agreement		(584,080	)		—
Purchase of property and equipment		(213,494	)		(65,792	)
Net cash used in investing activities		(797,574	)		(65,792	)
Cash flows from financing activities:
Net proceeds from sale of common stock		2,000,000			1,542,600
Proceeds from sale of Series A preferred stock		5,500,000			—
Proceeds from exercise of warrants		150,000			—
Proceeds from exercise of options		1,500			—
Purchase and cancellation of previously issued warrants		(50,000	)		—
Net cash provided by financing activities		7,601,500			1,542,600
Net increase (decrease) in cash and cash equivalents		1,107,009			(1,491,200	)
Cash and cash equivalents at beginning of period		724,782			2,747,294
Cash and cash equivalents at end of period	$	1,831,791		$	1,256,094
Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest	$	—		$	—
Cash paid during period for taxes	$	—		$	—
Non-cash investing and financing activities:
Common stock issued in exchange for previously incurred debt	$	—		$	4,022,000
Property, plant and equipment acquired, included in accounts payable	$	325,402		$	—
See the accompanying notes to the unaudited condensed consolidated financial statements

3

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES

General

The accompanying unaudited condensed consolidated interim financial statements as of June 30, 2013 and for the three and nine months ended June 30, 2013 and 2012 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended June 30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2013. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended September 30, 2012 and footnotes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC.

The condensed consolidated balance sheet as of September 30, 2012 contained herein has been derived from the audited consolidated financial statements as of September 30, 2012, but do not include all disclosures required by GAAP.

Business and Basis of Presentation

On September 16, 2002, Applied DNA Sciences, Inc. (the “Company”) was incorporated under the laws of the State of Nevada. Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware.  The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe. To date, the Company has generated limited sales revenues from its services and products; it has incurred expenses and has sustained losses.  Consequently, its operations are subject to all the risks inherent in the establishment of an early stage operating company. For the period from inception through June 30, 2013, the Company has accumulated losses of $182,975,140.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Applied DNA Operations Management, Inc., APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited. Significant inter-company transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures.  Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  The most complex and subjective estimates include:  recoverability of long-lived assets, including the value assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies and allowance for doubtful accounts.  Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the condensed consolidated interim financial statements in the period they are deemed to be necessary.  Accordingly, actual results could differ from those estimates.

Revenue Recognition

Revenues are derived from research, development, qualification and production testing for certain commercial products. Revenue from fixed price testing contracts is generally recorded upon completion of the contracts, which are generally short-term, or upon completion of identifiable contractual tasks. At the time the Company enters into a contract that includes multiple tasks, the Company estimates the amount of actual labor and other costs that will be required to complete each task based on historical experience. Revenues are recognized which provide for a profit margin relative to the testing performed. Revenue relative to each task and from contracts which are time and materials based is recorded as effort is expended. Billings in excess of amounts earned are deferred. Any anticipated losses on contracts are charged to income when identified. To the extent management does not accurately forecast the level of effort required to complete a contract, or individual tasks within a contract, and the Company is unable to negotiate additional billings with a customer for cost over-runs, the Company may incur losses on individual contracts.

4

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

For revenue from product sales, the Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required. At June 30, 2013 and September 30, 2012, the Company did not record any deferred revenue for the respective periods.

Cash Equivalents

For the purpose of the accompanying unaudited condensed consolidated interim financial statements, all highly liquid investments with a maturity of three months or less are considered to be cash equivalents.

Accounts Receivable

The Company provides an allowance for doubtful accounts equal to the estimated uncollectible amounts. The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable. It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change. At June 30, 2013 and September 30, 2012, the Company had an allowance for doubtful accounts of $70,000 and $0, respectively.  The Company writes-off receivables that are deemed uncollectible.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes include, but are not limited to, accounting for intangibles, warrants, equity based compensation and depreciation and amortization.

The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized.  During the three and nine months ended June 30, 2013 and 2012, the Company incurred losses from operations.  Based upon these results, and trends in the Company’s performance projected through 2013, it is more likely than not that the Company will not realize any benefit from the deferred tax assets recorded by the Company in previous periods.  Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability.  In management’s opinion, adequate provisions for income taxes have been made for all years.  If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.  The Company has identified its federal tax return and its state tax return in New York as “major” tax jurisdictions. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s condensed consolidated interim financial statements.  The Company’s evaluation was performed for tax years 2009 through 2012.  The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position.  It is the Company’s policy to accrue interest and penalties on unrecognized tax benefits as components of income tax provision.

5

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Property Plant and Equipment

Property plant and equipment are stated at cost and are depreciated using the straight line method over their estimated useful lives.  The estimated useful lives for computer equipment, lab equipment and furniture is 3 to 5 years and leasehold improvements are amortized over the shorter of their useful life or the lease term.  Property plant and equipment consist of:

	June 30, 2013 (unaudited)			September 30, 2012
Computer equipment	$	38,640		$	33,464
Lab equipment		589,737			296,904
Furniture		151,039			132,435
Leasehold improvements		222,283			—
Total		1,001,699			462,803
Accumulated depreciation		(337,593	)		(251,958	)
Property and equipment, net	$	664,106		$	210,845

Impairment of Long-Lived Assets

The Company accounts for its long-lived assets in accordance with ASC 360, Property, Plant and Equipment (“ASC 360”) for purposes of determining and measuring impairment of its long-lived assets other than goodwill. ASC 360 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset.  ASC 360 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.

Comprehensive Income

The Company does not have any items of comprehensive income in any of the periods presented.

Segment Information

The Company follows the provisions of ASC 280, Segment Reporting (“ASC 280”). ASC 280 establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders.  ASC 280 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision- making group, in making decisions how to allocate resources and assess performance.  The information disclosed herein, materially represents all of the financial information related to the Company’s single principal operating segment.

Loss per Share

The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share.  Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants. For the three and nine months ended June 30, 2013 and 2012, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

Fully diluted shares outstanding were 835,560,840 and 798,128,629 for the three and nine months ended June 30, 2013, respectively. Fully diluted shares outstanding were 646,110,663 and 641,715,691 for the three and nine months ended June 30, 2012, respectively.

6

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Stock Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Stock Compensation.  ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.  Stock-based compensation expense recognized under ASC 718 for the three and nine months ended June 30, 2013 were $870,576 and $1,743,598 (including the stock option modification, see Note F), respectively, and for the three and nine months ended June 30, 2012 were $389,533 and $1,564,311, respectively.

As of June 30, 2013, 121,354,192 employee stock options were outstanding with 91,892,325 shares vested and exercisable.

Concentrations

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables.  The Company places its cash and temporary cash investments with high credit quality institutions.  At times, such investments may be in excess of the FDIC insurance limit.

The Company’s revenues earned from sale of products and services for the nine months ended June 30, 2013 included an aggregate of 14% from one customer of the Company’s total revenues.  No customers represented greater than 10% of the Company’s total revenues for the three months ended June 30, 2013.

Two and one customer(s) accounted for 59% and 46% of the Company’s revenues earned from sale of products and services for the three and nine months ended June 30, 2012, respectively.

One and two customer(s) accounted for 10% and 54% of the Company’s total accounts receivable at June 30, 2013 and September 30, 2012, respectively.

Research and Development

The Company accounts for research and development costs in accordance with the ASC 730, Research and Development (“ASC 730”).  Under ASC 730, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.  The Company incurred research and development expenses of $184,981 and $99,958 for the three month periods ended June 30, 2013 and 2012, respectively, and $509,132 and $274,528 for the nine month periods ended June 30, 2013 and 2012, respectively.

Advertising

The Company follows the policy of charging the costs of advertising to expense as incurred.  The Company charged to operations $21,825 and $158,636 as advertising costs for the three and nine month periods ended June 30, 2013 and $13,244 and $68,148 for the three and nine month periods ended June 30, 2012, respectively.

7

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE A — SUMMARY OF ACCOUNTING POLICIES (continued)

Intangible Assets

The Company amortizes its intangible assets using the straight-line method over their estimated period of benefit.  The estimated useful life for patents is five years while other intellectual property uses a seven year useful life. The Company periodically evaluates the recoverability of intangible assets and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists.  All of the Company’s intangible assets are subject to amortization.

Fair Value of Financial Instruments

The Company’s financial instruments are primarily composed of cash, accounts receivable, accounts payable and accrued liabilities, and warrants. The fair value of cash, accounts receivable, accounts payable and accrued liabilities, as reflected in the condensed consolidated balance sheet, approximate its fair value due to the short-term maturity of these instruments.

The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.

The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.

For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.

As of June 30, 2013, there were no transfers in or out of Level 3 from other levels.

The fair value of each warrant is estimated using the Binomial Lattice option valuation model. Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility, in isolation, can significantly increase or decrease the fair value of the warrant. See Note I.

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.

Subsequent Events

The Company has evaluated events that occurred subsequent to the balance sheet date and through the date the financial statements were available to be issued. Other than those events disclosed in the notes to these financial statements, management concluded that no additional subsequent events required disclosure in these financial statements.

8

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE B – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at June 30, 2013 and September 30, 2012 are as follows:

	June 30,
	2013			September 30,
	(unaudited)			2012
Accounts payable		$	1,248,944		$	473,060
Accrued consulting & legal fees			148,622			102,500
Accrued salaries payable			135,912			16,449
Total		$	1,533,478		$	592,009

 NOTE C – WARRANT LIABILITY

As more fully described in Note E below, on November 28, 2012, the Company entered into a securities purchase agreement (“Purchase Agreement”) with Crede CG II, Ltd. (“Crede”). In connection with the Purchase Agreement, the Company issued Series A, B and C Warrants allowing Crede to purchase 10,752,688, 29,569,892 and 26,881,720 shares of Common Stock, respectively.

The Company determined that the Series A and B Warrants described above should be classified as a liability due to transactions which may cause an adjustment to the conversion rate (reset provisions) contained in the warrant agreements and remeasured at each reporting date at their fair value with the changes reported in earnings (loss). Due to a callable provision of the Series C Warrants, the Company deemed such as an equity instrument. The Series C Warrants were repurchased by the Company for $50,000 on January 22, 2013.  Liability classification of the Series A and B Warrants will end upon expiration of reset provisions, at which time the Warrants will be reclassified to equity based on their then fair value. The Company determined the allocated fair value of the Warrants to be $1,181,324 on the issuance date using the Binomial Lattice model with the following assumptions: fair value of the Company’s Common Stock $0.20 per share; dividend yield 0%; expected terms 5 years; risk free interest rate: 0.64%; expected volatility of: 146.32%; and the expected price at which holders are likely to exercise their Warrants of $0.2232.

On April 25, 2013, Crede effected the cashless exercise of the Series A and Series B Warrants (see Note E).  At April 25, 2013 (date of exercise), the Company determined the fair value of the Warrants to be $7,326,553 using the Binomial Lattice model with the following assumptions: fair value of the Company’s Common Stock $0.221 per share; dividend yield 0%; expected term: 4.54 years; risk free interest rate: 0.71%; expected volatility of: 125.97%; and an exercise price of $0.2232. The change in fair value of the warrant liability amounted to a (gain) loss of $(707,289) and $6,145,229 for the three months and nine months ended June 30, 2013, respectively and was included in the results of operations.  Upon exercise, the fair value of the Series A and Series B Warrants were reclassified to equity.

NOTE D - RELATED PARTY TRANSACTIONS

The Company has consulting agreements with outside contractors, certain of whom are also Company stockholders. The agreements are generally month to month.

NOTE E - CAPITAL STOCK

The Company is authorized to issue 1,350,000,000 shares of Common Stock with a par value of $0.001, as the result of a vote of stockholders conducted on January 27, 2012 which effected an increase in the authorized shares of Common Stock from 800,000,000 to 1,350,000,000.  In addition, the Company is authorized to issue 10,000,000 shares of preferred stock with a $0.001 par value per share. As of June 30, 2013 and September 30, 2012, there were 733,524,076 and 646,182,550 shares of Common Stock issued and outstanding, respectively, and no shares of Preferred Stock issued and outstanding.

During the three months ended June 30, 2013 and 2012, the Company expensed $15,018 and $0 related to stock based compensation, respectively. During the nine month periods ended June 30, 2013 and 2012, the Company has expensed $28,256 and $58,238 related to stock based compensation, respectively.

9

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE E - CAPITAL STOCK (continued)

Preferred and Common Stock Transactions during the Nine Months Ended June 30, 2013:

On January 7, 2013, the Company completed the Second Closing of its transaction with Crede pursuant to the Purchase Agreement with Crede. The Company sold 5,500 shares of Series A Preferred Stock (“Series A Preferred”) to Crede at a price of $1,000 per share. The Company received gross proceeds of $5,500,000.   The Company exercised its option on January 8, 2013 and converted the Series A Preferred held by Crede into 25,462,963 shares of the Company’s Common Stock at a conversion price of $0.216 per share.

The Series A Preferred was convertible at the option of the holder thereof, in whole or in part, from time to time and at any time, at the lesser of (i) the Fixed Conversion Price and (ii) the Non-Fixed Conversion Price. The Fixed Conversion Price was equal to $0.186, which was the purchase price for the Common Stock at the Initial Closing. The Non-Fixed Conversion Price was equal to the consolidated closing bid price of the Company’s Common Stock for the most recently completed trading day as of the time of conversion. The Series A Preferred was convertible into Common Stock at the Company’s option, in whole or in part, from time to time during the ten trading day period beginning one trading day following the effectiveness of the registration statement (as described below) through the eleventh trading day following effectiveness of such registration statement, at the Non-Fixed Conversion Price, provided that certain equity conditions were met and the Company was not in breach of certain conditions. The Series A Preferred would have been automatically converted into Common Stock on the one year anniversary of the issuance of the Series A Preferred at the then applicable Non-Fixed Conversion Price, provided that certain equity conditions are met and the Company is not in breach of certain conditions. The Series A Preferred contained weighted average anti-dilution protection. The Series A Preferred did not accrue dividends except to the extent dividends are paid on the Common Stock. The Company’s Common Stock was junior in rank to the Series A Preferred with respect to preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company. The Series A Preferred generally had no voting rights except as required by law.

Pursuant to the Purchase Agreement, Crede agreed to purchase the Series A Preferred on the first business day following the date a registration statement covering the resale of all shares of Common Stock issuable pursuant to the Purchase Agreement, including those underlying the Series A Preferred and Series A, B and C Warrants, was declared effective by the SEC. The Company’s registration statement on Form S-3 was declared effective by the SEC on January 4, 2013.

Pursuant to the Purchase Agreement, Crede purchased at the Initial Closing, held on November 29, 2012, 10,752,688 shares of the Company’s Common Stock at a price of $0.186 per share, resulting in gross proceeds to the Company of $2,000,000. In addition, at the Initial Closing, Crede was issued (i) five year Series A Warrants allowing it to initially purchase 10,752,688 shares of Common Stock at a price of $0.2232 per share, (ii) five year Series B Warrants allowing it to initially purchase 29,569,892 shares of Common Stock at a price of $0.2232 per share which became exercisable at the Second Closing and (iii) Series C Warrants to initially purchase 26,881,720 shares of Common Stock which became exercisable for six months after the eleventh trading day following the Second Closing.  Crede may also exchange the Warrants for Common Stock pursuant to a Black-Scholes formula. The Series A, B and C Warrants each contain a 9.9% “blocker” so that in no event shall any of the Warrants be exercisable or exchangeable into or for Common Stock to the extent that such exercise or exchange would result in Crede having “beneficial ownership” (within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 9.9% of the Company’s Common Stock.

On January 22, 2013, the Company exercised its option to repurchase the Series C Warrants issued to Crede for $50,000.

Crede may exercise Series A and Series B Warrants by paying in cash or on a cashless basis by exchanging such Warrants for Common Stock using the Black-Scholes value. In the event that the Common Stock trades at a price 25% or more above the exercise price of the Series A and Series B Warrants for a period of 20 consecutive days (with average daily dollar volume of Common Stock on the OTC Bulletin Board at least equal to $300,000), the Company may obligate Crede to exercise such Warrants for cash.  On April 25, 2013, Crede effected the cashless exercise of 10,752,688 Series A Warrants and 29,569,892 Series B Warrants, and the Company thereupon issued to Crede an aggregate of 31,257,045 shares of its Common Stock.

Crede has the right to participate in other equity or equity-linked financings completed by the Company for a period of 180 days from the later of the Initial Closing or the date the registration statement went effective.

10

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE E - CAPITAL STOCK (continued)

In addition, the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below $0.186 per share or the market price of the Common Stock on the date the registration statement was declared effective, for a period of 180 days from the effective date of the registration statement, except for issuances (i) pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar arrangements, (ii) to employees, consultants, directors and officers approved by the Board or pursuant to a plan approved by the Board, (iii) pursuant to one or more contracts entered into by the Company with third parties which would result in revenues to the Company during a three-month period equal to an annual run rate of $15 Million in revenues and (iv) pursuant to a contract entered into by the Company with a third party which would reasonably be expected to result in more than $3 Million in annual receivables.

Until one year after the Second Closing, the Company is prohibited from entering into any transaction to (i) sell any convertible securities at a conversion rate or other price that is generally based on and/or varies with the trading prices of the Company’s Common Stock at any time after the initial issuance of such convertible securities or (ii) sell securities at a future determined price, including, without limitation, an “equity line of credit” or an “at the market offering.”

On July 19, 2013, the Company entered into another securities purchase agreement (“Purchase Agreement”) with an affiliate of Crede; see Note K, Subsequent Events, for further details on the new financing.

NOTE F - STOCK OPTIONS AND WARRANTS

Warrants

The following table summarizes the changes in warrants outstanding and the related prices for the shares of Common Stock issued to non-employees of the Company.  These warrants were granted in lieu of cash compensation for services performed or financing expenses in connection with the sale of Common Stock.

			Warrants
			Outstanding	Weighted			Exercisable
			Remaining	Average		Weighted	Weighted
Exercise		Number	Contractual	Exercise		Average	Average
Prices		Outstanding	Life (Years)	Price		Exercisable	Exercise Price
$	0.04000	3,000,000	2.17	$	0.04000	3,000,000	$	0.04000
$	0.04405	510,784	4.04	$	0.04405	510,784	$	0.04405
$	0.04750	3,789,489	5.04	$	0.04750	3,789,489	$	0.04750
$	0.05529	226,081	4.53	$	0.05529	226,081	$	0.05529
$	0.06000	2,000,000	0.64	$	0.06000	2,000,000	$	0.06000
$	0.07100	1,000,000	1.57	$	0.07100	1,000,000	$	0.07100
$	0.09000	6,900,000	3.18	$	0.09000	6,900,000	$	0.09000
$	0.17900	100,000	2.35	$	0.17900	100,000	$	0.17900
$	0.21400	100,000	2.85	$	0.21400	—		—
$	0.50000	1,600,000	0.32	$	0.50000	1,600,000	$	0.50000
		19,226,354	2.83	$	0.10331	19,126,354	$	0.10273

11

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE F - STOCK OPTIONS AND WARRANTS (continued)

Transactions involving warrants are summarized as follows:

	Number of Shares			Weighted Average Price Per Share
Balance, October 1, 2011		58,205,280		$	0.140
Granted		1,075,000			0.071
Exercised		(5,039,633	)		(0.045	)
Cancelled or expired		(8,400,000	)		(0.161	)
Balance at September 30, 2012		45,840,647		$	0.145
Granted		67,404,300			0.223
Exercised		(60,236,873	)		(0.170	)
Cancelled or expired		(33,781,720	)		(0.280	)
Balance, June 30, 2013		19,226,354		$	0.103

Transactions involving warrants are summarized as follows:

On November 7, 2012, 100,000 warrants were issued in connection with services. The warrants are exercisable on or after May 7, 2013 for three years at an exercise price of $0.179 per share. The fair value of the warrants of $13,238 was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 129.56% and risk free rate from 0.36% and were charged to current period operations.

On November 29, 2012, in connection with a securities purchase agreement as described in Note E above, the Company issued an aggregate of 67,204,300 warrants to purchase the Company’s common stock exercisable for one to five years after defined date or events, at an exercise price of $0.2232.

In March 2013, the Company issued an aggregate of 1,500,000 shares of its common stock in connection with the exercise of warrants at an exercise price of $0.10 per share; net proceeds of $150,000.

In April 2013, the Company issued 11,285,376 shares of its common stock in connection with the cashless exercise of 15,438,337 warrants to acquire the Company’s stock at a weighted average exercise price of $0.063 per share.

In May 2013, the Company issued 2,418,971 shares of its common stock in connection with the cashless exercise of 2,975,956 warrants to acquire the Company’s stock at a weighted average exercise price of $0.042 per share.

On May 7, 2013, 100,000 warrants were issued in connection with services. The warrants are exercisable on or after November 7, 2013 for three years at an exercise price of $0.214 per share.  The fair value of the warrants of $15,018 was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 119.72% and risk free rate from 0.35% and were charged to current period operations.

As described in Note E above, on January 22, 2013, the Company exercised its option to repurchase 26,881,720 Series C Warrants issued to Crede for $50,000.  On April 25, 2013, Crede effected the cashless exercise of 10,752,688 Series A Warrants and 29,569,892 Series B Warrants, and the Company thereupon issued to Crede an aggregate of 31,257,045 shares of its Common Stock.

12

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE F - STOCK OPTIONS AND WARRANTS (continued)

Employee Stock Options

On January 26, 2005, the Board of Directors, and on February 15, 2005, the holders of a majority of the outstanding shares of Common Stock approved the 2005 Incentive Stock Plan and authorized the issuance of 16,000,000 shares of Common Stock as stock awards and stock options there under. On May 16, 2007, at the annual meeting of stockholders, the holders of a majority of the outstanding shares of Common Stock approved an increase in the number of shares subject to the 2005 Incentive Stock Plan to 20,000,000 shares of Common Stock.  On June 17, 2008, the Board of Directors unanimously adopted an amendment to the 2005 Incentive Stock Plan that increased the total number of shares of Common Stock issuable pursuant to the 2005 Incentive Stock Plan from a total of 20,000,000 shares to a total of 100,000,000 shares, which was approved by our stockholders at the 2008 annual meeting of stockholders held on December 16, 2008.  On November 30, 2011, the Board of Directors unanimously adopted an amendment to the 2005 Incentive Stock Plan that increased the total number of shares of Common Stock issuable there under to 350,000,000 and the number of shares of Common Stock that can be covered by awards made to any participant in any calendar year to 50,000,000, which was approved by our stockholders at the 2012 annual meeting of stockholders held on January 27, 2012.

The 2005 Incentive Stock Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to the Company’s success with an award of options to purchase shares of Common Stock.  As of June 30, 2013, a total of 137,583,192 shares have been issued and options to purchase 121,354,192 shares are outstanding under the 2005 Incentive Stock Plan.

The following table summarizes the changes in options outstanding and the related prices for the shares of Common Stock issued to employees of the Company under the 2005 Incentive Stock Plan:

Options Outstanding				Options Exercisable
Exercise Prices		Number Outstanding	Weighted Average Remaining Contractual  Life (Years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
$	0.0500	24,000,000	1.91	$	0.0500	24,000,000	$	0.0500
$	0.0585	50,000,000	5.04	$	0.0585	31,250,000	$	0.0585
$	0.0600	30,000,000	2.00	$	0.0600	22,500,000	$	0.0600
$	0.0650	634,825	3.43	$	0.6500	634,825	$	0.0650
$	0.0680	4,770,000	3.42	$	0.0680	4,770,000	$	0.0680
$	0.0700	2,850,000	1.86	$	0.0700	1,837,500	$	0.0700
$	0.0900	1,500,000	3.17	$	0.0900	1,500,000	$	0.0900
$	0.1100	5,400,000	4.96	$	0.1100	5,400,000	$	0.1100
$	0.1799	2,099,367	4.42	$	0.1799	—	$	—
$	0.2000	100,000	4.88	$	0.2000	—	$	—
		121,354,192	3.49	$	0.0628	91,892,325	$	0.0610

13

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE F - STOCK OPTIONS AND WARRANTS (continued)

Transactions involving stock options issued to employees are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value
Outstanding at October 1, 2011		120,650,000		$	0.060
Granted		6,558,825			0.070
Exercised		(500,000	)		(0.080	)
Cancelled or expired		(1,500,000	)		(0.080	)
Outstanding at September 30, 2012		125,208,825		$	0.060
Granted		7,599,367			0.131
Exercised		(5,979,000	)		(0.042	)
Canceled or expired		(5,475,000	)		(0.109	)
Outstanding at June 30, 2013		121,354,192		$	0.063
Vested at June 30, 2013		91,892,325		$	0.061		$	0.138
Non-vested at June 30, 2013		29,461,867		$	0.068		$	0.131

Transactions involving stock options granted to employees are summarized as follows:

On November 30, 2012, the Company granted an aggregate of 2,099,367 options to non-employee board of director members (except Mr. Catenacci) under the 2005 Incentive Stock Plan. The options are exercisable at $0.1799 per share for five years, vesting one year from the date of issuance. The fair value of options was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 146.33% and risk free rate of 0.82%.

On May 12, 2013, the Company granted an aggregate of 100,000 options to an employee under the 2005 Incentive Stock Plan.  The options are exercisable at $0.20 per share for five years, vesting at 25% each anniversary for the next four years. The fair value of the options was determined using the Black Scholes Option Pricing Model with the following assumptions:  dividend yield $-0-, volatility of 117.57% and risk free rate of 0.60%.

During the nine months ended June 30, 2013, the Company issued 4,639,483 shares of its Common Stock in connection with the cashless exercise of 5,954,000 options to acquire the Company stock at weighted average $.053 per share. The Company also issued 25,000 shares of its Common Stock in connection with the exercise of 25,000 options at $0.06 per share.

On May 15, 2013 the Company extended the term of 5,400,000 options that were set to expire to June 16, 2018.  The Company recorded $408,605 of stock compensation expense for the three and nine months ended June 30, 2013 in connection with this modification as the incremental difference between the fair value of the stock options immediately before and after the modification.

The Company recorded $870,576 and $1,743,598 (including the stock option modification) as stock compensation expense for the three and nine month periods ended June 30, 2013, respectively, and $389,533 and $1,564,311 for the three and nine month periods ended June 30, 2012, respectively, for the vesting portion of all employee options outstanding. As of June 30, 2013, unrecorded compensation cost related to non-vested awards was $289,106, which is expected to be recognized through 2018.

NOTE G - COMMITMENTS AND CONTINGENCIES

On June 14, 2013, the Company entered into an operating lease agreement for its new corporate headquarters located in Stony Brook, New York.  The lease is for a 30,000 square foot building.  The term of the lease commenced on June 15, 2013 and expires on May 31, 2016, with the option to extend the lease for two additional three-year periods.  The base rent during the initial lease term is $449,142 per annum.  This new location replaces a lesser amount of space leased by the Company in an adjacent building, which was for corporate use.   Total lease rental expenses for the three and nine month periods ended June 30, 2013 were $82,033 and $226,581, respectively.  Total lease rental expenses for the three and nine month periods ended on June 30, 2012 were $63,200 and $173,502, respectively.

14

Employment and Consulting Agreements

The Company has employment agreements with the Chief Executive Officer and Chief Financial Officer as disclosed in the notes to audited consolidated financial statements included in its Annual Report on Form 10-K for the fiscal year ended September 30, 2012 filed with the SEC. Also, the Company has consulting agreements with outside contractors, certain of whom are also Company stockholders. The agreements are generally month to month.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.  When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business.

Demodulation, Inc. v. Applied DNA Sciences, Inc., et al. (Civil Action No. - 2:11-cv-00296-WJM-MF, District of New Jersey):

On May 18, 2011, the Company was served with a complaint in a lawsuit brought by Demodulation, Inc. against the Company, Corning Incorporated, Alfred University, and Alfred Technology Resources, Inc. On July 8, 2011, the Company filed a motion to dismiss the complaint. In response, on August 3, 2011, Demodulation, Inc. filed an amended complaint. Demodulation, Inc. alleged that it was unable to bring its microwire technology to market due to the wrongful acts of defendants, who allegedly conspired to steal Demodulation, Inc.’s trade secrets and other intellectual property and to interfere in its business opportunities. Of the 17 claims alleged in the amended complaint, five were asserted against the Company, including alleged misappropriation of trade secrets, antitrust violations, civil RICO, and patent infringement. Demodulation, Inc. sought damages and injunctive relief against the Company. The Company believes these claims were without merit.  On January 27, 2012, the Company filed a motion to dismiss the amended complaint for failure to state a claim and on other grounds. On December 12, 2012, the Court entered an order on the Company’s motion to dismiss the amended complaint. The Court granted in part and denied in part the Company’s motion to dismiss. The Court dismissed four out of the five claims asserted against the Company without prejudice, leaving only the patent infringement claim.  Subsequently, the parties stipulated to sever the patent infringement claim against the Company from the claims against the other defendants.  The Court entered an order severing the patent claim on February 20, 2013, and terminated the main lawsuit against the Company.  Demodulation, Inc. may seek to re-file its patent claim as a separate action, but to date has not done so. If Demodulation re-files its action, the Company intends to vigorously defend the action.

Smartwater, Ltd. v. Applied DNA Sciences, Inc. (No. 12-CV-05731-JS-AKT (E.D.N.Y.))

On June 6, 2012, a complaint for patent infringement was filed against the Company by Smartwater, Ltd. in the United States District Court for the District of Massachusetts in an action entitled Smartwater, Ltd. v. Applied DNA Sciences, Inc., No. 1:12-cv-11009-PBS. The complaint alleged that the Company infringed one or more claims under two of plaintiff’s patents by selling or offering for sale, manufacturing and using certain of the Company’s products, by inducing others to infringe and by contributing to infringement by others. The plaintiff sought injunctive relief with respect to the patents as well as awards of damages and attorneys’ fees. The Company had not been served with the complaint and on August 24, 2012 the plaintiff voluntarily dismissed the complaint and refiled a similar complaint in the United States District Court for the Southern District of Florida, No. 12-61660-DMM (S.D. Fla.). On August 30, 2012, plaintiff served the Company with the complaint. The refiled complaint seeks injunctive relief with respect to one of the patents as well as awards of damages and attorneys’ fees. The Company filed a motion to dismiss and a motion to transfer the action to the Eastern District of New York. On November 19, 2012, the Court granted the Company’s motion to transfer the action to the Eastern District of New York. The Company’s motion to dismiss is pending before the Court in the Eastern District of New York.  An initial conference with the Court was held on February 21, 2013, at which time the Court directed the conduct of limited document discovery pending the Court’s decision on the motion to dismiss. On June 21, 2013, plaintiff filed a motion seeking leave from the Court to file an amended complaint asserting additional allegations in support of its claims.  The Company filed its opposition to the motion on July 29, 2013.  The Company believes that none of its products infringe any claims under either of plaintiff’s patents, and moreover notes that one of plaintiff’s patents has expiredand the other is due to expire on February 25, 2014.  The Company believes the allegations in the complaint are without merit and intends to defend the action vigorously. The ultimate outcome of this claim cannot be determined at the date of this report.

15

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE H - LIQUIDITY

The Company incurred a net loss of $13,968,001 and generated negative operating cash flow of $5,696,917 for the nine months ended June 30, 2013. However, the Company has attained positive working capital of $1,027,531 as of June 30, 2013.  Management believes that the positive cash balance and working capital as of June 30, 2013 as well as the proceeds from the securities purchase agreement with Crede entered into on July 19, 2013 (see Note K) along with the current customer base, the projected cash flow and the minimum guaranteed revenues for the next fiscal year will allow the Company to continue to improve its working capital and to have sufficient capital resources to meet projected cash flow requirements.

NOTE I - FAIR VALUE

The carrying value of cash, accounts receivable, accounts payable and accrued expenses approximate estimated fair values because of their short maturities.

The carrying value of the warrant liability is determined using the Binomial Lattice model option pricing model as described in Note C. Certain assumptions used in the calculation of the warrants liability represent level-3 unobservable inputs. The Company did not have any assets or liabilities categorized as Level 1 or 2 as of June 30, 2013.

The following table summarizes the activity of Level 3 inputs measured on a recurring basis:

Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)	Nine Months Ended June 30,
	2013			2012
Balance at October 1,	$	—		$	—
Issuance of Series A and B Warrants		1,181,324			—
Adjustment resulting from change in value recognized in earnings (a)		6,145,229			—
Reclassification to equity upon exercise		(7,326,553	)		—
Balance at June 30,	$	—		$	—

(a) Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to liabilities held at the reporting date. The unrealized gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

NOTE J – ASSET PURCHASE AGREEMENT

On May 10, 2013, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with RedWeb Technologies Limited (“RedWeb”), a corporation incorporated and registered under the laws of England & Wales, to purchase certain assets of RedWeb (“Purchased Assets”) relating to its forensic tagging security system for a purchase price of £400,000 ($624,080). The Company completed the acquisition of the Purchased Assets on the same day. The Purchased Assets include RedWeb’s Sentry 500 Intruder Spray System, RedWeb’s Advanced Molecular Taggent Technology and all products relating thereto, certain intellectual property and supplies relating to the foregoing. £40,000 ($62,408) of the purchase price shall be held in escrow for up to one year to be applied against the indemnification obligations of RedWeb pursuant to the Asset Purchase Agreement. This transaction was accounted for as an asset acquisition in accordance with ASC 805.  The Company assigned $584,080 of the purchase price to intellectual property and the remaining $40,000 was for supplies, which were expensed during the three months ended June 30, 2013.

16

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE K – SUBSEQUENT EVENTS

Securities Purchase Agreement

On July 19, 2013, the Company entered into a securities purchase agreement (“Purchase Agreement”) with Crede CG III, Ltd. (“Crede”).  Pursuant to the Purchase Agreement, at the initial closing on July 19, 2013 (“Initial Closing”), Crede purchased 10,695,187 shares of the Company’s Common Stock at a price of $0.187 per share which was the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement.  The Company received gross proceeds of $2,000,000.  Pursuant to the Purchase Agreement, Crede agreed to purchase an additional $5,500,000 of the Company’s Series B Convertible Preferred Stock (“Series B Preferred”) at a purchase price of $1,000 per share on the date a registration statement (as described below) is declared effective by the SEC (“Second Closing”).

The Series B Preferred is convertible at the option of the holder thereof, in whole or in part, from time to time and at any time, at the lesser of (i) the Fixed Conversion Price and (ii) the Non-Fixed Conversion Price. The Fixed Conversion Price is equal to $0.187 per share which is the purchase price for the Common Stock at the Initial Closing.  The Non-Fixed Conversion Price is equal to the consolidated closing bid price of the Company’s Common Stock for the most recently completed trading day as of the time of conversion.  The Series B Preferred will be convertible into Common Stock at the Company’s option, in whole or in part, from time to time during the period beginning one trading day following the effectiveness of the registration statement (as described below) through the eleventh trading day following effectiveness of such registration statement, at the Non-Fixed Conversion Price, provided that certain equity conditions are met and the Company is not in breach of certain conditions.  The Series B Preferred will be automatically converted into Common Stock on the one year anniversary of the issuance of the Series B Preferred at the then applicable Non-Fixed Conversion Price, provided that certain equity conditions are met and the Company is not in breach of certain conditions.  The Series B Preferred contains weighted average anti-dilution protection.  The Series B Preferred will not accrue dividends except to the extent dividends are paid on the Common Stock.  The Company’s Common Stock will be junior in rank to the Series B Preferred with respect to preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company.  The Series B Preferred will generally have no voting rights except as required by law.

The Company also issued Crede at the Initial Closing Warrants with a term of five years (though such term may be extended in certain instances) (“Series A Warrants”) allowing it to purchase 10,695,187 shares of Common Stock at a price of $0.2431 per share which is equal to a 30% premium to the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement.  At the Initial Closing, the Company also issued Crede a second set of Warrants (“Series B Warrants”) allowing it to purchase 29,411,764 shares of Common Stock, which is equal to one share of Common Stock for every share of Common Stock which would be issuable to it if it fully converted the Series B Preferred into Common Stock at the Fixed Conversion Price.  The exercise price of the Series B Warrants is $0.2431 per share, which is equal to a 30% premium to the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement.  The Series B Warrants are not exercisable until the earlier of (i) November 7, 2013 and (ii) the Second Closing, and have a term of five years (though such term may be extended in certain instances).

 In addition, at the Initial Closing, the Company issued to Crede a third set of Warrants (“Series C Warrants”) which is only exercisable for six months from the earlier of (i) November 7, 2013 and (ii) after the eleventh trading day following the Second Closing.  The Series C Warrants will allow Crede to purchase, at a price of $0.2431 per share (equal to a 30% premium to the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement), 26,737,967 shares of Common Stock, which is equal to one-third the sum of (i) the number of shares of Common Stock issued at the Initial Closing, (ii) the number of shares of Common Stock which would be issuable to it if it fully converted the Series B Preferred into Common Stock at the Fixed Conversion Price, (iii) the number of shares of Common Stock subject to the Series A Warrants and (iv) the number of shares of Common Stock subject to the Series B Warrants.

The Series B and Series C Warrants provide the Company with an option to repurchase any remaining unexercised portion of such Warrants for a repurchase price equal to $50,000, if the Second Closing is terminated pursuant to the Purchase Agreement. The Company also has the option to repurchase the Series C Warrants at an aggregate repurchase price equal to $10,000 at the close of trading on the tenth trading day immediately following the Second Closing but only if the registration statement (described below) is effective and covers and is available for use for the resale of (i) all shares of Common Stock issued at the First Closing, (ii) all shares of Common Stock issued upon conversion of the Series B Preferred, (iii) all shares of Common Stock which would then be issuable if the full then unconverted portion of the Series B Preferred were then fully converted into Common Stock at the then applicable conversion price, (iv) all shares of Common Stock subject to the Series A Warrants and (v) all shares of Common Stock subject to the Series B Warrants.

17

APPLIED DNA SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2013

(unaudited)

NOTE K – SUBSEQUENT EVENTS (continued)

Crede may exercise Series A and Series B Warrants by paying in cash or on a cashless basis by exchanging such Warrants for Common Stock using a negotiated Black-Scholes value.  In the event that the Common Stock trades at a price 25% or more above the exercise price of the Series A and Series B Warrants for a period of 20 consecutive days (with average daily dollar volume of Common Stock on the OTC Bulletin Board at least equal to $300,000), the Company may obligate Crede to exercise such Warrants for cash.

Pursuant to a registration rights agreement between the Company and Crede, the Company agreed to file a registration statement within 30 days of the Initial Closing and to use its best efforts to get such registration statement effective within 90 days.  The registration statement will cover the resale of all shares of Common Stock issuable pursuant to the Purchase Agreement, including the shares of Common Stock underlying the Series B Preferred and Series A, B and C Warrants.  The registration statement was declared effective by the SEC on July 31, 2013.  The Company has also agreed to prepare and file amendments and supplements to the registration statement to the extent necessary to keep the registration statement effective for the period of time required under the Purchase Agreement.  In the event the registration statement failed to be declared effective within the 90 day period, the Company would have been subject to monthly penalties which would expire six months after the Initial Closing.

The Company agreed to pay Crede an investment fee equal to $100,000 at the Initial Closing and $265,000 at the Second Closing.

The Series B Preferred and the Series A, B and C Warrants each contain a 9.9% “blocker” so that in no event shall the Series B Preferred or any of the Series A, B and C Warrants be convertible or exercisable (including through the cashless exercise exchange provision) into or for Common Stock to the extent that such conversion or exercise would result in Crede having “beneficial ownership” (within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 9.9% of the Common Stock. Crede would, however, have the right from time to time to convert, exercise or exchange for shares of Common Stock, which over time would aggregate to greater than 9.9% beneficial ownership if all such shares of Common Stock so acquired had been held at one time by Crede.

Crede has the right to participate in other equity or equity-linked financings completed by the Company for a period of 180 days from the later of the Initial Closing or the date the registration statement goes effective.

In addition, the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below $0.187 per share or the market price of the Common Stock on the date the registration statement is declared effective, for a period of 180 days from the effective date of the registration statement, except for issuances (i) pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar arrangements, (ii) to employees, consultants, directors and officers approved by the Board or pursuant to a plan approved by the Board, (iii) pursuant to one or more contracts entered into by the Company with third parties which would result in revenues to the Company during a three-month period equal to an annual run rate of $15 Million in revenues and (iv) pursuant to a contract entered into by the Company with a third party which would reasonably be expected to result in more than $3 Million in annual receivables.

Until one year after the Second Closing, the Company is prohibited from entering into any transaction to (i) sell any convertible securities at a conversion rate or other price that is generally based on and/or varies with the trading prices of the Company’s Common Stock at any time after the initial issuance of such convertible securities or (ii) sell securities at a future determined price, including, without limitation, an “equity line of credit” or an “at the market offering.”

On July 31, 2013, the Company completed the Second Closing of its transaction with Crede and sold 5,500 shares of Series B Preferred to Crede at a price of $1,000 per share.  The Company received gross proceeds of $5,500,000 less an investment fee of $265,000.

18

Item 2. - Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our Unaudited Condensed Consolidated Financial Statements and Notes thereto, included elsewhere within this report.  The Quarterly Report contains forward-looking statements , including statements using terminology such as “can,” “may,” “believe,” “designated to,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “potential,” or “continue,” or the negative thereof or other comparable terminology regarding beliefs, plans, expectations or intentions regarding the future. You should read statements that contain these words carefully because they:

● discuss our future expectations;

● contain projections of our future results of operations or of our financial condition; and

● state other “forward-looking” information.

We believe it is important to communicate our expectations. However, forward looking statements involve risks and uncertainties and our actual results and the timing of certain events could differ materially from those discussed in forward-looking statements as a result of certain factors, including those set forth under “Risk Factors,” “Business” and elsewhere in our Annual Report on Form 10-K for the fiscal year ended September 30, 2012.  All forward-looking statements and risk factors included in this document are made as of the date hereof, based on information available to us as of the date thereof, and we assume no obligations to update any forward-looking statement or risk factor, unless we are required to do so by law.

Introduction

We are a provider of modified and derivatized botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, and protect governments and consumers from theft, counterfeiting, fraud and diversion.  SigNature® DNA, SmartDNA®, DNANet®, BioMaterial Genotyping™, digitalDNA®, and Cashield®, our principal anti-counterfeiting and product authentication solutions, can be used in numerous industries, including cash-in-transit (transport and storage of banknotes), microcircuits and other electronics, homeland security, textiles and apparel, identity cards and other secure documents, law enforcement, pharmaceuticals, wine, and luxury consumer goods.

SigNature DNA. We use the DNA of plants to manufacture highly customized and encrypted botanical DNA markers, or SigNature DNA Markers, which we believe are virtually impossible to replicate. We have embedded SigNature DNA Markers into a range of our customers’ products, including various inks, dyes, textile treatments, thermal ribbons, threads, varnishes and adhesives. These items can then be tested for the presence of SigNature DNA Markers through an instant field detection or a forensic level authentication. Our SigNature DNA solution provides a secure, accurate and cost-effective means for users to incorporate our SigNature DNA Markers in, and then quickly and reliably authenticate and identify, a broad range of items, such as recovered banknotes, branded textiles and apparel products, microcircuits and other electronics, pharmaceuticals and cosmetic products, identity cards and other secure documents, digital media, artwork and collectibles and fine wine. Having the ability to reliably authenticate and identify counterfeit versions of such items enables companies and governments to detect, deter, interdict and prosecute counterfeiting enterprises and individuals.

SmartDNA.SmartDNA is a unique and patented security system based on botanical DNA, a new and effective crime protection system for stores, warehouses, banks, pharmacies, ATMs and the protection of valuables. The system contains a water-based, non-toxic spray which may be triggered during a crime, marking the perpetrator and remaining on their person for weeks after the crime. Each SmartDNA product is designed to be unique to each store, warehouse or sting operation allowing the police and prosecutors to link criminals to the crimes.

DNANet. We have recently developed DNANet tactical DNA products for law enforcement, in the form of DNA-marked sprays and liquids. These products, which are being marketed to global police forces, were created to help link criminals to crimes. DNANet is a tactical forensic system providing unique DNA codes for covert operations that require absolute proof of authentication. DNANet is now included in the SmartDNA family of products.

BioMaterial GenoTyping. Our BioMaterial GenoTyping solution refers to the development of genetic assays to distinguish between varieties or strains of biomaterials, such as cotton, wool, tobacco, fermented beverages, natural drugs and foods, that contain their own source DNA. We have developed two proprietary genetic tests (FiberTyping® and PimaTyping®) to track American Pima cotton from the field to finished garments. These genetic assays provide the cotton industry with what we believe to be the first authentication tools that can be applied throughout the U.S. and global cotton industry from cotton growers, mills, wholesalers, distributors, manufacturers and retailers through trade groups and government agencies.

19

digitalDNA. digitalDNA is a DNA-secured form of the QR (“quick read”) code. digitalDNA is a new security tool that utilizes the flexibility of mobile communications, the instant accessibility of secure, cloud-based data, and the absolute certainty of DNA to make item tracking and authentication fast, easy and definitive, while providing the opportunity to create a new customer interface. The product uses forensic authentication of a botanical DNA marker, sequence-encrypted within a secure QR code, and physically included within the ink used to digitally print the code. The resulting pattern or “rune” can be scanned via an Apple-approved app with an iPhone to assure originality. These mobile scans can be performed anywhere along the supply chain without limit. Tracking information is fed into “tunable algorithms” that use pattern recognition to automatically identify supply-chain risks, for counterfeits or product diversion. Rapid-reading reporters, associated with the DNA marker, are also embedded in the ink, and prevent the secure code from being digitally copied.

The digitalDNA platform is designed to meet compliance specifications defined by the PCI (Payment Card Industry) Security Standards Council, the new and strict standards developed for handling credit card transactions, and HIPAA (Health Insurance Portability and Accountability Act), the stringent requirements for protecting personal health information.

Cashield. Cashield is a family of cash degradation inks that permanently stain banknotes stolen from cash-handling or ATM systems. Cashield extends our offering beyond our prior singular product, AzSure®, to a family of security inks that include Red, Violet, Green, Teal, Indigo, and the original AzSure® Blue. Current degradation dyes suffer from a critical technical weakness, as the dyes may be removed by the use of solvents. We initiated the development of Cashield in response to demand for a more effective carrier for our SigNature DNA markers. Cashield has been certified for use in the European Union by the Laboratoire National de Métrologie et d’Essais (LNE) and passed all 47 individual dye penetration and wash-out-resistance tests. Additionally, a CViT study presented by the University of Leeds cited Cashield AzSure Blue ink as having improved performance versus staining inks from other suppliers. In this study, the AzSure Blue ink was tested across a range of currencies, including British pounds, Euros, and U.S. dollars. The evaluation involved exposure to numerous industrial solvents. Final analysis of the results concluded that the AzSure Blue ink was bound strongly in five seconds or less to a variety of banknotes, and could not be removed with any solvent.

Plan of Operations

General

To date, the substantial portion of our revenues has been generated from sales of our SigNature DNA and BioMaterial Genotyping, our principal anti-counterfeiting and product authentication solutions (“authentication services”).  We have continued to incur expenses in expanding our laboratory and office facilities and increasing our personnel to meet anticipated future demand.   We expect to generate revenues from sales of our SigNature Program, Cashield, DNANet, SmartDNA, digitalDNA and BioMaterial Genotyping offerings.  We have developed or are currently attempting to develop business in the following target markets: homeland security, cash-in-transit, textile and apparel authentication, secure documents, pharmaceuticals, consumer products, law enforcement, fine wine, art and collectibles, and digital and recording media.  Our developments in the cash-in-transit, component authentication and textile and apparel authentication markets have contributed to our revenues. We intend to pursue both domestic and international sales opportunities in each of these vertical markets.

Critical Accounting Policies

Financial Reporting Release No. 60, published by the SEC, recommends that all companies include a discussion of critical accounting policies used in the preparation of their financial statements. While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our consolidated financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. 

We believe that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause a material effect on our consolidated results of operations, financial position or liquidity for the periods presented in this report.

The accounting policies identified as critical are as follows:

●           Revenue recognition;

●           Allowance for doubtful accounts; and

●           Equity based compensation.

20

Revenue Recognition

Revenues are derived from research, development, qualification and production testing for certain commercial products. Revenue from fixed price testing contracts is generally recorded upon completion of the contracts, which are generally short-term, or upon completion of identifiable contractual tasks. At the time we enter into a contract that includes multiple tasks, we estimate the amount of actual labor and other costs that will be required to complete each task based on historical experience. Revenues are recognized which provide for a profit margin relative to the testing performed. Revenue relative to each task and from contracts which are time and materials based is recorded as effort is expended. Billings in excess of amounts earned are deferred. Any anticipated losses on contracts are charged to income when identified. To the extent management does not accurately forecast the level of effort required to complete a contract, or individual tasks within a contract, and we are unable to negotiate additional billings with a customer for cost over-runs, we may incur losses on individual contracts.

For revenue from product sales, we recognize revenue in accordance with ASC 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. We defer any revenue for which the product has not been delivered or is subject to refund until such time that we and the customer jointly determine that the product has been delivered or no refund will be required.

ASC 605 incorporates ASC subtopic 605-25, Multiple-Element Arraignments (“ASC 605-25”). ASC 605-25 addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. The effect of implementing ASC 605-25 on our financial position and results of operations are not significant.

Allowance for Uncollectible Receivables

The Company provides an allowance for doubtful accounts equal to the estimated uncollectible amounts. The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable. It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change. At June 30, 2013 and September 30, 2012, the Company had an allowance for doubtful accounts of $70,000 and $0, respectively.  The Company writes-off receivables that are deemed uncollectible.

Equity Based Compensation

The Company follows ASC 718, Compensation (“ASC 718”) which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the statement of operations based on their fair values.

Use of Estimates

In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the reporting period. Actual results could differ from those estimates.

Comparison of Results of Operations for the Three Months Ended June 30, 2013 and 2012

Revenues

For the three months ended June 30, 2013, we generated $644,842 in revenues from operations principally from the sales of authentication services. For the three months ended June 30, 2012, we generated $528,574 in revenues from operations. The $116,268 or 22.0% increase in sales for the three months ended June 30, 2013 compared to the three months ended June 30, 2012 was primarily caused by SigNature DNA sales to suppliers of the United States Defense Logistics Agency (“DLA”).  In late January 2013, the DLA announced that it would subsidize SigNature DNA marking costs for its trusted suppliers, and in March 2013, after this and other mechanisms were in place, we were able to begin SigNature DNA shipments for this market. The sales to these third party suppliers during the three months ended June 30, 2013 was offset by a decrease in sales due to the completion of our prior pilot contract with the Logistics Management Institute (“LMI”).

21

Costs and Expenses

Selling, General and Administrative

Selling, general and administrative expenses increased from $1,752,501 for the three months ended June 30, 2012 to $3,240,815 for the three months ended June 30, 2013.  The increase of $1,488,314, or 84.9%, is primarily attributable to higher professional fees, specifically for legal and consulting, increased salary due to the increase in headcount by approximately 60.0% from June 30, 2012 as compared to June 30, 2013 and bad debt expense of $70,000 for the three months ended June 30, 2013 as compared to $0 for the three months ended June 30, 2012.  The increase is also due to expenses incurred for the relocation of our corporate office during the three months ended June 30, 2013.

Research and Development

Research and development expenses increased from $99,958 for the three months ended June 30, 2012 to $184,981 for the three months ended June 30, 2013. The increase of $85,023 or 85.1% is attributable to additional research and development activity needed to support the increase in current operations.

Depreciation and Amortization

In the three months ended June 30, 2013, depreciation and amortization decreased by $41,058 or 39.7% from $103,338 for the three months ended June 30, 2012 to $62,280 for the three months ended June 30, 2013.  The decrease is primarily attributable to completion of the amortization of our intangible property which we incurred approximately $90,000 of amortization expense during the three months ended June 30, 2012 as compared to $19,470 for the three months ended June 30, 2013.  The amortization during the three months ended June 30, 2013 related to the intellectual property acquired from RedWeb.  This decrease was offset by an increase in depreciation and amortization expense for the leasehold improvements and lab equipment purchased associated with the relocation of our corporate office and intellectual property acquired with the RedWeb asset purchase agreement during the three months ended June 30, 2013.

Total Operating Expenses

Total operating expenses increased to $3,488,076 for the three months ended June 30, 2013 from $1,955,797 for the three months ended June 30, 2012, for an increase of $1,532,279 or 78.3% primarily attributable to an increase in professional fees, salaries paid and in R&D expenditures, which was offset by a decrease in depreciation and amortization expense, as described above.

Interest, net

Interest, net for the three months ended June 30, 2013 was income of $333 from a net interest expense of $2,422 for the three months ended June 30, 2012. The decrease in interest expense was due to no outstanding notes payable as of June 30, 2013.

Gain from Change in Fair Value of Warrant Liability

In November 2012, we issued warrants containing certain reset provisions which require us to classify them as a liability and mark these warrants to market and record the change in fair value each reporting period as a non-cash adjustment to our current period operations.  This resulted in a gain of $707,289 for the three months ended June 30, 2013 which is included in current period operations as compared to $-0- for the same period last year.  These warrants were reclassified to equity upon exercise on April 25, 2013.

Net Loss

Net loss for the three months ended June 30, 2013 increased to $2,135,612 from a net loss of $1,429,645 for the three months ended June 30, 2012, which is primarily attributable to factors described above.

Comparison of Results of Operations for the Nine Months Ended June 30, 2013 and 2012

Revenues

For the nine months ended June 30, 2013, we generated $1,307,117 in revenues from operations principally from the sales of authentication services. For the nine months ended June 30, 2012, we generated $1,563,880 in revenues from operations. The decrease of $256,763 or 16.4% in sales for the nine months ended June 30, 2013 compared to the nine months ended June 30, 2012 was primarily caused by the completion of our prior pilot contract with LMI, and a slower than anticipated replacement of that revenue by DNA marking contracts with commercial electronics manufacturers.  In late January 2013, DLA announced that it would subsidize SigNature DNA marking costs for its trusted suppliers, and in March 2013, after this and other mechanisms were in place, we were able to begin SigNature DNA shipments for this market.

22

Costs and Expenses

Selling, General and Administrative

Selling, general and administrative expenses increased from $5,729,575 for the nine months ended June 30, 2012 to $8,516,390 for the nine months ended June 30, 2013. The increase of $2,786,815, or 48.6%, is primarily attributable to higher professional fees, specifically for legal and consulting, increased salary due to an approximate increase in headcount of 60.0% from June 30, 2012 as compared to June 30, 2013 and bad debt expense of $70,000 for the nine months ended June 30, 2013 as compared to $0 for the nine months ended June 30, 2012.

Research and Development

Research and development expenses increased from $274,528 for the nine months ended June 30, 2012 to $509,132 for the nine months ended June 30, 2013. The increase of $234,604 or 85.5% is attributable to additional research and development activity needed with current operations.

Depreciation and Amortization

In the nine months ended June 30, 2013, depreciation and amortization decreased by $195,314 or 65.0% from $300,419 for the nine months ended June 30, 2012 to $105,105 for the nine months ended June 30, 2013.   The decrease is primarily attributable to completion of the amortization of our intangible property which we incurred approximately $270,000 of amortization expense during the nine months ended June 30, 2012 as compared to $19,470 for the nine months ended June 30, 2013.  The amortization during the nine months ended June 30, 2013 related to the intellectual property acquired from RedWeb.  This decrease was offset by an increase in depreciation and amortization expense for the leasehold improvements, lab equipment and assets acquired with the RedWeb asset purchase agreement during the nine months ended June 30, 2013.

Total Operating Expenses

Total operating expenses increased to $9,130,627 for the nine months ended June 30, 2013 from $6,304,522 for the nine months ended June 30, 2012, or an increase of $2,826,105 or 44.8% primarily attributable to an increase in professional fees paid, salaries and in R&D expenditures which was offset by a decrease in depreciation and amortization expense.

Interest, net

Interest, net for the nine months ended June 30, 2013 was income of $738 from a net interest expense of $642,790 for the nine months ended June 30, 2012. The decrease in interest expense was due to no outstanding notes payable as of June 30, 2013.

Loss from Change in Fair Value of Warrant Liability

In November 2012, we issued warrants containing certain reset provisions which require us to classify them as a liability and mark the warrants to market and record the change in fair value each reporting period as a non-cash adjustment to our current period operations.  This resulted in a $6,145,229 charge to current period operations as compared to $-0- for the same period last year.  These warrants were reclassified to equity upon exercise on April 25, 2013.

Net Loss

Net loss for the nine months ended June 30, 2013 increased to $13,968,001 from a net loss of $5,383,432 for the nine months ended June 30, 2012, which is primarily attributable to factors described above.

Liquidity and Capital Resources

Our liquidity needs consist of our working capital requirements and research and development expenditure funding. As of June 30, 2013, we had working capital of $1,027,531. For the nine months ended June 30, 2013, we generated a net cash flow deficit from operating activities of $5,696,917 consisting primarily of our loss of $13,968,001, net with non-cash adjustments of $105,105 in depreciation and amortization charges, $70,000 in bad debt expense, $1,771,854 for equity based compensation and $6,145,229 change in fair value of warrant liability. Additionally, we had a net increase in operating assets of $437,171 and a net increase in operating liabilities of $616,067. Cash used in investing activities was $797,574 consisting primarily of $584,080 of assets acquired under the RedWeb asset purchase agreement and $213,494 for the purchase of equipment and leasehold improvement related to the relocation of our corporate office. Cash provided by financing activities for the nine months ended June 30, 2013 totaled $7,601,500 consisting primarily of proceeds of $5,500,000 from the sale of our Series A Preferred, $2,000,000 from the sale of our common stock, $150,000 from the exercise of warrants, net with $50,000 paid to re-acquire previously issued warrants.

23

On January 7, 2013, we completed the second closing (“Second Closing”) of our transaction with Crede CG II, Ltd. (“Crede”) and sold to Crede 5,500 shares of our Series A Preferred at a price of $1,000 per share, resulting in gross proceeds to us of $5,500,000. On January 8, 2013, we exercised our option and converted the Series A Preferred held by Crede into 25,462,963 shares of our Common Stock at a conversion price of $0.216 per share.

We had entered into a Securities Purchase Agreement (“Purchase Agreement”) with Crede dated November 28, 2012 pursuant to which Crede agreed to purchase the Series A Preferred on the first business day following the date a registration statement covering the resale of all shares of Common Stock issuable pursuant to the Purchase Agreement, including those underlying the Series A Preferred and Series A, B and C Warrants, is declared effective by the SEC. The Company’s registration statement on Form S-3 was declared effective by the SEC on January 4, 2013.

Pursuant to the Purchase Agreement, Crede purchased at the initial closing held on November 29, 2012 (“Initial Closing”) 10,752,688 shares of our Common Stock at a price of $0.186 per share, resulting in gross proceeds to us of $2,000,000. In addition, at the Initial Closing, Crede was issued (i) five year Series A Warrants allowing it to initially purchase 10,752,688 shares of Common Stock at a price of $0.2232 per share, (ii) five year Series B Warrants allowing it to initially purchase 29,569,892 shares of Common Stock at a price of $0.2232 which became exercisable at the Second Closing and (iii) Series C Warrants allowing it to initially purchase 26,881,720 shares of Common Stock which became exercisable for six months after the eleventh trading day following the Second Closing. Crede may also exchange the Warrants for Common Stock pursuant to a Black-Scholes formula. The Series A, B and C Warrants each contain a 9.9% “blocker” so that in no event shall any of the Warrants be exercisable or exchangeable into or for Common Stock to the extent that such exercise or exchange would result in Crede having “beneficial ownership” (within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 9.9% of the Company’s Common Stock.

On January 22, 2013, the Company exercised its option to repurchase the Series C Warrants issued to Crede for $50,000.  On April 25, 2013, Crede effected the cashless exercise of 10,752,688 Series A Warrants and 29,569,862 Series B Warrants, and the Company thereupon issued to Crede an aggregate of 31,257,045 shares of its Common Stock.

Crede has the right to participate in other equity or equity –linked financings completed by the Company for a period of 180 days from January 4, 2013. In addition, the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below $0.186 per share or the market price of the Common Stock on the date the registration statement was is declared effective, for a period of 180 days from the effective date of the registration statement, except for issuances (i) pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar arrangements, (ii) to employees, consultants, directors and officers approved by the Board or pursuant to a plan approved by the Board, (iii) pursuant to one or more contracts entered into by us with third parties which would result in revenues to us during a three-month period equal to an annual run rate of $15 Million in revenues and (iv) pursuant to a contract entered into by us with a third party which would reasonably be expected to result in more than $3 Million in annual receivables.

Until one year after the Second Closing, we are prohibited from entering into any transaction to (i) sell any convertible securities at a conversion rate or other price that is generally based on and/or varies with the trading prices of the our Common Stock at any time after the initial issuance of such convertible securities or (ii) sell securities at a future determined price, including, without limitation, an “equity line of credit” or an “at the market offering.”

Management believes that our positive cash balance and working capital as of June 30, 2013, as well as the proceeds from the securities purchase agreement with Crede entered into on July 19, 2013,  along with our current customer base, projected cash flow and the minimum guaranteed revenues for the next fiscal year will allow us to continue to improve our working capital and to have sufficient capital resources to meet projected cash flow requirements.

We expect capital expenditures to be less than $1,000,000 in fiscal 2013. Our primary investments will be in laboratory equipment to support prototyping, manufacturing and our authentication services.

We may be required to seek additional capital should our current positive working capital fall short. We have no commitments for any future funding and may not be able to obtain additional financing or grants on terms acceptable to us, if at all, in the future. If we are unable to obtain additional capital this could restrict our ability to grow. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock.  In addition, certain of the terms described above in connection with the Crede financing may negatively impact the Company’s ability to obtain financing for the periods indicated.

24

Substantially all of the real property used in our business is leased.

Asset Purchase Agreement

On May 10, 2013, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with RedWeb Technologies Limited (“RedWeb”), a corporation incorporated and registered under the laws of England & Wales, to purchase certain assets of RedWeb (“Purchased Assets”) relating to its forensic tagging security system for a purchase price of £400,000 ($624,080). The Company completed the acquisition of the Purchased Assets on the same day. The Purchased Assets include RedWeb’s Sentry 500 Intruder Spray System, RedWeb’s Advanced Molecular Taggent Technology and all products relating thereto, certain intellectual property and supplies relating to the foregoing. £40,000 ($62,408) of the purchase price shall be held in escrow for up to one year to be applied against the indemnification obligations of RedWeb pursuant to the Asset Purchase Agreement.  The Company assigned $584,080 of the purchase price to intellectual property and the remaining $40,000 was for supplies, which were expensed during the three months ended June 30, 2013.

Subsequent Events

As previously reported on the Current Report on Form 8-K filed by the Company on July 22, 2013, the Company entered into a securities purchase agreement (“Purchase Agreement”) with Crede CG III, Ltd. (“Crede”).  Pursuant to the Purchase Agreement, at the initial closing on July 19, 2013 (“Initial Closing”), Crede purchased 10,695,187 shares of the Company’s Common Stock at a price of $0.187 per share which was the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement.  The Company received gross proceeds of $2,000,000.  Pursuant to the Purchase Agreement, Crede agreed to purchase an additional $5,500,000 of the Company’s Series B Convertible Preferred Stock (“Series B Preferred”) at a purchase price of $1,000 per share on the date a registration statement (as described below) is declared effective by the SEC (“Second Closing”).

The Series B Preferred is convertible at the option of the holder thereof, in whole or in part, from time to time and at any time, at the lesser of (i) the Fixed Conversion Price and (ii) the Non-Fixed Conversion Price. The Fixed Conversion Price is equal to $0.187 per share which is the purchase price for the Common Stock at the Initial Closing.  The Non-Fixed Conversion Price is equal to the consolidated closing bid price of the Company’s Common Stock for the most recently completed trading day as of the time of conversion.  The Series B Preferred will be convertible into Common Stock at the Company’s option, in whole or in part, from time to time during the period beginning one trading day following the effectiveness of the registration statement (as described below) through the eleventh trading day following effectiveness of such registration statement, at the Non-Fixed Conversion Price, provided that certain equity conditions are met and the Company is not in breach of certain conditions.  The Series B Preferred will be automatically converted into Common Stock on the one year anniversary of the issuance of the Series B Preferred at the then applicable Non-Fixed Conversion Price, provided that certain equity conditions are met and the Company is not in breach of certain conditions.  The Series B Preferred contains weighted average anti-dilution protection.  The Series B Preferred will not accrue dividends except to the extent dividends are paid on the Common Stock.  The Company’s Common Stock will be junior in rank to the Series B Preferred with respect to preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company.  The Series B Preferred will generally have no voting rights except as required by law.

The Company also issued Crede at the Initial Closing Warrants with a term of five years (though such term may be extended in certain instances) (“Series A Warrants”) allowing it to purchase 10,695,187 shares of Common Stock at a price of $0.2431 per share which is equal to a 30% premium to the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement.  At the Initial Closing, the Company also issued Crede a second set of Warrants (“Series B Warrants”) allowing it to purchase 29,411,764 shares of Common Stock, which is equal to one share of Common Stock for every share of Common Stock which would be issuable to it if it fully converted the Series B Preferred into Common Stock at the Fixed Conversion Price.  The exercise price of the Series B Warrants is $0.2431 per share, which is equal to a 30% premium to the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement.  The Series B Warrants are not exercisable until the earlier of (i) November 7, 2013 and (ii) the Second Closing, and have a term of five years (though such term may be extended in certain instances).

In addition, at the Initial Closing, the Company issued to Crede a third set of Warrants (“Series C Warrants”) which is only exercisable for six months from the earlier of (i) November 7, 2013 and (ii) after the eleventh trading day following the Second Closing.  The Series C Warrants will allow Crede to purchase, at a price of $0.2431 per share (equal to a 30% premium to the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement), 26,737,967 shares of Common Stock, which is equal to one-third the sum of (i) the number of shares of Common Stock issued at the Initial Closing, (ii) the number of shares of Common Stock which would be issuable to it if it fully converted the Series B Preferred into Common Stock at the Fixed Conversion Price, (iii) the number of shares of Common Stock subject to the Series A Warrants and (iv) the number of shares of Common Stock subject to the Series B Warrants.

25

The Series B and Series C Warrants provide the Company with an option to repurchase any remaining unexercised portion of such Warrants for a repurchase price equal to $50,000, if the Second Closing is terminated pursuant to the Purchase Agreement. The Company also has the option to repurchase the Series C Warrants at an aggregate repurchase price equal to $10,000 at the close of trading on the tenth trading day immediately following the Second Closing but only if the registration statement (described below) is effective and covers and is available for use for the resale of (i) all shares of Common Stock issued at the First Closing, (ii) all shares of Common Stock issued upon conversion of the Series B Preferred, (iii) all shares of Common Stock which would then be issuable if the full then unconverted portion of the Series B Preferred were then fully converted into Common Stock at the then applicable conversion price, (iv) all shares of Common Stock subject to the Series A Warrants and (v) all shares of Common Stock subject to the Series B Warrants.

Crede may exercise Series A and Series B Warrants by paying in cash or on a cashless basis by exchanging such Warrants for Common Stock using a negotiated Black-Scholes value.  In the event that the Common Stock trades at a price 25% or more above the exercise price of the Series A and Series B Warrants for a period of 20 consecutive days (with average daily dollar volume of Common Stock on the OTC Bulletin Board at least equal to $300,000), the Company may obligate Crede to exercise such Warrants for cash.

Pursuant to a registration rights agreement between the Company and Crede, the Company agreed to file a registration statement within 30 days of the Initial Closing and to use its best efforts to get such registration statement effective within 90 days.  The registration statement will cover the resale of all shares of Common Stock issuable pursuant to the Purchase Agreement, including the shares of Common Stock underlying the Series B Preferred and Series A, B and C Warrants.  The registration statement was declared effective by the SEC on July 31, 2013.  The Company has also agreed to prepare and file amendments and supplements to the registration statement to the extent necessary to keep the registration statement effective for the period of time required under the Purchase Agreement.  In the event the registration statement failed to be declared effective within the 90 day period, the Company would have been subject to monthly penalties which would expire six months after the Initial Closing.

The Company agreed to pay Crede an investment fee equal to $100,000 at the Initial Closing and $265,000 at the Second Closing.

The Series B Preferred and the Series A, B and C Warrants each contain a 9.9% “blocker” so that in no event shall the Series B Preferred or any of the Series A, B and C Warrants be convertible or exercisable (including through the cashless exercise exchange provision) into or for Common Stock to the extent that such conversion or exercise would result in Crede having “beneficial ownership” (within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 9.9% of the Common Stock. Crede would, however, have the right from time to time to convert, exercise or exchange for shares of Common Stock, which over time would aggregate to greater than 9.9% beneficial ownership if all such shares of Common Stock so acquired had been held at one time by Crede.

Crede has the right to participate in other equity or equity-linked financings completed by the Company for a period of 180 days from the later of the Initial Closing or the date the registration statement goes effective.

In addition, the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below $0.187 per share or the market price of the Common Stock on the date the registration statement is declared effective, for a period of 180 days from the effective date of the registration statement, except for issuances (i) pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar arrangements, (ii) to employees, consultants, directors and officers approved by the Board or pursuant to a plan approved by the Board, (iii) pursuant to one or more contracts entered into by the Company with third parties which would result in revenues to the Company during a three-month period equal to an annual run rate of $15 Million in revenues and (iv) pursuant to a contract entered into by the Company with a third party which would reasonably be expected to result in more than $3 Million in annual receivables.

Until one year after the Second Closing, the Company is prohibited from entering into any transaction to (i) sell any convertible securities at a conversion rate or other price that is generally based on and/or varies with the trading prices of the Company’s Common Stock at any time after the initial issuance of such convertible securities or (ii) sell securities at a future determined price, including, without limitation, an “equity line of credit” or an “at the market offering.”

On July 31, 2013, the Company completed the Second Closing of its transaction with Crede and sold 5,500 shares of Series B Preferred to Crede at a price of $1,000 per share.  The Company received gross proceeds of $5,500,000 less an investment fee of $265,000.

Product Research and Development

We anticipate spending approximately $600,000 for product research and development activities during the next twelve months.

Acquisition of Plant and Equipment and Other Assets

We do not anticipate the sale of any material property, plant or equipment during the next 12 months.  We do anticipate spending approximately $800,000 on the acquisition of intellectual rights and leasehold improvements during the next 12 months To manage our expected growth, if any, over the next 2 to 3 years.  As disclosed in Note G in the accompanying condensed consolidated financial statements, during June 2013 we relocated our corporate office to a larger facility.

26

Number of Employees

We currently have 44 full-time employees and four part-time employees, including three in management, 34 in operations, 9 in sales and marketing, one in human resources, and one in investor relations.   Expenses related to travel, marketing, salaries, and general overhead will be increased as necessary to support our anticipated growth in revenue.  In order for us to attract and retain quality personnel, we anticipate we will have to offer competitive salaries to future employees.  We anticipate that it may become desirable to add additional full and/ or part time employees to discharge certain critical functions during the next 12 months.    There is no guarantee that we will be successful in raising the funds required or generating revenues sufficient to fund the projected increase in the number of employees.  As we continue to expand, we will incur additional costs for personnel. As of June 23, 2012, we began working with Insperity Inc. to help us manage many of our back-end administrative human resources responsibilities. This change is being done to provide Fortune 500 type benefits to our current employees, making us more attractive to new hires as well as saving us money by not having to build out an internal HR department at this point in time. Insperity Inc. is a publicly traded company (NYSE: NSP) that supports businesses with payroll, medical benefits, online-training, and human resources services and support.

We do not have any off-balance sheet arrangements.

Inflation

The effect of inflation on our revenue and operating results was not significant.

Item 3. - Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 under the Exchange Act of 1934, as amended (the “Exchange Act”) and are not required to provide the information required under this item.

Item 4. - Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief  Financial Officer, of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act).  Based on the evaluation of these disclosure controls and procedures, the Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, 2013, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

During the fiscal quarter ended June 30, 2013, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

27

Part II - Other Information

Item 1 – Legal Proceedings

“Item 3 – Legal Proceedings” of our most recent Annual Report on Form 10-K filed on December 20, 2012 and “Item 1 – Legal Proceedings” of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, as filed on May 15, 2013, include a discussion of our legal proceedings.  During the fiscal quarter ended June 30, 2013, there have been no material changes from the legal proceedings discussed in our Form 10-K and Form 10-Q except as follows:

Smartwater, Ltd. v. Applied DNA Sciences, Inc. (No. 12-CV-05731-S-AKT (E.D.N.Y.)

The Company’s motion to dismiss plaintiff’s complaint is pending before the Court in the Eastern District of New York. An initial conference with the Court was held on February 21, 2013, at which time the Court directed the conduct of limited document discovery pending the Court’s decision on the motion to dismiss. On June 21, 2013, plaintiff filed a motion seeking leave from the Court to file an amended complaint asserting additional allegations in support of its claims. The Company filed its opposition to the motion on July 29, 2013. The Company believes that none of its products infringe any claims under either of plaintiff’s patents, and moreover notes that one of plaintiff’s patents has expired and the other is due to expire on February 25, 2014. The Company believes the allegations in the complaint are without merit and intends to defend the action vigorously. The ultimate outcome of this claim cannot be determined at the date of this report.

28

Item 6 – Exhibits

10.1*	Asset Purchase Agreement, dated May 10, 2013, between Applied DNA Sciences, Inc. and RedWeb Technologies Limited
10.2*	Agreement of Lease, dated June 14, 2013, between Applied DNA Sciences, Inc. and Long Island High Technology Incubator, Inc.
31.1*	Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended
31.2*	Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as amended
32.1**	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)
32.2**	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)
101 INS***	XBRL Instance Document
101 SCH***	XBRL Taxonomy Extension Schema Document
101 CAL***	XBRL Taxonomy Extension Calculation Linkbase Document
101 LAB***	XBRL Extension Label Linkbase Document
101 PRE***	XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** Furnished herewith.

*** In accordance with Rule 406T of Regulation S-T, the information in Exhibit 101 is furnished and deemed not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Exchange Act of 1934, and otherwise is not subject to liability under these sections and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

29

Signatures

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Applied DNA Sciences, Inc.
Dated: August 13, 2013	/s/ JAMES A. HAYWARD, PH. D.
	James A. Hayward, Ph. D.
	Chief Executive Officer  (Duly authorized officer)

/s/ KURT H. JENSEN

Kurt H. Jensen

Chief Financial Officer

 (Duly authorized officer and

 principal financial officer)

30

EX-10.1

Execution Version

ASSET PURCHASE AGREEMENT

between

REDWEB TECHNOLOGIES LIMITED

and

APPLIED DNA SCIENCES, INC.

dated as of

May 10, 2013

TABLE OF CONTENTS

		Page
ARTICLE I           PURCHASE AND SALE		1
Section 1.01	Purchase and Sale of Assets	1
Section 1.02	No Liabilities	1
Section 1.03	Purchase Price	1
Section 1.04	Inventory	2
Section 1.05	Passing of Title and Risk	2
ARTICLE II          CLOSING		2
Section 2.01	Closing	2
Section 2.02	Closing Deliverables	3
ARTICLE III         REPRESENTATIONS AND WARRANTIES OF SELLER		4
Section 3.01	Organization and Authority of Seller; Enforceability	4
Section 3.02	No Conflicts; Consents	4
Section 3.03	Title to Purchased Assets	4
Section 3.04	Condition of Assets	4
Section 3.05	Inventory	5
Section 3.06	Intellectual Property	5
Section 3.07	Compliance With Laws	6
Section 3.08	Legal Proceedings	6
Section 3.09	Brokers	6
ARTICLE IV         REPRESENTATIONS AND WARRANTIES OF BUYER		6
Section 4.01	Organization and Authority of Buyer; Enforceability	6
Section 4.02	No Conflicts; Consents	7
Section 4.03	Legal Proceedings	7
Section 4.04	Brokers	7
ARTICLE V          COVENANTS		7
Section 5.01	Intellectual Property Transfer	7
Section 5.02	Public Announcements	7
Section 5.03	Bulk Sales Laws	8
Section 5.04	Transfer Taxes	8
Section 5.05	Further Assurances	8

-i-

TABLE OF CONTENTS

(continued)

		Page
Section 5.06	Non-Competition	8
Section 5.07	Use of Name	8
Section 5.08	Transition and Cooperation	9
ARTICLE VI         INDEMNIFICATION		9
Section 6.01	Survival	9
Section 6.02	Indemnification By Seller	9
Section 6.03	Indemnification By Buyer	11
Section 6.04	Indemnification Procedures	11
Section 6.05	Escrow Fund	11
Section 6.06	Tax Treatment of Indemnification Payments	12
Section 6.07	Effect of Investigation	12
Section 6.08	Cumulative Remedies	12
ARTICLE VII        MISCELLANEOUS		12
Section 7.01	Expenses	12
Section 7.02	Notices	13
Section 7.03	Interpretation	13
Section 7.04	Severability	13
Section 7.05	Entire Agreement	14
Section 7.06	Successors and Assigns	14
Section 7.07	No Third-party Beneficiaries	14
Section 7.08	Amendment and Modification	14
Section 7.09	Waiver	14
Section 7.10	Governing Law	14
Section 7.11	Submission to Jurisdiction	14
Section 7.12	Specific Performance	15
Section 7.13	Counterparts	15

-ii-

ASSET PURCHASE AGREEMENT

This Asset Purchase Agreement (this “Agreement”), dated as of May 10, 2013, is entered into between RedWeb Technologies Limited, a corporation incorporated and registered  under the laws of England & Wales with company number 06997431 (“Seller”) and Applied DNA Sciences, Inc., a corporation organized under the laws of the State of Delaware (“Buyer”).

RECITALS

WHEREAS, Seller wishes to sell and assign to Buyer, and Buyer wishes to purchase and assume from Seller, the rights and obligations of Seller to the Purchased Assets  (as defined herein), subject to the terms and conditions set forth herein;

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

ARTICLE I

PURCHASE AND SALE

Section 1.01     Purchase and Sale of Assets.  Subject to the terms and conditions set forth herein, Seller shall sell, assign, transfer, convey and deliver to Buyer, and Buyer shall purchase from Seller, all of Seller’s right, title and interest in the assets set forth in Section 1.01 of the disclosure schedules (“Disclosure Schedules”) attached hereto (the “Purchased Assets”), free and clear of any mortgage, pledge, lien, charge, security interest, claim or other encumbrance of any kind (“Encumbrance”).  The Purchased Assets shall exclude Seller’s Trackable Assets and GPS Tracking products (“Excluded Assets”).

Section 1.02     No Liabilities.  Buyer shall not assume any liabilities or obligations of Seller of any kind, whether known or unknown, contingent, matured or otherwise, whether currently existing or hereinafter created (“Seller Liability”).  Without limiting the generality of the foregoing, Buyer shall not assume any Seller Liability arising out of or constituting (i) the operation of Seller’s business prior to the Closing Date, including those related to Purchased Assets, (ii) any contingent liability, (iii) any contract of Seller, (iv) any fees or expenses arising out of this Agreement or the Closing, (v) any Action as defined in Section 3.08 existing on the Closing Date whether or not related to the Purchased Assets, (vi) any Taxes of Seller for any period, or arising out of or owing through operation of Seller’s business prior to the Closing Date, and (vii) any actions or omissions of Seller on or prior to the Closing Date.

Section 1.03     Purchase Price.

(a)           The purchase price (the “Purchase Price”) for the Purchased Assets shall be £400,000.  At the Closing, Buyer shall pay (i) to Seller £360,000 by wire transfer of immediately available funds in accordance with the wire transfer instructions set forth in Section 1.03 of the Disclosure Schedules and (ii) £40,000 (the “Escrow Fund”) by wire transfer of immediately available funds to a bank account that Buyer shall open and maintain for the purpose of holding such Escrow Fund.

(b)           Exhibit A sets forth an allocation of the Purchase Price (and other capitalized costs) among the Purchased Assets. Buyer and Seller shall report any federal, state, local and foreign Tax consequences of the transaction in a manner consistent with such allocation. Buyer and Seller further covenant and agree not to take a position with respect to Taxes that is inconsistent with such allocation on any Tax return or otherwise, except as may be required by law.

Section 1.04     Inventory.  Within thirty (30) days of Closing, Buyer will perform an audit of the Inventory (“Audited Inventory”) to verify the accuracy of the Inventory count in Section 1.01 of the Disclosure Schedules. If such audit shows that the Audited Inventory count is less than the Inventory count specified in Section 1.01 of the Disclosure Schedules, then Buyer shall be entitled to a reimbursement (“Inventory Reimbursement”). The Inventory Reimbursement shall be calculated by subtracting the Audited Inventory count from the Inventory count as specified in Section 1.01 of the Disclosure Schedules and multiplying the difference by the Seller-established price for such Inventory item. Such Inventory Reimbursement shall be paid to Buyer by Seller  in accordance with the indemnification procedures set forth in Section 6.04, provided, that Buyer shall include in its written notice to Seller its calculation of the Inventory Reimbursement.

Section 1.05     Passing of Title and Risk.

(a)           Title to and beneficial ownership of:

(i)           The Purchased Assets which are capable of transfer by delivery shall pass on their delivery and such delivery shall be deemed to take place on their being made available by Seller for collection on Closing in accordance with Section 2.02(b); and

(ii)          All other Purchased Assets shall pass on Closing.

(b)           The risk in respect of all Purchased Assets shall pass to Buyer as from the time when title to them passes.

(c)           All of the Purchased Assets shall as from Closing (pending any necessary legal assignment or assurance of them) be held by Seller on trust for Buyer absolutely and Seller shall exercise all rights in respect of them for and on behalf of Buyer and as Buyer may reasonably request.

ARTICLE II

CLOSING

Section 2.01     Closing.  The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place simultaneously with the execution of this Agreement on the date of this Agreement (the “Closing Date”) at the offices of Fulbright & Jaworski L.L.P., 666 Fifth Avenue, New York, N.Y. 10103.  The consummation of the transactions contemplated by this Agreement shall be deemed to occur at 12:01 a.m. on the Closing Date.

2

Section 2.02     Closing Deliverables.

(a)           At the Closing, Seller shall deliver to Buyer the following:

(i)            a bill of sale in the form of Exhibit B hereto (the “Bill of Sale”) and duly executed by Seller, transferring the Purchased Assets to Buyer;

(ii)           the patent, trademark, and domain name assignments in the form of Exhibit C hereto (the “Intellectual Property Assignments”) and duly executed by Seller, transferring all of Seller’s right, title and interest in and to the trademark registrations and applications, patents and patent applications and domain name registrations included in the Purchased Assets to Buyer;

(iii)          all documents of title or other records establishing title to the Purchased Assets (or any of them);

(iv)          a certificate of the Secretary or Assistant Secretary (or equivalent officer) of Seller certifying as to (A) the resolutions of the board of directors of Seller, duly adopted and in effect, which authorize the execution, delivery and performance of this Agreement and the transactions contemplated hereby, and (B) the names and signatures of the officers of Seller authorized to sign this Agreement and the documents to be delivered hereunder; and

(v)           such other customary instruments of transfer, assumption, filings or documents, in form and substance reasonably satisfactory to Buyer, as may be required to give effect to this Agreement.

(b)           At the Closing, Seller shall make available for collection at the premises at which they are currently held, used or stored, such of the Purchased Assets as are transferable by delivery.

(c)           At the Closing, Buyer shall deliver to Seller the following:

(i)            The Purchase Price;

(ii)           the Bill of Sale executed by Buyer;

(iii)          the Intellectual Property Assignments duly executed by Buyer; and

(iv)          a certificate of the Secretary or Assistant Secretary (or equivalent officer) of Buyer certifying as to (A) the resolutions of the board of directors of Buyer, duly adopted and in effect, which authorize the execution, delivery and performance of this Agreement and the transactions contemplated hereby, and (B) the names and signatures of the officers of Buyer authorized to sign this Agreement and the documents to be delivered hereunder.

3

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF SELLER

Seller represents and warrants to Buyer that the statements contained in this Article III are true and correct as of the date hereof.  For purposes of this Article III, “Seller’s knowledge,” “knowledge of Seller” and any similar phrases shall mean the actual or constructive knowledge of any director or officer of Seller, after due inquiry.

Section 3.01     Organization and Authority of Seller; Enforceability.  Seller is a corporation duly incorporated and registered in England & Wales with company number 06997431 and is validly existing and in good standing under the laws thereunder.  Seller has full corporate power and authority to enter into this Agreement and the documents to be delivered hereunder, to carry out its obligations hereunder and to consummate the transactions contemplated hereby.  The execution, delivery and performance by Seller of this Agreement and the documents to be delivered hereunder and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action on the part of Seller.  This Agreement and the documents to be delivered hereunder have been duly executed and delivered by Seller, and (assuming due authorization, execution and delivery by Buyer) this Agreement and the documents to be delivered hereunder constitute legal, valid and binding obligations of Seller, enforceable against Seller in accordance with their respective terms, in each case, subject to bankruptcy, insolvency, reorganization, moratorium and similar requirements of general application relating to or affecting creditor’ rights and to general principles of equity.

Section 3.02     No Conflicts; Consents.  The execution, delivery and performance by Seller of this Agreement and the documents to be delivered hereunder, and the consummation of the transactions contemplated hereby, do not and will not: (a) violate or conflict with the certificate of incorporation, by-laws or other organizational documents of Seller; (b) violate or conflict with any judgment, order, decree, statute, law, ordinance, rule or regulation applicable to Seller or the Purchased Assets; (c) conflict with, or result in (with or without notice or lapse of time or both) any violation of, or default under, or give rise to a right of termination, acceleration or modification of any obligation or loss of any benefit under any contract or other instrument to which Seller is a party or to which any of the Purchased Assets are subject; or (d) result in the creation or imposition of any Encumbrance on the Purchased Assets.  No consent, approval, waiver or authorization is required to be obtained by Seller from any person or entity (including any governmental authority) in connection with the execution, delivery and performance by Seller of this Agreement and the consummation of the transactions contemplated hereby.

Section 3.03     Title to Purchased Assets.  Seller owns and has good title to the Purchased Assets, free and clear of Encumbrances.

Section 3.04     Condition of Assets.  The Purchased Assets are in good condition and are adequate for the uses to which they are being put, and none of such Purchased Assets are in need of maintenance or repairs except for ordinary, routine maintenance and repairs that are not material in nature or cost.  The Products are free from defects in design, workmanship and materials and are in conformity with their applicable specifications.

4

Section 3.05     Inventory.  All inventory, finished goods, raw materials, work in progress, packaging, supplies, parts and other inventories (collectively “Inventory”) included in the Purchased Assets consist of a quality and quantity usable and salable in the ordinary course of business consistent with past practice.  All Inventory is owned by Seller free and clear of all Encumbrances, and no Inventory is held on a consignment basis.

Section 3.06     Intellectual Property.

(a)           Section 3.06(a) of the Disclosure Schedules is a complete and accurate list of  all (i) registered Seller Trademarks, registered domain names and issued Seller Patents; and (ii) each pending application with respect to any Intellectual Property specified in (i) above (“Seller Intellectual Property”).  Seller possesses all right, title, and interest in and to and has adequate, valid and enforceable rights to use all the Seller Intellectual Property free and clear of all Encumbrances.  Seller is not bound by any outstanding judgment, injunction, order or decree restricting the use of the Seller Intellectual Property, or restricting the licensing or assignment thereof to any person or entity.  Seller has not granted any license, option, covenant not to sue or other right to a third party to use or commercially exploit Seller Intellectual Property.  Seller has not been required to pay any royalties or make any payments to any third party to use the Seller Intellectual Property or to reproduce, make derivative works, reproduce, make, sell or otherwise commercially exploit any products or services using the Seller Intellectual Property and to its knowledge after the Seller Intellectual Property has been transferred to Buyer, Buyer will not be required to make any payments to any third party to use the Seller Intellectual Property or to reproduce, make derivative works, reproduce, make, sell or otherwise commercially exploit any products or services using the Seller Intellectual Property.  With respect to Seller Intellectual Property, (i) the Seller has not received any notice that such Intellectual Property is not valid, subsisting, enforceable and in full force and effect and (ii) Seller has paid all maintenance fees and made all filings required to maintain Seller’s ownership thereof.  For all such Seller Intellectual Property (except for Know-How), Section 3.06(a) of the Disclosure Schedules lists (A) the jurisdiction where the application or registration is located, (B) the application or registration number, and (C) the application or registration date.

(b)           The Seller has not received any notice that the Seller’s prior and current use of the Seller Intellectual Property has or does infringe, violate, dilute or misappropriate the Intellectual Property of any person or entity and there are no claims pending or threatened by any person or entity with respect to the ownership, validity, enforceability, effectiveness or use of the Seller Intellectual Property and to its knowledge after the Seller Intellectual Property has been transferred to Buyer, Buyer’s use will not infringe, violate, dilute or misappropriate the Intellectual Property of any person or entity.  No person or entity is infringing, misappropriating, diluting or otherwise violating any of the Seller Intellectual Property, and neither Seller nor any affiliate of Seller has made or asserted any claim, demand or notice against any person or entity alleging any such infringement, misappropriation, dilution or other violation.  Seller has not received any communication, and no action has been instituted, settled or threatened that alleges any such infringement, misappropriation, dilution or other violation.  Other than the Seller Intellectual Property assigned hereunder, no other Intellectual Property is needed to make or sell the RedWeb Sentry 500 Intruder Spray, the Box System, the Forensic Tagging Products (as defined in Section 1.01) and enigmaTAG.

5

(c)           All current and former employees, agents, and consultants of the Seller who have made material contributions to the development of the Seller Intellectual Property or who have had access in any material respect to the Seller’s confidential and proprietary information with respect to the Seller Intellectual Property have entered into enforceable contractual obligation with Seller whereby (a) Seller is entitled to all ownership rights in any Seller Intellectual Property, that the employee, agent, or consultant may have invented, discovered, originated, made, or conceived while working for Seller, and all such ownership rights are duly assigned to Seller, and (b) the employee, agent, or consultant has agreed, subject to applicable Law, to hold and maintain in confidence all confidential and proprietary information of the Seller.  The Seller’s general practice has been to require all employees, agents, and consultants who contribute to the development of Intellectual Property, or who have had access to confidential and proprietary information with respect to the Intellectual Property, to enter into Invention and Confidentiality Agreements.  For any Seller Intellectual Property where an employee may have rights under laws related to employees’ rights in and to their own inventions made in the course of their employment, Seller has timely taken steps to protect Sellers’ ownership in such Seller Intellectual Property.

Section 3.07     Compliance With Laws.  So far as the Seller is aware, Seller has complied, and is now complying, with all applicable federal, state and local laws and regulations applicable to the manufacture sale, packaging and labeling of the Purchased Assets.

Section 3.08     Legal Proceedings.  There is no claim, action, suit, proceeding or governmental investigation (“Action”) of any nature pending or, to Seller’s knowledge, threatened against or by Seller (a) relating to or affecting the Purchased Assets; or (b) that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.  No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

Section 3.09     Brokers.  No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF BUYER

Buyer represents and warrants to Seller that the statements contained in this Article IV are true and correct as of the date hereof.  For purposes of this Article IV, “Buyer’s knowledge,” “knowledge of Buyer” and any similar phrases shall mean the actual or constructive knowledge of any director or officer of Buyer, after due inquiry.

Section 4.01     Organization and Authority of Buyer; Enforceability.  Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware.  Buyer has full corporate power and authority to enter into this Agreement and the documents to be delivered hereunder, to carry out its obligations hereunder and to consummate the transactions contemplated hereby.  The execution, delivery and performance by Buyer of this Agreement and the documents to be delivered hereunder and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action on the part of Buyer.  This Agreement and the documents to be delivered hereunder have been duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by Seller) this Agreement and the documents to be delivered hereunder constitute legal, valid and binding obligations of Buyer enforceable against Buyer in accordance with their respective terms, in each case, subject to bankruptcy, insolvency, reorganization, moratorium and similar requirements of general application relating to or affecting creditor’ rights and to general principles of equity.

6

Section 4.02     No Conflicts; Consents.  The execution, delivery and performance by Buyer of this Agreement and the documents to be delivered hereunder, and the consummation of the transactions contemplated hereby, do not and will not: (a) violate or conflict with the certificate of incorporation, by-laws or other organizational documents of Buyer; or (b) violate or conflict with any judgment, order, decree, statute, law, ordinance, rule or regulation applicable to Buyer.  No consent, approval, waiver or authorization is required to be obtained by Buyer from any person or entity (including any governmental authority) in connection with the execution, delivery and performance by Buyer of this Agreement and the consummation of the transactions contemplated hereby.

Section 4.03     Legal Proceedings.  There is no Action of any nature pending or, to Buyer’s knowledge, threatened against or by Buyer that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.  No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

Section 4.04     Brokers.  No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Buyer.

ARTICLE V

COVENANTS

Section 5.01     Intellectual Property Transfer.  To enable Buyer to exercise the rights granted under this Agreement, Seller will promptly deliver or otherwise provide to Buyer Seller Know-How within the possession or Control of Seller or any of its Affiliates.  Seller will promptly deliver to Buyer tangible copies of Seller Know-How including documents, files, diagrams, specifications, designs, schematics, reports, records, laboratory notebooks, data, materials, prototypes, test devices, models and simulations, inventory or other written or other tangible material in Seller’s or its Affiliates’ possession or Control in any media, to the extent it discloses or embodies Seller Know-How.

Section 5.02     Public Announcements.  Unless otherwise required by applicable law, neither party shall make any public announcements regarding this Agreement or the transactions contemplated hereby without the prior written consent of the other party (which consent shall not be unreasonably withheld or delayed), it being understood that Buyer will have to make a filing on Form 8-K with the Securities and Exchange Commission.

7

Section 5.03     Bulk Sales Laws.  Except as required by law, the parties hereby waive (to the extent permitted by applicable law) compliance with the provisions of any bulk sales, bulk transfer or similar laws of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Purchased Assets to Buyer.

Section 5.04     Transfer Taxes.  All transfer, documentary, sales, use, stamp, registration, and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement and the documents to be delivered hereunder shall be borne and paid by Buyer when due, other than any Taxes payable in respect of the income, profits or chargeable gains of Seller, which shall be borne and paid by Seller. The parties acknowledge and agree that it is considered that section 49(1) of VATA and article 5 of the Value Added Tax (Special Provisions) Order 1995 will apply to the transaction contemplated by this Agreement, so that the transaction is treated as a transfer of a going concern. Seller and Buyer shall use all reasonable endeavours to secure that pursuant to such provisions the transaction contemplated by this Agreement is treated as neither a supply of goods nor a supply of services for VAT purposes. If notwithstanding the foregoing, UK VAT is chargeable, Buyer shall pay such VAT against production of a valid VAT invoice from Seller.

Section 5.05     Further Assurances.  Following the Closing, each of the parties hereto shall execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement and the documents to be delivered hereunder.

Section 5.06     Non-Competition.  Seller undertakes with Buyer that it shall not, and that it shall procure that no member of Seller’s group shall, and that the Seller’s majority stockholder, Valhalla Investments, Inc., shall not, for a period of 36 months following the Closing: (i)  directly or indirectly, in any capacity, compete in the United States and Europe with (x) the business of Buyer in the manufacture, production, distribution or sale of any of the Purchased Assets or (y) the supply of any services Buyer provides in connection with the Purchased Assets, (ii) make any use of or disclose any Confidential Information of Buyer, including that related to the Purchased Assets, and (iii) solicit or employ any employees of or consultants to Buyer.  “Confidential Information” means information with respect to Buyer’s business, including the business arising out of the Purchased Assets, relating to customers, suppliers, pricing information, other financial information, techniques and capabilities, intellectual property, product information, market information, processes, formulae, trade secrets, marketing plans, etc. For the avoidance of doubt, nothing in this Section 5.06 shall restrict the Seller in the manufacture, production, distribution or sale of the Excluded Assets.

Section 5.07     Use of Name.

(a)           Seller agrees that following the Closing it will not use the name “RedWeb” or any variation thereof or any name containing “RedWeb” with respect to its business, products, website, advertising or any promotional materials (except as specifically provided for in Section 5.07(b) below) and that it will immediately following the Closing change its corporate name to a name not including “RedWeb.” In addition, Seller shall change the domain name of its website so as not to include “RedWeb” in its website (except as specifically provided for in Section 5.07(b) below) and shall execute a domain name assignment as set forth on Exhibit D. The Buyer agrees that for a period of 2 years following the Closing it shall maintain the domain name redwebsecurity.com and shall ensure that (i) all e-mails sent to the e-mail addresses alex.shaw@redwebsecurity.com and alex@redwebsecurity.com are automatically forwarded to such e-mail address as the Seller shall nominate and (ii) the web link http://gps.redwebsecurity.com is automatically re-directed to such web page as the Seller shall nominate.

8

(b)           For the avoidance of doubt, nothing in Section 5.07(a) shall prevent Seller, Valhalla Investments, Inc. or any company in which either of them is a shareholder from: (i) using the name “RedWeb Trackers,” (ii) using any trademark relating to the tracking business of Seller or (iii) operating a website under the domain names redwebtrackers.co.uk or redwebtrackers.com, in all cases, only as they specifically relate to the Trackable Assets and GPS Tracking products currently sold by Seller.

Section 5.08     Transition and Cooperation.  From and after the Closing, Buyer shall make reasonable commercial efforts to cause Chris Taylor to assist Seller in transitioning or transferring the control and enjoyment of the Purchased Assets to Buyer.

ARTICLE VI

INDEMNIFICATION

Section 6.01     Survival.  Subject to the limitations and other provisions of this Agreement, the representations and warranties contained herein shall survive the Closing and shall remain in full force and effect until the date that is one year from the Closing Date; provided, that the indemnification provisions set forth in Section 6.02(b) shall survive indefinitely. All covenants and agreements of the parties contained herein shall survive the Closing indefinitely or for the period explicitly specified therein.

Section 6.02     Indemnification By Seller.

(a)           Subject to the other terms and conditions of this Article VI, Seller shall defend, indemnify and hold harmless Buyer, its affiliates and their respective stockholders, directors, officers and employees from and against all claims, judgments, damages, liabilities, settlements, losses, costs and expenses, including attorneys’ fees and disbursements, arising from or relating to:

(i)        any inaccuracy in or breach of any of the representations or warranties of Seller contained in this Agreement;

(ii)       any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Seller pursuant to this Agreement or any document to be delivered hereunder; or

(iii)      any asset which is not a Purchased Asset or any Seller Liability (including but not limited to those set forth in Section 1.02).

(b)           It is the intention of the parties that all employees and workers of Seller (and any Seller Affiliates, or suppliers of services to Seller or Seller Affiliates (“Supplier”)) will remain employed by Seller (or relevant Seller Affiliate or Supplier). Therefore, if as a consequence of the transaction contemplated by this Agreement, any:

9

(i)           contract of employment of any employee, worker, former employee or former worker of Seller or any Seller Affiliate or Supplier shall or shall be alleged to have transferred from Seller (or relevant Seller Affiliate or Supplier) to Buyer (or any Buyer Affiliate) pursuant to the Transfer of Undertakings (Protection of Employment) Regulations 2006, as amended (the “Transfer Regulations”) or otherwise by operation of law (“Undisclosed Employee”) at any time; or

(ii)          liability in respect of the employment (including any obligation or liability in relation to a pension scheme) or the termination of employment of any employee, worker, former employee or former worker of Seller or any Seller Affiliate or Supplier shall or shall be alleged to have transferred from Seller (or relevant Seller Affiliate or Supplier) to Buyer (or any Buyer Affiliate) pursuant to the Transfer Regulations or otherwise by operation of law (“Undisclosed Liability”) at any time; then:

1.           Buyer (or relevant Buyer Affiliate), may, upon becoming aware of a transfer of an Undisclosed Employee or allegation thereof, terminate such contract forthwith; and

2.           Seller shall indemnify Buyer (on behalf of itself and each Buyer Affiliate) against all Termination Costs and all Legal Proceedings and Losses arising as a result of the termination of any Undisclosed Employee’s employment, any Undisclosed Liability and any and all liabilities arising out of any failure or alleged failure of any party to comply with its obligations under the Transfer Regulations (including, but not limited to, Regulation 13 and 15 of the Transfer Regulations). There shall be no limit on Seller’s liability in respect of any claims arising under this Section 6.02(b).

(iii)           Buyer shall consult with Seller before terminating the contract of any Undisclosed Employee or settling any Undisclosed Liability and the Seller shall be entitled at its own cost and expense, to defend any claim brought by an Undisclosed Employee or in respect of an Undisclosed Liability using such legal advisers as it sees fit.

(c)           If the EPO patent (filing number 12152848) (“European Patent”) has not issued with adequate claims to cover the commercial product by the date that is the one-year anniversary of the Closing Date, then Seller shall reimburse Buyer in the amount of £35,000. Such reimbursement shall be paid to Buyer in accordance with the indemnification procedures set forth in Section 6.04. Buyer will take reasonable steps to timely prosecute claims to cover the commercial product in the European Patent.

(d)          The aggregate liability of Seller in respect of all claims under this Agreement or any document to be delivered hereunder shall not exceed the amount of the Escrow Fund, except as specifically provided for in Section 6.02(b) above.

10

Section 6.03     Indemnification By Buyer.  Subject to the other terms and conditions of this Article VI, Buyer shall defend, indemnify and hold harmless Seller, its affiliates and their respective stockholders, directors, officers and employees from and against all claims, judgments, damages, liabilities, settlements, losses, costs and expenses, including attorneys’ fees and disbursements, arising from or relating to:

(a)           any inaccuracy in or breach of any of the representations or warranties of Buyer contained in this Agreement or any document to be delivered hereunder; or

(b)           any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Buyer pursuant to this Agreement or any document to be delivered hereunder.

Section 6.04     Indemnification Procedures.

(a)           Whenever any claim shall arise for indemnification hereunder, the party entitled to indemnification (the “Indemnified Party”) shall promptly provide written notice of such claim to the other party (the “Indemnifying Party”), which notice shall contain sufficient detail to allow the Indemnifying Party to reasonably assess the nature and amount of the claim.

(b)           In connection with any claim giving rise to indemnity hereunder resulting from or arising out of any Action by a person or entity who is not a party to this Agreement, the Indemnifying Party, at its sole cost and expense and upon written notice to the Indemnified Party, may assume the defense of any such Action with counsel reasonably satisfactory to the Indemnified Party.  The Indemnified Party shall be entitled to participate in the defense of any such Action, with its counsel and at its own cost and expense.  If the Indemnifying Party does not assume the defense of any such Action, the Indemnified Party may, but shall not be obligated to, defend against such Action in such manner as it may deem appropriate, including, but not limited to, settling such Action, after giving notice of it to the Indemnifying Party, on such terms as the Indemnified Party may deem appropriate and no action taken by the Indemnified Party in accordance with such defense and settlement shall relieve the Indemnifying Party of its indemnification obligations herein provided with respect to any damages resulting therefrom.  The Indemnifying Party shall not settle any Action without the Indemnified Party’s prior written consent (which consent shall not be unreasonably withheld or delayed).

(c)           Buyer shall seek recovery of losses in connection with any indemnification claims as follows:

(i)        first, from the amounts held in the Escrow Fund (as described below), until (x) such funds have been depleted or (y) the remaining balance of the Escrow Fund has been released to Seller (minus the aggregate amount of all outstanding claims on such date) upon the expiration of the twelve (12) month escrow period, in accordance with Section 6.05(c); and

(ii)       second, and only in the case of those claims arising from Section 6.02(b), directly from Seller.

Section 6.05     Escrow Fund.

(a)           At the Closing, Buyer shall deposit the Escrow Fund into a bank account opened and maintained by Buyer. The Escrow Fund shall be maintained for twelve (12) months from the Closing Date. The bank shall require joint signatures from both Buyer and Seller in order to release any portion of the Escrow Funds to Buyer.

11

(b)           In order to recover losses in connection with any indemnification claims from the Escrow Fund, Buyer shall provide notice of such claim to Seller in accordance with Section 6.04(a). Seller shall have five (5) days from its receipt of such notice to: (x) deliver to the bank its signature allowing for the release of the amount of such claim or (y) deliver to Buyer a written objection to any claim or portion thereof or the amount of such claim. If Seller delivers a written objection pursuant to clause (y) above, the parties agree that they shall make commercially reasonable efforts to negotiate and resolve the dispute. If no resolution is reached, then the parties shall resolve such dispute in an appropriate court of law in accordance with Section 7.11.

(c)           Within five (5) days after the twelve (12) month anniversary of the Closing Date, Buyer shall notify Seller of the remaining balance of the Escrow Fund, if any, minus the aggregate amount of all outstanding claims on such date. Seller shall either (x) deliver to the bank its signature allowing for the release of such remaining balance or (y) deliver to Buyer a written objection to the amount of such remaining balance. If Seller delivers a written objection pursuant to clause (y) above, the parties shall resolve such dispute as provided above in Section 6.05(b).

Section 6.06     Tax Treatment of Indemnification Payments.  All indemnification payments made by Seller under this Agreement shall be treated by the parties as an adjustment to the Purchase Price for tax purposes, unless otherwise required by law.

Section 6.07     Effect of Investigation.  Buyer’s right to indemnification or other remedy based on the representations, warranties, covenants and agreements of Seller contained herein will not be affected by any investigation conducted by Buyer with respect to, or any knowledge acquired by Buyer at any time, with respect to the accuracy or inaccuracy of or compliance with, any such representation, warranty, covenant or agreement. Notwithstanding the foregoing, as of the date hereof, neither Buyer nor any of its officers, employees, consultants or agents has knowledge that Seller is in breach of any of its representations, warranties, covenants or agreements.

Section 6.08     Cumulative Remedies.  The rights and remedies provided in this Article VI are cumulative and are in addition to and not in substitution for any other rights and remedies available at law or in equity or otherwise.

ARTICLE VII

MISCELLANEOUS

Section 7.01     Expenses.  All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses.

12

Section 7.02     Notices.  All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or (d) on the fifth day after the date mailed, by certified or registered airmail, return receipt requested, postage prepaid.  Such communications must be sent to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section 7.02):

If to Seller:	Redweb Technologies Limited Venture Point, Towers Business Park Wheelhouse Rd., Rugeley Staffordshire WS15 1UZ Facsimile:           0871 508 1229 E-mail:     duncan@valhallinvestmentsinc.com Attention:          Duncan Cheadle
with a copy to:	Everyman Legal Limited, Unit 1G Network Point, Range Road, Windrush Park, Witney, Oxfordshire, United Kingdom OX29 YN Facsimile:           +44 845 868 0961 E-mail:     stephen.evans @everymanlegal.com Attention:         Stephen Evans
If to Buyer:	Applied DNA Sciences, Inc. 25 Health Sciences Drive Suite 215 Stony Brook, New York  11790 Facsimile:           631-444-8848 E-mail:     Kurt.Jensen@adnas.com Attention:          Kurt Jensen, Chief Financial Officer
with a copy to:	Fulbright & Jaworski L.L.P. Facsimile:           212-318-3400 E-mail: mkraines@fulbright.com Attention:          Merrill M. Kraines

Section 7.03     Interpretation.  The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement. The parties have jointly participated in the negotiation and drafting of this Agreement. In the event of an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumptions or burdens of proof shall arise favoring any party by virtue of the authorship of any of the provisions of this Agreement.

Section 7.04     Severability.  If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction.

13

Section 7.05     Entire Agreement.  This Agreement and the documents to be delivered hereunder constitute the sole and entire agreement of the parties to this Agreement with respect to the subject matter contained herein, and supersede all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter.  In the event of any inconsistency between the statements in the body of this Agreement and the documents to be delivered hereunder, the Exhibits and Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules), the statements in the body of this Agreement will control.

Section 7.06     Successors and Assigns.  This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns.  Neither party may assign its rights or obligations hereunder without the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed.  No assignment shall relieve the assigning party of any of its obligations hereunder.

Section 7.07     No Third-party Beneficiaries.  Except as provided in Article VI, this Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

Section 7.08     Amendment and Modification.  This Agreement may only be amended, modified or supplemented by an agreement in writing signed by each party hereto.

Section 7.09     Waiver.  No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving.  No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver.  No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

Section 7.10     Governing Law.  This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of New York.

Section 7.11     Submission to Jurisdiction.  Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby shall be brought and maintained exclusively in the United States District Court for the Eastern District of New York, or if such court is without subject matter jurisdiction of such suit, action or proceeding, in the  Supreme Court of the State of New York in and for the County of New York, and each party hereby irrevocably consents to the exclusive personal jurisdiction and venue of such court in any such suit, action or proceeding.

14

Section 7.12      Specific Performance.  The parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.

Section 7.13     Counterparts.  This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement.  A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

[SIGNATURE PAGE FOLLOWS]

15

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

REDWEB TECHNOLOGIES LIMITED

By

Name:

Title:

APPLIED DNA SCIENCES, INC.

By

Name:

Title:

AGREED WITH RESPECT

TO SECTION 5.07:

VALHALLA INVESTMENTS, INC.

By: 

Name:

Title:

16

DEFINITIONS

(i)           “Affiliate” means, with respect to any Person, any other Person who directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person.  The term “control” means the ownership of a majority of the voting securities of the applicable Person, and the terms “controlled” and “controlling” have meanings correlative thereto.

(ii)          “Control” or “Controlled” means, with respect to any Intellectual Property right, possession by a party (including its Affiliates) of the right (whether by ownership, license or otherwise) to grant to another party a license or a sublicense under such Intellectual Property right without violating the terms of any agreement or other arrangement with any third party.

(iii)         “Copyrights” means all original works of authorship in any medium of expression, whether or not published, all copyrights (whether registered or unregistered), all registrations and applications for registration of such copyrights, and all issuances, extensions and renewals of such registrations and applications.

(iv)         “Intellectual Property” means all of the following and similar intangible property and related proprietary rights, interests and protections, however arising, pursuant to the laws of any jurisdiction throughout the world: (a) Trademarks; (b) Copyrights; (c) Know-How; (d) Patents; (e) copies and tangible embodiments of the foregoing (in whatever form or medium); and (f) all rights to sue and recover and retain damages, costs and attorneys’ fees for past, present and future infringement and any other rights relating to any of the foregoing.

(v)          “Know-How” means all confidential information, trade secrets, confidential business information (including ideas, inventions, formulas, designs, devices, technology, know-how, research and development, inventions, methods, processes, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals) and computer software (including all data and related documentation) whether or not patentable or copyrightable.

(vi)         “Legal Proceedings” shall mean any action, proceedings, claim, challenge, demand or other legal recourse brought against Buyer and/or any Buyer Affiliate.

(vii)        “Losses” shall mean any liability, damage, loss, compensation, award (including any tribunal award), cost, expense, charge, fine, penalty or outgoing suffered or incurred by Buyer and/or any Buyer Affiliate.

(viii)       “Patents” means all patented and patentable designs and inventions and improvements thereto, all design, plant and utility patents, letters patent, utility models, pending patent applications and provisional applications and all issuances, divisions, continuations, continuations-in-part, reissues, extensions, reexaminations, renewals and foreign counterparts of such patents and applications.

(ix)           “Person” means an individual, partnership, corporation, limited liability company, joint stock company, unincorporated organization or association, trust, joint venture, association or other similar entity, whether or not a legal entity.

(x)            “Tax” (including with correlative meaning the term “Taxes”) means (i) any federal, state, local or foreign income, gross receipts, capital, franchise, import, goods and services, value added, sales and use, estimated, alternative minimum, add-on minimum, sales, use, transfer, registration, excise, natural resources, severance, stamp, occupation, premium, windfall profit, environmental, customs, duties, real property, personal property, capital stock, social security, unemployment, disability, payroll, license, employee withholding, unclaimed property, escheat or other tax of any kind whatsoever, including any interest, penalties or additions to tax or additional amounts in respect of the foregoing, (ii) any liability for the payment of any amounts of the type described in clause (i) as a result of being a member of a consolidated, combined, unitary or aggregate group for any taxable period, and (iii) any liability for the payment of any amounts of the type described in clause (i) or clause (ii) as a result of being a transferee or successor to any person or as a result of any express or implied obligation to indemnify any other person.

(xi)           “Termination Costs” means:

1.           the cost of termination of the employment of any Undisclosed Employee;

2.           any costs associated with employing any Undisclosed Employee from the transfer date to the date of their dismissal and any social security or other similar costs payable thereon;

3.           any Losses resulting from an obligation to provide to an Undisclosed Employee any defined benefits payable on early retirement  (including, but not limited to, any entitlement to benefits arising from a right to be considered for early retirement or the loss of opportunity to increase the number of years of pensionable service) or redundancy which derive from the Undisclosed Employee’s membership of any pension scheme, and which claim is founded on an assertion that an obligation to provide such benefits transferred by virtue of the Transfer Regulations the Acquired Rights Directive 77/187/EC or 2001/23/EC (as appropriate); and

4.           any obligation to pay any pension contributions in respect of any Undisclosed Employee.

(xii)           “Trademarks” means all trademarks, service marks, trade names, brand names, logos, trade dress and other proprietary indicia of goods and services, vanity numbers whether registered or unregistered, internet domain names registered in any top-level domain by any authorized private registrar or governmental authority and all registrations and applications for registration of such trademarks, including intent-to-use translations, adaptations, derivations, and combinations, applications, all issuances, extensions and renewals of such registrations and applications and the goodwill connected with the use of and symbolized by any of the foregoing.

2

EX-10.2

AGREEMENT OF LEASE BETWEEN

LONG ISLAND HIGH TECHNOLOGY INCUBATOR, INC.,

LANDLORD

AND

APPLIED DNA SCIENCES, INC.,

TENANT

50 Health Sciences Drive

Stony Brook, New York

AGREEMENT OF LEASE

This Agreement of Lease (this “Lease”), dated as of 6/14, 2013, is by and between LONG ISLAND HIGH TECHNOLOGY INCUBATOR, INC., a nonprofit educational corporation existing under the laws of the State of New York, having its principal place of business located at 25 Health Sciences Drive, Stony Brook, New York 11790, hereinafter referred to as “Landlord”, and Applied DNA Sciences, Inc., having its principal place of business located at 25 Health Sciences Drive, Stony Brook, New York 11790, hereinafter referred to as “Tenant”.

WHEREAS, the New York State Legislature (hereinafter called the “Legislature”) has determined that the development and operation of a high technology incubator with related service, business and technical facilities on the campus of the State University of New York at Stony Brook (the “Stony Brook Campus”) fulfills a necessary and desirable public purpose and promotes employment and educational opportunities within the Long Island Region served by the State University of New York at Stony Brook (“SBU”); and

WHEREAS, the Legislature finds that encouraging the development of high technology incubator space at institutions of higher education has heretofore been declared to be the policy of New York State; and

WHEREAS, the Legislature enacted certain legislation to enable the Trustees of the State University of New York (the State University of New York being hereinafter referred to as “Overlandlord”) to enter into a lease (“Ground Lease”) with Landlord for the development, construction and operation of industrial and high technology incubator space and research and development facilities on a portion of the Stony Brook Campus, said enabling legislation being hereinafter referred to as the “Enabling Act”; and

WHEREAS, the Enabling Act has become Chapter 304 of the Laws of 1988; and

WHEREAS, such facility is located at 25 and 50 Health Sciences Drive, Stony Brook, NY 11790, as more particularly shown on Exhibit Aattached hereto and made a part hereof (the “Facility”); and

WHEREAS, Landlord and Tenant believe that Tenant qualifies as a high technology company in the area of DNA encryption technology, as provided in the January 22, 1986 Resolution of the State University of New York Board of Trustees “Use of University Facilities by Emerging Technology Enterprises” (SUNY Document Number 5604; furnished upon request); and

WHEREAS, Tenant has developed competence and expertise in technical matters relating to DNA encryption, counterfeit protection, and authentication, as well as expertise in development of a biotechnology company, and wishes to support the goals and objectives of SBU as outlined in Attachment Aannexed hereto; and

Page 1 of 28

WHEREAS, Tenant wishes to support growth of future emerging high technology companies in the incubator program at the Facility and will contribute to such program as an anchor tenant at the Facility and use the Premises for purposes consonant with the provisions of Chapter 304 of the Laws of 1988 and with the mission and programs of SBU as articulated by the Board of Trustees of SBU in the “Program Policy Statement” contained in Schedule C of the Ground Lease; and

WHEREAS, Tenant currently occupies certain premises in the building known as 25 Health Sciences Drive, Stony Brook, New York pursuant to a sublease between Landlord and Tenant dated November 1, 2005; and

WHEREAS, Tenant desires to relocate to and lease from Landlord the entire building known as 50 Health Sciences Drive (the “Building”) pursuant to the terms herein.

WHEREAS, Tenant’s occupancy of the Building will support Overlandlord, Landlord and the Stony Brook Campus to continue to prepare itself and its students for participation in a high technology economy engaged in research, development and commercialization efforts vital to the educational mission of SBU.

NOW, THEREFORE, in consideration of ten ($10.00) dollars and other good and valuable consideration, Landlord and Tenant hereby agree as follows:

1.Premises. Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, the Building, which Landlord and Tenant agree consists of approximately 30,000 rentable square feet (the “Premises”) together with the right to use in common with Overlandlord, Landlord and others, the parking area and grounds located within the Facility and all public or private streets, roads, highways, alleys, driveways, sidewalks, easements, rights of way and appurtenances which give vehicle or pedestrian access to the Premises as more particularly shown on Exhibit Aannexed to this Lease. Under State University Board of Trustees resolution of January 22, 1986 and further referenced in paragraph (b) of the Patents and Inventions Policy of State University of New York dated September 19, 1979, and amended November 16, 1988, the Premises are considered Tenant facilities and not state university facilities for purposes of patent and copyright ownership.

2.Term. The term of this Lease shall be for two years and eleven and one half months from June 15, 2013 (“Commencement Date”) through May 31, 2016, (“Expiration Date”) -unless earlier terminated or extended in writing in accordance with the terms of this Lease.

3.             Rent. The rent payable hereunder is $449,142 per year, which sum shall be payable in equal monthly installments of $37,428.50 on the first day of each month during the term of this Lease. Rent payable by Tenant under this Lease shall be paid when due without prior demand therefor and without any deductions or setoffs or counterclaims whatsoever.

Page 2 of 28

Any sums of money required to be paid under this Lease by Tenant in addition to the Rent herein provided, shall be deemed “Additional Rent” due and payable after demand therefor with the Rent next due (provided Tenant shall have been given ten (10) days’ notice of any such Additional Rent) or as may be otherwise provided herein. Such Additional Rent shall be deemed to be and shall constitute Rent hereunder and shall be collectible in the same manner and with the same remedies as if they had been Rent originally reserved herein. Tenant’s obligation to pay Additional Rent accruing during the term of the Lease shall survive the earlier termination and/or expiration of the term of this Lease. If Landlord receives from Tenant any payment less than the sum of the monthly Rent including Additional Rent and other charges then due and owing, Landlord, in its sole discretion, may allocate such payment in whole or in part to any Rent, any Additional Rent, and/or other charge then due or to any combination thereof.

Installments of the Rent and any Additional Rent payable hereunder shall be made payable to Landlord or to such other party as Landlord may designate from time to time by written notice to Tenant hereunder. Rent for any partial month during the term of the Lease shall be ratably apportioned based on the actual number of days therein.

4.             Services. Landlord shall supply all ordinary and necessary water, gas, electrical, and sewage services to Tenant and Tenant shall pay the charges for such services at the same rates charged by the local public utility companies providing such utility, or at such discounted rate as may be available to Tenant or Landlord within thirty (30) days of Tenant’s receipt of a bill for the same. In addition, such services that have not been separately metered (water and sewer) may be separately metered by Landlord and Tenant agrees to pay for such services in accordance with such metering as set forth above. Should Landlord decide to separately meter the Premises, the installation, maintenance and/or repair of such meters shall be Landlord’s sole responsibility and at Landlord’s sole cost and expense. Tenant may avail itself of other campus services at established third-party rates. The parties acknowledge that Tenant is eligible for discounts on such services as set forth under the Excelsior contract with New York State.

All activities of the Tenant involving the facilities and services of SBU will be consistent with applicable policies and guidelines of SBU.

Page 3 of 28

Except as otherwise expressly provided in this Lease, Landlord shall not be liable to Tenant for any loss or damage or expense which Tenant may sustain or incur by reason of any failure, inadequacy or defect in the character, quantity, quality or supply of electric current furnished to the Premises for any cause beyond Landlord’s reasonable control. No diminution or abatement of Rent, Additional Rent, or other compensation shall be or will be claimed by Tenant, nor shall this Lease or any of the obligations of Tenant hereunder be affected or reduced by reason of such interruptions, stoppages or curtailments, nor shall the same give rise to a claim in Tenant’s favor that such failure constitutes actual or constructive, total or partial eviction from the Premises, unless such interruptions, stoppages or curtailments have been due to the arbitrary, willful or negligent act, or failure to act, of Landlord.

5.            Changes and Alterations. Tenant shall have the right to make decorative alterations, such as painting, wall coverings and floor coverings (collectively “Decorative Alterations”) without Landlord’s consent. In addition, Tenant shall have the right to make non-structural changes to the Premises which do not adversely affect any building systems and do not exceed $100,000.00 per year in the aggregate, without Landlord’s consent, provided that Tenant provides Landlord with a copy of any existing plans and/or sketches prior to the commencement of work. However, Tenant shall not make any other changes to the Premises, or any part thereof, without Landlord’s consent and Landlord’s agent consent (currently the Office of Campus Planning, Design and Construction hereinafter referred to as “PDC,” at SBU), which consent shall not be unreasonably withheld, conditioned or delayed. Within fifteen (15) days of Landlord’s receipt of any request by Tenant for approval of proposed changes to the Premises, Landlord shall approve or disapprove (stating in reasonable detail the reasons for any disapproval) such request. If Landlord fails to approve or disapprove such request within said fifteen (15) day period, Landlord’s consent to such changes shall be deemed given. All work must be approved for compliance with applicable building codes and energy conservation codes by the CPDC Code Compliance Manager prior to the start of any work. At Tenant’s request, Landlord shall join in any applications for any authorizations required from any authority in connection with any approved alterations and otherwise cooperate, without cost, with Tenant regarding the same. Plans prepared by Tenant shall be provided to Landlord in connection with all alterations. All alterations for which the Landlord has provided its written consent pursuant to this Section shall be accomplished at Tenant’s expense by contractors approved in writing by Landlord, such consent not to be unreasonably withheld, conditioned, or delayed. Should Landlord fail to respond to any request to approve any contractor within fifteen (15) days after such request, such contractor(s) shall be deemed approved.

With respect to any alterations described herein, Tenant agrees that it shall: (i) obtain, prior to commencing any alterations and at its own expense, all permits, approvals and certificates required by any governmental or quasi-governmental authorities and provide to Landlord, upon completion, any necessary certificates of final approval thereof as well as duplicates of all such required permits, approvals and certificates; and (ii) cause its contractors and subcontractors to carry such workers’ compensation, general liability, and personal property damage insurance as Landlord may reasonably require.

Page 4 of 28

All installations installed in the Premises at any time, either by Tenant or Landlord on behalf of Tenant, shall be surrendered with the Premises (unless as to any structural alterations or other types of alterations such as chemical storage areas, radioactive areas, walk-in cold or warm rooms, changes to slab flooring, reinforcing dividing walls, installation of blow-out safety devices/windows, roof penetrations or the like and that create a permanent impediment for future use of the Premises, Landlord, by written notice to Tenant given with its consent to such alterations, elects to have them removed by Tenant, in which event the same shall be removed by Tenant at Tenant’s expense upon expiration of the term of this Lease.) All installations installed in the Premises at any time (excluding movable fixtures, trade fixtures, attached furniture, personal property not constituting leasehold improvements, and specialty installations), either by Tenant or Landlord on behalf of Tenant, shall, upon installation, become the property of Landlord.

6.           Tenant Repairs and Maintenance. Tenant shall take proper care of the Premises including repair and maintenance of plumbing, gas, electric, heating, cooling, ventilation, compressed air and other building systems serving the Premises exclusively.

7.            Landlord Repairs and Maintenance. Notwithstanding anything above to the contrary, Landlord shall, at its sole cost and expense, replace the HVAC systems and all equipment and fixtures located outside the Premises but serving the Premises at the end of their useful lives or as may otherwise be necessary or required, unless such replacement is necessary due to damage to such systems, equipment or fixtures caused by Tenant or its agents or employees. In addition, Landlord, at its sole cost and expense, shall repair, maintain and replace, as necessary or required, the structure and roof (including the roof membrane) of the Premises and make all other structural repairs and replacements to and in the Premises as are necessary or required to keep the same in good condition and repair. Landlord agrees that it shall install a new roof on the Premises within twelve (12) months after the Commencement Date. Landlord shall further (i) maintain and make all necessary repairs to the Common Areas (as defined below) including keeping the same clear of snow, ice and debris, (ii) keep the Common Areas in good condition in a first class, high grade manner consistent with reputable business standards and practices, (iii) keep the Common Areas in compliance with all applicable federal, state and local laws and regulations and insurance requirements and (iv) at no additional cost to Tenant, keep all parking areas adequately lit at all times. “Common Areas” shall mean the areas and equipment at the Facility, the Premises or of any other land or property made available by Landlord for the safety, benefit or convenience of the Tenant and Tenant’s employees or invitees, including but not limited to, parking areas, driveways, truck service ways, sidewalks and curbs; entrances and exits from the adjacent streets; traffic lights, traffic islands, landscaped areas; fencing; lighting facilities; sprinkler system serving landscaped areas or buildings; sewage system; directional or safety signs; pylon signs and sign panels which identify the Premises. Notwithstanding anything to the contrary herein, if Overlandlord fails to keep the access roads serving the Facility clear of snow at any time during the term of this Lease and if Landlord is unable to provide such service, Tenant may, after notice to Landlord (which may be oral) and an opportunity to cure (which shall not exceed four (4) hours), perform such snow removal, and Landlord shall pay the actual reasonable costs incurred by Tenant. Such request shall be reasonably supported by invoices for the work that has been completed.

Page 5 of 28

Tenant shall be solely responsible for the disposal of all waste in the Premises; provided, however, Landlord shall, at its sole cost and expense, promptly dispose of and remediate any pre-existing Hazardous Materials (as hereinafter defined) at the Premises. Subject to Landlord’s repair obligations and except as otherwise expressly provided herein, Tenant hereby assumes the full and sole responsibility for the condition, operation, repair, replacement, maintenance and management of the Premises.

Except as specifically provided in this Lease, there shall be no allowance to Tenant for a diminution of rental value and no liability on the part of Landlord by reason of inconvenience, annoyance or injury to business arising from Landlord, Tenant or others making any repairs, alterations, additions or improvements in or to any portion of the Premises or in and to the fixtures, appurtenances or equipment thereof in accordance with the provisions of this Lease. Landlord agrees that in performing any repairs, alterations, additions or improvements in or to any portion of the Premises or the Facility or in or to the fixtures, appurtenances or equipment thereof, Landlord shall use commercially reasonable efforts not to interfere with Tenant’s conduct of its business at the Premises. The provisions of this Article with respect to the making of repairs shall not apply in the case of fire or other casualty which are dealt with in Article 22 hereof.

8.            Security Deposit. Tenant agrees to provide an amount equal to $50,000.00, as a security deposit to be held by Landlord in trust in a separate, non-interest bearing account for the faithful performance and observance by Tenant of the terms, provisions and conditions of this Lease. If Tenant pays the rents and performs all of its other obligations under this Lease, Landlord will return the unused portion of the security deposit within thirty (30) days after the end of the term of this Lease. It is agreed that in the event Tenant defaults in respect of any of the terms, provisions and conditions of this Lease beyond applicable notice and cure periods, including, but not limited to, the payment of Rent and Additional Rent, Landlord may use, apply or retain the whole or any part of the security so deposited to the extent required for the payment of any Rent and Additional Rent or any other sum as to which Tenant is in default or for any sum which Landlord may reasonably expend or may be required to expend by reason of Tenant’s default in respect of any of the terms, covenants and conditions of this Lease. In the event Landlord applies or retains any portion or all of the security deposited, Tenant shall forthwith restore the amount so applied or retained so that at all times the amount deposited shall be the sum stipulated above.

Page 6 of 28

In the event of a sale or assignment of Landlord’s leasehold interest in the Building, Landlord shall have the right to transfer the security to the assignee. Landlord shall thereupon be released by Tenant from all liability for the return of such security, and Tenant agrees to look to the new landlord solely for the return of said security. It is agreed that the provisions hereof shall apply to every transfer or assignment made of the security to a new landlord. Tenant further covenants that it will not assign or encumber or attempt to assign or encumber the monies deposited herein as security and that neither Landlord nor its successors or assigns shall be bound by any such assignment, encumbrance, attempted assignment or attempted encumbrance.

9.Rules and Regulations. Tenant shall comply with established Landlord and SBU regulations (including, but not limited to, SBU environmental rules and regulations) and policies provided that same are not discriminatorily applied within the Facility and copies thereof shall be delivered to Tenant in advance of the enforcement thereof, and all laws, rules, orders, regulations, and the requirements of federal, state and municipal governments applicable to Tenant’s use of the Premises. Tenant shall obtain and keep in force at its sole cost and expense any permits or licenses which may be required in this jurisdiction for conduct of its operations and shall exhibit same to Landlord or SBU upon request.

10.No Relationship Between Tenant and SBU or NYS. Tenant specifically agrees that, notwithstanding anything contained herein to the contrary, this Lease does not create a relationship of landlord and tenant between the State of New York or the State University of New York and Tenant regarding the use of New York State controlled property including the Premises to which this Lease relates.

11.Conflict Between Lease and New York State or SBU. Tenant specifically agrees that any portion of this Lease which relates to the use of New York State controlled property and which is inconsistent with the laws of New York State or which in any way conflicts with the purpose or objective of the State University of New York or SBU shall be void and of no further force and effect.

12.Condition of Premises. Landlord shall deliver the Premises to Tenant broom clean, free of all tenancies and in compliance with all applicable laws. Except as set forth in the preceding sentence or as specifically set forth elsewhere in this Lease, Tenant agrees to accept the Premises as-is and, except as set forth above, specifically agrees to pay all additional costs related to any alterations of the Premises during the term of this Lease. Landlord shall not be required to provide furnishings, fixtures or decorations in the Premises. At Tenant’s sole cost and expense, Landlord will permit Tenant to install equipment, furniture and furnishings in the Premises and the removal of Tenant’s equipment, furniture and decorations at the end of the term of this Lease, or upon any extension or earlier termination thereof. In the event Tenant fails to so remove any of its equipment, furniture and decorations, same shall be deemed abandoned and Landlord may do so at Tenant’s expense. Landlord shall ensure that the plumbing, electric, heating and cooling systems and the elevators are fully operational and in good working order before the Commencement Date.

Page 7 of 28

13.           Use. Tenant shall use and occupy the Premises for purposes of developing technology related to DNA encryption, biotech security, counterfeit protection, and authentication and for any other related and lawful purpose, which uses (those expressly set forth herein and any related thereto) are consistent with the Program Policy Statement set forth in the Ground Lease (“Permitted Use”). Tenant shall have the right, so long as this Lease shall remain in effect, to enter upon the SBU campus for the purposes set forth herein. However, if, in the reasonable judgment of Landlord, any activity of Tenant or its personnel or clients is deemed incompatible with the purposes contemplated by this Lease, then such activity shall constitute a default by Tenant under this Lease if the same is not altered within thirty (30) days after Tenant’s receipt of Notice from Landlord of such incompatibility or such earlier time period as may be provided under the Ground Lease.

14.           No Representation. Tenant specifically agrees not to hold itself out as representing the State of New York, the State University of New York, The Research Foundation of SUNY, SBU or Landlord in connection with the use of New York State owned property to which this Lease relates, if any, nor shall the name of the State of New York, the State University of New York, The Research Foundation of SUNY, SBU or Landlord be used by Tenant for any purpose without prior, specific written approval of the party whose name is to be used.

15.           Indemnification and Hold Harmless. Tenant assumes all risks incidental to its use of the Premises, appurtenances and surrounding grounds. Tenant shall be solely responsible for any and all accidents and injuries to persons (including death) caused by the acts or omissions of Tenant, including to Tenant’s agents, employees, licensees and invitees. Tenant shall be solely responsible for property damage caused by the acts or omissions of Tenant, its agents, employees, licensees and invitees. Tenant hereby covenants and agrees to indemnify and hold harmless the State of New York, the State University of New York, The Research Foundation of SUNY, SBU or Landlord and their respective directors, shareholders, members, contractors, managers, principals, trustees, officers employees, agents, contractors and assigns (collectively, the “Indemnified Parties”) against and from (i) any and all claims against the Indemnified Parties of whatever nature arising from any acts or omissions of Tenant, its contractors, licensees, subtenants, agents, servants, employees, invitees or visitors, (ii) all claims against the Indemnified Parties arising from any accident, injury or damage whatsoever caused to any person or to the property of any person and occurring during the term of this Lease in or about the Premises, and (iii) all claims against the Indemnified Parties arising from any accident, injury or damage occurring outside of the Premises but anywhere within or about the Facility, where such accident, injury or damage results or is claimed to have resulted from an act or omission of Tenant or Tenant’s agents, employees, subtenants, invitees or visitors (collectively “Claims”). This indemnity and hold harmless agreement shall include indemnity from and against any and all liability, fines, suits, demands, reasonable costs and expenses of any kind or nature incurred in or in connection with any such claim or proceeding brought thereon, and the defense thereof. Tenant further agrees, upon request, to assume the defense of and to defend, at its own cost and expense, any such Claims brought at any time against the Indemnified Parties.

Page 8 of 28

16.           Insurance. During the term, Tenant shall maintain with responsible companies reasonably approved by Landlord:

                                   (i)               Intentionally Omitted;

(ii)             Commercial General Liability Insurance against all claims, demands or actions for personal injury to or death of any person in an amount of not less than $1,000,000.00 per occurrence liability limit, umbrella liability coverage of $4,000,000.00 and not less than $1,000,000.00 general aggregate liability limit for damage to property made by or on behalf of any person, arising from, related to, or in any way connected with the conduct and operations of Tenant’s use or occupancy of the Premises, or caused by actions or omissions to act, where there is a duty to act, of Tenant, its agents, servants and contractors, which insurance shall name Landlord, the State of New York, the State University of New York, the Research Foundation of SUNY and SBU, the State of New York, and Landlord’s managing agent as additional insureds, and such insurance shall be endorsed to provide that the insurance shall be primary and not contributory to any similar insurance carried by Landlord;

(iii)            fire insurance, with such extended coverage, vandalism, malicious mischief and sprinkler leakage endorsements attached as Landlord reasonably may, from time to time, require, covering all fixtures and equipment, stock in trade, furniture, furnishings, improvements or betterments installed or made by Tenant in, on or about the Premises to the extent of at least 90% of their replacement value, without deduction for depreciation, but in any event in an amount sufficient to prevent Tenant from becoming a co-insurer under provisions of applicable policies;

(iv)             worker’s compensation insurance covering all persons employed by Tenant or in connection with any work performed by Tenant; and

(v)             business interruption insurance.

Nothing shall be construed herein to limit any of Tenant’s contractual obligations under the terms of this Lease except as otherwise expressly provided hereinabove, and the minimum limits of liability set forth in (ii) above may be achieved by including Tenant’s primary coverage and Tenant’s excess liability (umbrella) coverage allocable to the Premises.

Page 9 of 28

All of Tenant’s insurance may be provided under blanket policies and shall provide that it shall not be subject to cancellation, termination or change except after at least thirty (30) days prior written notice to Landlord. All policies required pursuant to this Article or duly executed certificates for the same shall be deposited with Landlord not less than one (1) day prior to the day Tenant takes occupancy. Renewals of said policies shall be deposited with Landlord not less than fifteen (15) days prior to the expiration of the term of such coverage. Notwithstanding anything in this Lease to the contrary, Landlord and Tenant mutually agree that with respect to any loss which is covered by insurance then being carried by the party suffering a loss, or being carried by another party under which the party suffering the loss is an additional insured or loss-payee or required to be carried by such party, or as to any coverage which Landlord waives Tenant’s obligation to provide insurance, the party suffering a loss, releases the other of and from any and all claims with respect to such loss to the extent of such insurance; and they further agree to evidence such waiver by endorsements in their respective insurance policies. In the event that an extra premium is payable by either party as a result of this provision, the other party shall reimburse the party paying such premium the amount of such extra premium. If, at the written request of one party, the requirement that this release and nonsubrogation provision be contained in the other party’s insurance policy or policies is waived, then the obligation of reimbursement shall cease for such period of time as such waiver shall be effective, but nothing contained in this Article shall be deemed to modify or otherwise affect releases elsewhere herein contained of either party from liability from claims.

During the term, Landlord shall maintain, and Tenant shall pay to Landlord as Additional Rent the premiums therefor, insurance against loss or damage by fire (and against such other risks as would be covered by “SPECIAL-FORM” insurance to the extent that such insurance is reasonably available), in an amount not less than 100% of the then full insurable value of the Building and building equipment. The term “full insurable value” shall mean the actual replacement value (excluding foundation and excavation costs) and said “full insurable value” shall be reasonably determined by Landlord or Landlord’s insurance carrier. Tenant shall pay to Landlord as Additional Rent the premiums for such insurance within thirty (30) days after bills therefor are mailed to Tenant.

Page 10 of 28

17.           Notice. Any notice (“Notice”) to either party hereunder must be in writing, signed by the party giving it or such party’s attorney, and shall be served either by (i) hand delivery, (ii) certified mail, return receipt requested, or (iii) nationally recognized overnight carrier and addressed as follows:

TO LANDLORD:	TO TENANT:
Long Island High Technology Incubator, Inc.	Prior to the Commencement Date:
25 Health Sciences Drive	Applied DNA Sciences, Inc.

Stony Brook, New York 11790	25 Health Sciences Drive
	Stony Brook, New York 11790;
Attn: Anilkumar- Dhundale, PhD	Attn: Chief Financial Officer
	thereafter:
	Applied DNA Sciences, Inc.
	50 Health Sciences Drive
	Stony Brook, New York 11790
	Attn: Chief Financial Officer

WITH A COPY TO:	WITH A COPY TO:
Farrell Fritz, P.C.	Fulbright & Jaworski L.L.P.
1320 RXR Plaza	666 Fifth Avenue
Uniondale, NY 11556	New York, NY 10103
Attn: Robert E. Sandler, Esq.	Attn.: Merrill M. Kraines, Esq.

or to such other addresses as may be designated by the party giving it in writing. All Notices become effective upon (i) receipt, if delivered by hand, (ii) delivery, if delivered by overnight carrier, and (iii) three (3) days after posting, if delivered by certified mail.

18.          Renewal Option. Provided that Tenant is not in default hereunder past all applicable notice and cure periods at the time of the election of the respective renewal term or the date of commencement of same, Tenant shall have the right to renew this Lease at its option for two (2) additional three (3) year periods, commencing at the end of the then current term (the “renewal term”), by providing written notice of its intent to renew to Landlord at least one hundred and eighty (180) days prior to the expiration of the then current term of this Lease, time of the essence. If the option to renew is exercised by Tenant, the renewal period shall be upon the same terms and conditions as set forth herein except that the Rent for the renewal term shall be subject to increase but not decrease, based upon the percentage increase, if any, in the Consumer Price Index during the initial term of this Lease as more fully set forth below:

Page 11 of 28

(a) The term “Consumer Price Index” or “CPI” shall mean the Consumer Price Index published by the Bureau of Labor Statistics of the United States Department of Labor, all items, relating to New York, New York - Northeastern New Jersey, for Urban Wage Earners and Clerical Workers with 1982/1984=100, as the basis of calculation.

(b) The term “Base Price Index” shall mean the CPI for the month of May, 2013.

(c) The Rent for a renewal term shall be calculated by increasing the Rent in effect during the initial term of this Lease by that amount derived by multiplying $449,142 by a percentage equal to a fraction, the numerator of which shall be the excess, if any, of the CPI for the month immediately preceding the commencement date of the renewal term over the Base Price Index, and the denominator of which shall be the Base Price Index.

(d) In the event that the Consumer Price Index ceases to use 1982/1984=100 as the basis of calculation or if a substantial change is made in the terms or number of items contained in the CPI or if the CPI is altered, modified, converted or revised in any other substantial way, then Landlord and Tenant shall agree upon the use of an alternative and reliable governmental publication evaluating substantially all the information used in determining the CPI and which most closely resembles the CPI in order to effectuate the intent of the parties as set forth above.

19.           Additional Terms and Conditions. In addition to those otherwise set forth herein, this Lease is subject to the following terms and conditions:

(a) General institutional services provided to the Tenant by SBU at the request of Tenant must be paid for promptly after receipt by Tenant of a bill for the same.

(b)           Tenant may provide employment opportunities for SBU students during the academic year subject to student employment policies.

 20.           Subletting and Assignment. Tenant shall not sublease, assign, mortgage, pledge, encumber the Premises or in any manner transfer the Lease or part thereof without the prior written consent of Landlord, which consent may not be unreasonably withheld, conditioned or delayed unless such sublease shall be in conflict with the stated purposes in the January 22, 1986 Resolution of the State University of New York Board of Trustees “Use of University Facilities by Emerging Technology Enterprises” (SUNY Document Number 5604; furnished upon request), and the Incubator Guidelines and Procedures of the State University of New York at Stony Brook (furnished upon request). Landlord may assign this Lease in accordance with existing mortgage and loan agreements or otherwise, provided that any assignee delivers to Tenant an assignment and assumption agreement and any new mortgagee delivers to Tenant a subordination and non-disturbance agreement in the customary form of such mortgagee. This Lease shall not constitute a partnership or joint venture agreement between the parties hereto.

Page 12 of 28

Except where Tenant is a publicly traded corporation, any assignment, transfer, disposition, sale or acquiring of a controlling interest in Tenant to or by any person, entity or group of related persons or affiliated entities, whether in a single transaction or in a series of related and unrelated transactions shall be deemed to constitute an assignment of the Lease. For purposes of the immediately preceding sentence, a “controlling interest” of Tenant shall mean fifty (50%) percent or more of the aggregate issued and outstanding equitable interest (whether stock, partnership interest or otherwise) thereof.

Notwithstanding anything to the contrary herein, Tenant shall have the right, without the consent of Landlord, to assign its interest in this Lease or sublease the Premises to a parent, subsidiary or affiliate of Tenant, any entity under common control with Tenant or any entity which is a direct or indirect successor to Tenant either by merger or consolidation, or in connection with the transfer of all of the business and assets of the Tenant or a public offering of Tenant’s stock. No such assignment or sublease shall be valid unless, within ten (10) days after the effective date thereof, Tenant shall deliver to Landlord (i) a duplicate original instrument of assignment or sublease in form and substance reasonably satisfactory to Landlord, duly executed by Tenant, and (ii) in the case of an assignment, an instrument in form and substance reasonably satisfactory to Landlord, duly executed by the assignee, in which such assignee shall assume observance and performance of and to be personally bound by, all of the terms, covenants and conditions of this Lease on Tenant’s part to be observed and performed. Nothing herein shall be construed to release assignor from any of its obligations under this Lease in the event of any assignment of this Lease.

Notwithstanding anything to the contrary herein, Landlord shall not unreasonably withhold its consent to any assignment or subletting of all or a portion of the Premises provided that the following further conditions shall be fulfilled:

1.           Tenant shall not then be in default hereunder beyond the time herein provided, if any, to cure such default;

2.           The proposed assignee or subtenant shall be engaged in a business, and propose to use the Premises for the Permitted Use and in accordance with the Ground Lease; and

3.            In Landlord’s reasonable judgment the proposed assignee or subtenant shall have a financial standing acceptable to Landlord, taking into consideration Tenant’s obligations under this Lease, and is engaged in a business on the Premises or the relevant part thereof, which is limited to a use substantially similar to the use expressly permitted under this Lease. Nothing shall be construed herein to release assignor from any of its obligations under this Lease in the event of such assignment of this Lease. Notwithstanding anything to the contrary herein, if Landlord has not responded to Tenant’s request for Landlord’s consent to any assignment or subletting within thirty (30) days, Landlord’s consent shall be deemed given.

Page 13 of 28

Nothing in this Lease or any assignment, subletting, encumbrance or transfer of this Lease or any part thereof shall be deemed to permit the use of the Premises in any manner other than that authorized by Article 13 of this Lease without the prior consent of Landlord, which shall not be unreasonably withheld, conditioned, or delayed.

 21.          Default. Each of the following is a “Default” by Tenant under this lease: If Tenant (i) fails to pay any the Rent, any additional rent or other charges as herein specified and such failure continues for ten (10) days after Tenant’s receipt of written notice from Landlord specifying such failure, (ii) fails to fulfill any of the covenants, agreements or obligations of this Lease and such failure continues for thirty (30) days after Tenant’s receipt of written notice from Landlord specifying such failure, or, if such default cannot reasonably be cured within thirty (30) days, so long as Tenant has undertaken and is diligently pursuing a cure for such default, the same shall not be considered a Default, or (iii) if Tenant fails to comply with any laws, rules, regulations or requirements of the Federal, State or local governments or of SBU applicable to Tenant’s use of the Premises and such failure continues for thirty (30) days after Tenant’s receipt of written notice of the same (or such shorter notice if necessary due to any event of emergency), or (iv) if Tenant shall file, or there shall be filed against Tenant, a petition in bankruptcy or insolvency and such petition is not withdrawn within one hundred twenty (120) days of the filing of the same, or (v) if Tenant shall be adjudicated a bankrupt, or make an assignment for the benefit of creditors, or take advantage of any insolvency act.

Page 14 of 28

In the event of one or more of such Defaults, Landlord shall have the right to terminate this Lease upon fifteen (15) days written Notice to Tenant (the “Termination Notice”) and this Lease shall terminate on the fifteenth day after receipt by Tenant of such Termination Notice. In such event, (i) Rent and Additional Rent under this Lease up to the date of termination shall be immediately due and payable, together with such reasonable expenses as Landlord may incur for reasonable attorneys’ fees, brokerage fees and/or putting the Premises in good order or for preparing the same for re-rental; (ii) Landlord may re-let the Premises or any part or parts thereof, either in its own name or otherwise, for a term or terms which may, at its option, be shorter or longer than the period which would otherwise have constituted the remainder of the term of this Lease and may grant concessions or free Rent, to such extent as Landlord in Landlord’s reasonable judgment considers advisable and necessary to re-let the same; and (iii) Tenant or its successors shall also pay the Landlord as liquidated damages for the failure of Tenant to observe and perform its covenants contained herein any deficiency between the Rent and Additional Rent hereby reserved and the net amount, if any, of the rents collected on account of any lease or leases of the Premises or parts thereof to a third party in an arm’s-length transaction, for each month of the period which would otherwise have constituted the remainder of the term of this Lease. In computing such liquidated damages, there shall be added to said deficiency such reasonable expenses as Landlord shall incur in connection with such re-letting, such as reasonable attorneys’ fees, brokerage, advertising and for restoring the Premises to or keeping same in good working order. Any such liquidated damages shall be paid in monthly installments in the manner specified in this Lease and any suit brought to collect the amount of the deficiency for any month shall not prejudice in any way the rights of Landlord to collect the deficiency for any subsequent month by a similar proceeding. Upon Landlord’s permitted entry hereunder, Landlord, at its option, may make such alterations, repairs, replacements and decorations in the Premises as Landlord in its sole judgment considers advisable or necessary for the purpose of re-letting the Premises, and the making of such alterations and decorations shall not operate or be construed to release Tenant from liability hereunder. Landlord shall in no event be liable in any way whatsoever for failure to re-let the Premises, or, in the event that the Premises are re-let, for reasonable failure to collect the Rent thereof under such re-letting, and, in no event shall Tenant be entitled to receive any excess of such net rent collected above the sums payable by Tenant to Landlord hereunder. Mention in this Lease of any particular remedy shall not preclude Landlord from any other remedy in law or equity. Tenant hereby expressly waives any and all rights of redemption granted by or under any present or future laws in the event of Tenant being evicted or dispossessed, for any cause, or in the event of Landlord obtaining possession of the Premises by reason of the violation of Tenant of any of the covenants and conditions of this Lease, or otherwise. In the event of any such default, reentry, expiration or dispossession, Tenant and its personnel shall immediately vacate the Premises and Landlord may (but without obligation) re-enter and re-let the Premises, without liability of any kind to Tenant. Termination by Landlord as set forth above shall not relieve the Tenant of its obligations under this Lease and shall impose no obligation upon Landlord to make any effort or incur any expense to re-let the Premises; provided, however, that if Landlord does re-let the Premises then Tenant shall receive a credit for any rent received by Landlord after deducting any actual out-of- pocket expenses, reasonable attorneys’ fees or actual brokerage commissions incurred in re-letting the Premises. Landlord may without additional notice re-enter the Premises, and dispossess Tenant and the legal representative of Tenant or other occupant of the Premises by summary proceedings and hold the Premises as if this Lease had not been made, and Tenant and its legal representative or other occupant of the Premises hereby waive the service of notice of intention to re-enter or to institute legal proceedings to that end.

Page 15 of 28

In the case of any such default beyond applicable grace, notice, and cure periods and subsequent re-entry, expiration and/or dispossess by summary proceedings or otherwise, as aforesaid, the Rent and Additional Rent due at the time of said default shall become due thereupon and be paid up to the time of such re-entry, dispossess and/or expiration.

It is stipulated and agreed that in the event of the termination of this Lease pursuant to the provisions of this Article, Landlord shall forthwith, notwithstanding any other provisions of this Article or of this Lease to the contrary, in lieu of its remedies contained in the foregoing paragraph, be entitled to recover from Tenant as and for liquidated damages an amount equal to the difference between the Rent and Additional Rent for the unexpired portion of the term of this Lease and the then fair market value rental of the Premises, discounted at the rate of four (4%) percent per annum to present worth.

 22.          Casualty. In the event of a partial or total destruction of the improvements on the Premises, Tenant shall repair, restore, replace, or reconstruct the affected improvements within one hundred eighty (180) days after the receipt by Tenant of insurance proceeds, subject to force majeure events, or if the Premises cannot be repaired, restored, replaced, or reconstructed within such one hundred eighty (180) day period, within a reasonable time thereafter provided that Tenant diligently prosecutes such repair, restoration, replacement, or reconstruction to a condition comparable to their condition at the time of such destruction, subject to applicable law at the time of such repair, restoration, replacement, or reconstruction. Landlord shall promptly endorse any checks payable to Landlord or jointly payable to Landlord and Tenant (and, if applicable, Leasehold Mortgagee), in connection with such proceeds and shall deliver the same to Tenant, in trust to pay the costs of such repair, restoration, replacement, or reconstruction or deposit them as provided below:

(i)            If the proceeds do not exceed $250,000, Landlord shall pay the proceeds to the Tenant, which proceeds Tenant agrees shall be received in trust to pay the costs of such repair, restoration, replacement, or reconstruction; or

(ii)           If the proceeds exceed $250,000 (the “Major Casualty Proceeds”), such Major Casualty Proceeds shall be deposited into a trust account of Landlord and Tenant, controlled by both Landlord and Tenant, to be held at a federally insured bank selected by Tenant with its principal office in the State of New York and having capital of not less than $200,000,000, and to be used solely for such repair, restoration, replacement, or reconstruction, which Major Casualty Proceeds shall be disbursed to Tenant as follows:

Page 16 of 28

Landlord shall authorize the Major Casualty Proceeds to be disbursed to Tenant from such trust account, from time to time, but not more often than once a month, within thirty (30) days after receipt by Landlord of (a) with respect to any costs incurred by Tenant for any engineering, architectural or other professional fees, a paid invoice therefor, or (b) with respect to all other requisitions, (i) a request for payment executed by Tenant and accompanied by a completed requisition for payment (in form issued by the American Institute of Architects), certified by Tenant’s architect stating: (w) the amount of payment being requested, (x) the percentage of completion attained with respect to the repair, restoration, replacement, or reconstruction of the Premises, and the total cost estimated to be incurred by Tenant with respect to such repair, restoration, replacement, or reconstruction, (y) the aggregate amount theretofore expended with respect to such repair, restoration, replacement, or reconstruction, (z) that the portion of such repair, restoration, replacement, or reconstruction theretofore completed has been completed to the satisfaction of Tenant’s architect, substantially in accordance with Tenant’s plans and specifications and substantially in compliance with all applicable laws, ordinances, regulations and requirements of all public authorities having jurisdiction over the Premises, (ii) invoices from the consultants, vendors, contractors, subcontractors or materialmen for which payment is requested, and (iii) lien waivers (with respect to such portion of such repair, restoration, replacement, or reconstruction being paid at such time, to the extent obtainable, and in any event with respect to those portions of such repair, restoration, replacement, or reconstruction for which payments have theretofore been made).

Tenant shall cause to be prepared and delivered to Landlord, for approval, a set of final plans and specifications with respect to such repair, restoration, replacement, or reconstruction setting forth a reasonable description of such repair, restoration, replacement, or reconstruction. Such plans and specifications shall include the identities of the proposed general contractors to whom Tenant proposes to offer such repair, restoration, replacement, or reconstruction work for bidding. Landlord and Overlandlord shall have ten (10) days from receipt of such plans and specifications to review the same and to advise Tenant in writing of any respect in which Landlord reasonably determines such plans and specifications need to be modified in order to protect the safety and structural integrity of the Premises. Landlord and Tenant shall cooperate in good faith in meeting Tenant’s operational requirements and Tenant’s time requirements for completing such repair, restoration, replacement, or reconstruction.

Tenant will begin such repair, restoration, replacement, or reconstruction as soon as reasonably practicable after delivery of the insurance proceeds therefor to Tenant and will prosecute such repair, restoration, replacement, or reconstruction to completion with diligence, subject, however, to force majeure events (as such term is hereinafter defined). Such repair, restoration, replacement, or reconstruction will be completed free and clear of mechanics or other liens, and in accordance with the building codes and all applicable laws, ordinances, regulations, or orders of any public authority affecting such repair, restoration, replacement, or reconstruction, and also in accordance with all requirements of the insurance rating organization, or similar body.

Page 17 of 28

If the Premises shall be rendered totally or partially untenantable by reason of any such damage, all Rent and any Additional Rent payable hereunder shall be proportionately abated based on the portion(s) of the Premises rendered untenantable or unusable for the normal conduct of Tenant’s business until such time as such repair, restoration, replacement, or reconstruction of the Premises is completed, and Tenant has completed installations of Tenant’s equipment, movable fixtures, trade fixtures, attached furniture, personal property and specialty installations (such installations not to exceed sixty (60) days from the date of substantial completion of such repair, restoration, replacement or reconstruction of the Premises). Tenant hereby expressly waives the provisions of paragraph 227 of the New York Real Property Law, and of any successor law or like import then in force, and Tenant agrees the provisions of this paragraph shall govern and control in lieu thereof.

Notwithstanding the foregoing provisions of this Article 22, if during the last year of the term of this Lease, the Premises shall be totally damaged or rendered wholly untenantable by fire or other casualty, or partially damaged or rendered untenantable to the extent of fifty percent (50%) or more of the rentable square feet of the Premises, then in such event Landlord or Tenant may give to the other party within ninety (90) days after such fire or other casualty notice of termination of this Lease and in the event such notice is given this Lease shall come to an end and expire upon the expiration of said ninety (90) days with the same effect as if the date of expiration of said ninety (90) days were the expiration date set forth herein and all Rent and any Additional Rent shall be apportioned as of such date and any prepaid portion for any period after such date shall be refunded by Landlord to Tenant and all fire and casualty insurance proceeds required hereunder shall be paid to Landlord.

23.           Estoppel Certificates. Landlord and Tenant shall, at any time and from time to time, within fifteen (15) days following its receipt of a request from the other party, sign, acknowledge and deliver to the requesting party a certification that (a) this Lease is in full force and effect and has not been modified (or, if modified, setting forth all modifications), (b) the date to which the Rent has been paid, (c) stating whether or not, to the best of its knowledge, there is then a default or any event has occurred which, with the serving of notice or the passage of time, or both would give rise to a default which would give either party the right to terminate this Lease, and (d) any other certification reasonably requested by Landlord or Tenant. It is intended that any such statement may be relied upon by anyone with whom the party requesting such certificate may be dealing.

24.            Requirements of Law. Tenant shall give prompt notice to Landlord of any notice it receives of the violation of any law or requirements of any governmental authority with respect to the Premises or the use or occupation thereof. Tenant shall promptly comply with all present and future laws, orders and regulations of all state, federal, town, municipal and local governments, departments, commissions and boards or any direction of any public officer pursuant to law, and all orders, rules and regulations of the New York Board of Fire Underwriters or any similar body which shall impose any violation, order or duty upon Landlord or Tenant with respect to the Premises (and in the event such compliance can only be completed by Landlord, then Landlord shall effect such compliance at Tenant’s sole cost and expense, to the extent such cost and expense is reasonable and necessary); however, nothing set forth above shall require Tenant to make any structural alterations or repairs to the roof of the Premises unless such damage is caused by Tenant or its agents or employees. Tenant shall pay all reasonable costs, expenses, fines, penalties or damages, which may be imposed upon Landlord by reason of Tenant’s failure to comply with the provisions of this Article.

Page 18 of 28

25.            Access To Premises: Right To Perform. Landlord shall have the right upon reasonable advance written notice to Tenant, subject to all reasonable security precautions required by Tenant, to enter and pass through the Premises at reasonable times to examine the same to ensure that Tenant is in compliance with the terms of this Lease and to make such repairs, improvements or additions as Landlord may be required to make hereunder. Landlord may (upon reasonable advance written notice to Tenant) and accompanied by a representative of Tenant, exhibit the Premises to prospective purchasers or lenders (and to prospective tenants during the year prior to the expiration of the term of this Lease as may be extended by any remaining renewal options), at reasonable hours and without unreasonably interfering with Tenant’s business. If Tenant shall default in the observance or performance of any obligation of Tenant under this Lease, then, unless otherwise provided elsewhere hereunder, Landlord may, subject to the terms hereinabove, perform such obligation of Tenant without hereby waiving such default and if Landlord, in connection therewith, incurs any costs including, but not limited to, reasonable attorneys’ fees in instituting, prosecuting or defending any action or proceeding, such costs with interest at the rate of twelve (12%) percent per annum, shall be deemed to be Additional Rent hereunder and shall be paid by Tenant to Landlord within thirty (30) days of rendition of any bill or statement to Tenant therefor. Notwithstanding anything to the contrary herein, whenever Landlord or Overlandlord shall access the Premises, Landlord or Overlandlord, as applicable, shall be accompanied by a representative of Tenant (except in the case of emergencies when no such representative shall be available), shall use all commercially reasonable efforts to minimize any interference with Tenant’s business, and shall conform with Tenant’s security and confidentiality procedures for the Premises when accessing the Premises, provided such security and confidentiality procedures have been provided by Tenant to Landlord.

26.            Parking. Landlord hereby grants to Tenant on a non-exclusive basis the right to park for use by Tenant and Tenant’s guests and invitees in the automobile parking areas at the Facility. Landlord shall not be responsible to Tenant for enforcing Tenant’s rights set forth herein or for violation of said rights by other tenants of the Facility, by third parties, or guests or visitors to the Facility.

Page 19 of 28

27.            Hazardous Substances. Neither Landlord nor Tenant shall cause or permit any Hazardous Material (as hereinafter defined) to be brought upon, kept or used in or about the Premises by Landlord or Tenant, its agents, employees, contractors or invitees except in quantities and in a manner not prohibited by applicable Governmental Laws (defined below) and in connection with Landlord’s or Tenant’s business or incidental thereto. Tenant further covenants and agrees that it shall not discharge any Hazardous Material in the ground or sewer disposal system. If Tenant breaches the obligations stated in the preceding sentences, or if the presence of Hazardous Material on the Premises caused by Tenant, its employees, contractors, invitees, agents, servants, tenants or assigns, results in contamination of the Premises or if there is such a discharge, then Tenant shall (A) immediately give Landlord written notice thereof, and (B) indemnify, defend and hold harmless Landlord from any and all claims, judgments, damages, penalties, fines, costs, liabilities or losses which arise during or after the term as a result of such breach, contamination, or discharge. The foregoing indemnification includes, without limitation, costs incurred in connection with any investigation of site conditions or any cleanup, remediation, removal or restoration work required by any federal, state or local governmental agency or political subdivision. Without limiting the foregoing, if the presence of any Hazardous Material within the Premises caused or permitted by Tenant results in any contamination of the Premises or any other part of the Land, Tenant shall promptly take all actions at its sole expense as are necessary to return the Premises or any facility or property of Landlord to the condition existing prior to the introduction of any such Hazardous Material.

As used herein, the term “Governmental Laws” means all federal, state, regional, and local statutes, ordinances, rules, regulations, guidelines, and the like, and any notices and orders issued pursuant to any of the foregoing, concerning Hazardous Materials or public health and the environment. As used herein, the term “Hazardous Materials” means any pollutants, hazardous or toxic materials, substances or wastes, including, but not limited to: petroleum and petroleum products and derivatives; asbestos; radon; polychlorinated bi-phenyls (PCBs); urea-formaldehyde foam insulation; explosives; radioactive materials; laboratory wastes and medical wastes (including, without limitation, contaminated clothing, body fluids, contaminated medical instruments and equipment, catheters, used bandages, gauzes, needles and other sharps); and any chemicals, materials or substances designated or regulated, as hazardous or as toxic substances, materials, or wastes under any Governmental Laws.

Landlord and its agents shall have the right, but not the duty, to inspect the Premises as permitted by Article 25 of this Lease and without limitation to determine whether Tenant is complying with the terms of this Article. If Tenant is not in compliance with the provisions of this Article, and thereafter fails to comply with this Article within fifteen (15) days after written notice from Landlord, or if such compliance cannot be achieved within such fifteen (15) day period, and Tenant promptly commences and diligently proceeds to cure same, then within such additional reasonable time period, except that in the event of an emergency or where Landlord would otherwise suffer liability or damages for such non-compliance, no such cure period shall be required, Landlord shall have the right to immediately enter upon the Premises to remedy said noncompliance upon reasonable notice at Tenant’s expense and any expense incurred by Landlord shall be paid by Tenant upon demand and shall be deemed Additional Rent.

Page 20 of 28

Tenant acknowledges that Tenant shall be solely responsible for the proper and legal disposal of all medical, toxic and so-called “red bag” waste, as same may be defined from time to time, by all regulatory authorities having jurisdiction. Landlord shall have no liability to any person or entity in this regard. Tenant shall comply with all regulations issued by the federal government, New York State, the County of Suffolk, or any other agency, municipality or regulatory authority having jurisdiction with respect to the generation, storage and disposal of such waste. In addition, Tenant shall be required, at its own cost and expense to contract with a licensed medical and toxic waste disposal company for the disposal of all syringes, needles and other medical, toxic and red bag waste. Tenant shall furnish Landlord with a copy of the contract for disposal and renewals thereof upon request therefor. Failure (a) to maintain the aforesaid contract continuously and to furnish Landlord with evidence that the contract is in full force and effect upon Landlord’s request, or (b) to properly dispose of all medical, radioactive, toxic and red bag waste, shall be a material default under this Lease. Any failure by Landlord to take any action with respect to obtaining from Tenant all contracts and renewals, shall in no way relieve Tenant of its responsibility to provide same and to dispose of all such medical, toxic and red bag waste pursuant to all applicable law. Tenant shall, and does hereby, indemnify Landlord and holds Landlord harmless from any damage, loss, liability, claims, actions or proceedings, including, but not limited to, attorney’s fees and any fines or penalties, arising out of or relating to Tenant’s failure to perform any obligation under this Article. This Article shall survive the termination or expiration of this Lease.

28.           Condemnation.   If (a) the parking facilities shall be acquired or condemned by eminent domain, and Landlord is unable to provide reasonably similar replacement parking, or (b) more than twenty (20%) percent of the rentable square footage of the Premises shall be acquired or condemned by eminent domain, then in either such event Tenant may terminate the Lease and this Lease shall cease and terminate from the date of title vesting in such proceeding and Tenant shall not have a claim for the value of any unexpired term of said Lease. The Rent and all Additional Rent payable hereunder shall be payable up to the date of said title vesting in such proceeding. In the event that any part of the Premises shall be acquired or condemned by eminent domain and Tenant does not elect to terminate this Lease pursuant to this Article, this Lease shall be and remain unaffected by such eminent domain, unless otherwise provided herein, except that the Rent and other amounts payable hereunder shall be abated proportionately to the area of the Premises so condemned or taken, effective as of the date of said vesting in such proceeding.

If the whole of the Premises shall be taken for any public or quasi-public use by any lawful power or authority by exercise of the right of condemnation or of eminent domain, or by agreement between Landlord and those having the authority to exercise such right (hereinafter called “Taking”), the term of this Lease and all rights of Tenant hereunder except as hereinafter provided, shall cease and expire as of the date of vesting of title as a result of the Taking, and the Rent and Additional Rent payable under this Lease shall abate from the date on which the Taking occurs.

Page 21 of  28

In the event of a Taking of less than the whole of the Premises, or a portion of the parking area, this Lease shall cease and expire in respect of the portion of the Premises and/or parking area taken upon vesting of title as a result of the Taking and, if the Taking results in the portion of the Premises remaining after the Taking being inadequate, in the reasonable judgment of Tenant for the efficient, economical operation of the Tenant’s business conducted at such time in the Premises, Tenant may elect to terminate this Lease by giving notice to Landlord of such election not more than thirty (30) days after the actual Taking by the condemning authority stating the date of termination, which date shall be not more than thirty (30) days after the date of such notice to Landlord and upon said date, this Lease and the term hereof shall cease and expire. If Tenant does not elect to terminate this Lease as aforesaid: (i) the new Rent payable under this Lease shall be the product of the total Rent payable under this Lease multiplied by a fraction, the numerator of which is the rentable square foot area of the Premises remaining after the Taking, and the denominator of which is the rentable square foot area of the Premises immediately preceding the Taking, and (ii) the net award for the Taking shall be paid to and first used by Landlord (subject to the rights of any mortgagee) to restore the portion of the Premises remaining after the Taking to substantially the same condition and tenantability (hereinafter called “pre-taking condition”) as existed immediately preceding the date of the Taking. Notwithstanding anything to the contrary contained herein, in the event of a Taking of less than the whole of the Premises or a portion of the parking area, Tenant shall be entitled to the condemnation proceeds allocable to Tenant’s leasehold interest and leasehold improvements, to the extent same are affected by such Taking.

In the event of a Taking of the Premises or any part thereof, and whether or not this Lease is terminated, Tenant shall have no claim against Landlord or the condemning authority for the value of the unexpired term of this Lease. Tenant agrees that in any condemnation proceeding, Tenant may make a claim only for the value of Tenant’s fixtures, equipment, leasehold improvements and moving expenses.

29.End Of Term.   Upon the expiration or earlier termination of this Lease, Tenant shall quit and surrender to Landlord the Premises broom-clean and in good condition, ordinary wear and tear excepted. Tenant shall remove all of its property. Any property of Tenant not removed from the Premises shall be deemed abandoned by Tenant and may be disposed of in any manner deemed appropriate by Landlord, the cost of the removal and repairs occasioned by such removal to be at Tenant’s expense. Tenant’s obligations to observe or perform the terms of this Article shall survive the expiration or earlier termination of this Lease.

30.Successors And Assigns.   The terms, agreements, covenants and conditions contained in this Lease are binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns, except that Tenant shall have no right to assign this Lease or to sublease the space described herein except as expressly provided in this Lease.

Page 22 of  28

31.Limitation Of Liability.    Except to the extent caused by the negligence or willful misconduct of Landlord or its employees, agents or contractors, Landlord shall not be liable for any damages or injury to property of Tenant or of any other person, including property entrusted to employees of Landlord, nor loss of or damage to any property of Tenant by theft or otherwise, nor for any injury or damage to persons or property resulting from any cause whatsoever, nor shall Landlord or its agents or employees be liable for any such damage caused by other tenants or persons in, upon or about the Premises or the Facility, or caused by operations in construction of any private, public or quasi-public work.

32.Late Payments.    Any payment of Rent or Additional Rent, or any other charges or fees not made within fifteen (15) days of the due date thereof shall have a penalty of two (2%) percent added thereon for each thirty (30) day period plus interest at the rate of four (4%) percent over the Prime Rate (not to exceed twelve (12%) percent per annum) from the due date thereof; provided, however, that on one (1) occasion during each calendar year of the term of this Lease Landlord shall provide Tenant notice of such late payment and Tenant shall have a period of five (5) days thereafter within which to make such payment before any interest or late charge is assessed. If Tenant is late in making any such payment, Landlord shall, upon the request of Tenant, deliver to Tenant the amount of all penalties and the applicable interest rate at such time.

33.Broker.    The parties represent that there was no broker responsible for bringing about or negotiating this Lease. The parties agree to defend, indemnify, and hold each other harmless against any claims for brokerage commission or compensation with regard to the Premises by any broker claiming or alleging to have acted on behalf of or to have dealt with such party.

34.          Tenant’s Failure To Vacate.     In the event the Tenant does not vacate the Premises upon the Expiration Date of this Lease, or upon the expiration of any extension or renewal thereof, then and in that event the Tenant shall remain as a month to month Tenant at a monthly rental of one and one half times the monthly Rent plus 1/12 of the previous year’s charges for all Additional Rent payable on a recurring basis (if any) due under this Lease paid in the last month of the term payable as aforesaid. The acceptance by the Landlord of such rental after the expiration date of this Lease shall not be construed as consent to such continued occupancy.

35.Mechanic’s Liens     Notwithstanding anything to the contrary contained in this Lease, Tenant, its successors and assigns, warrant and guarantee to Landlord, its successors and assigns, that if any mechanic’s lien shall be filed against the Premises or Land of which the Premises forms a part, for work claimed to have been done for, or materials claimed to have been furnished to, Tenant (a) the same shall be discharged by Tenant, by either payment, by bond or otherwise, at the sole cost and expense of Tenant, within thirty (30) days of the giving of notice thereof by Landlord, (b) either a release or a satisfaction of lien, as the case may be, shall be filed with the County Clerk of the county in which the Premises is situate within such thirty (30) day period, and (c) a copy of such release or satisfaction, as the case may be, certified to by such County Clerk, shall be delivered to Landlord within seven (7) days after such filing.

Page 23 of  28

In the event such mechanic’s lien is not discharged timely, as aforesaid, Landlord may discharge same for the account of and at the expense of Tenant by payment, bonding or otherwise, without investigation as to the validity thereof or of any offsets or defenses thereto, and Tenant shall promptly reimburse Landlord, as Additional Rent, for all costs, disbursements, fees and expenses, including, without limitation, reasonable legal fees, incurred in connection with so discharging said mechanic’s lien, together with interest thereon from the time or times of payment until reimbursement by Tenant.

36.Exculpation.      Notwithstanding anything to the contrary contained herein, Tenant shall look solely to the interest of Landlord in the Ground Lease, the Premises, the rents derived therefrom and the proceeds of any insurance, sale or financing of Landlord’s interest in the Ground Lease or the Premises for the satisfaction of any of Tenant’s remedies with regard to the payment of money or otherwise, and no other property or assets of Landlord shall be subject to levy, execution or other enforcement procedures for the satisfaction of Tenant’s remedies or with respect to this Lease, the relationship of Landlord and Tenant hereunder or Tenant’s use or occupancy of the Premises, such exculpation of personal liability to be absolute. Subject to any rights that may be granted Tenant in a subordination non-disturbance and attornment agreement, as referenced in Article 38 below, Tenant specifically agrees that if this Lease is canceled or terminated for any reason, Tenant shall neither have nor assert any claim against the State of New York, State University of New York or SBU, nor their respective officers or employees, all of which claims whether existing now or which may arise in the future are hereby unconditionally and irrevocably waived. Tenant further specifically agrees that the State of New York, the State University of New York, The Research Foundation of SUNY and SBU and their directors, trustees, officers, employees, agents and assigns shall be forever relieved from any and all liability hereunder.

37.Effect Of Conveyance By Landlord.      If Landlord shall validly assign or transfer this Lease and deliver to Tenant an agreement, in recordable form or a counterpart thereof, executed by the assignee or transferee whereupon such assignee or transferee agrees to assume performance of all the covenants to be performed by Landlord from and after the date of such delivery to Tenant, then Landlord shall be relieved and discharged from any and all liabilities thereafter accruing under this Lease.

Page 24 of  28

38.Subordination, Attornment And Non-Disturbance.    Tenant agrees that this Lease is and shall be subject and subordinate to any ground and/or underlying lease (including, but not limited to, the Ground Lease), to all mortgages, and to all renewals, modifications, consolidations, participations, replacements and/or extensions thereof now or hereafter affecting the Premises or the Facility provided that as to any currently existing and future mortgagees, Landlord shall provide Tenant with a subordination non-disturbance and attornment agreement from such mortgagee in such mortgagee’s customary form. Landlord shall use reasonable efforts to obtain a subordination, non-disturbance and attornment agreement from OverLandlord in form and substance as provided in Section 21 of the Ground Lease.

This Lease shall not terminate or be terminable by Tenant by reason of any termination of any superior lease, by summary proceedings, or otherwise. Tenant agrees without further instruments of attornment in such case, to attorn to such lessor, to waive the provisions of any statute or rule of law now or hereafter in effect which may give or purport to give Tenant any right of election to terminate this Lease or to surrender possession of the Premises in the event such superior lease is terminated, and that this Lease shall not be affected in any way whatsoever by any such proceeding or termination. Tenant shall take no steps to terminate this Lease, whether or not such superior lease be terminated, without giving written notice to such lessor, and a reasonable opportunity to cure but not in excess of thirty (30) days longer than the period Landlord has to cure same, without such lessor being obligated to cure), any default on the part of Landlord under this Lease.

39.           Landlord and Tenant Compliance With Ground Lease.    The parties acknowledge and recognize the existence of the terms of the Ground Lease. Except as otherwise expressly provided herein, or except as the terms of the Ground Lease may be in conflict, or inconsistent with the terms herein provided, the terms, covenants and provisions in the Ground Lease and Exhibits thereto are hereby incorporated into and made part of this Lease with regard to the Premises to the extent applicable to the Premises. Tenant shall not do or permit to be done anything which would constitute a violation or breach of any of the terms, conditions or provisions of the Ground Lease or which would cause the Ground Lease to be terminated or forfeited by virtue of any rights of termination or forfeiture reserved by or vested in the Overlandlord. Tenant shall comply with all obligations contained in the Ground Lease required to be performed by or otherwise applicable to a subtenant of the Premises thereunder providing such terms are not inconsistent with the terms of this Lease. If Tenant shall cause a default in the performance of any of Landlord’s obligations under the Ground Lease due to a default by Tenant under the terms of this Lease, Landlord, without being under any obligation to do so and without thereby waiving such default, may remedy such default within the time periods provided in the Ground Lease, or sooner, for the account and at the expense of Tenant.

Landlord will comply with all of the terms of Ground Lease and will not voluntarily terminate the Ground Lease or amend the Ground Lease in a manner which would adversely affect Tenant’s rights under this Lease.

Page 25 of  28

40.           Entire Agreement. This Lease, including any attachments, constitutes the entire agreement between the parties hereto and all previous communications between the parties, whether written or oral, with reference to the subject matter of this lease are hereby superseded.

41.           Miscellaneous.

(a)         This Lease is transmitted for examination only and does not constitute an offer to lease. This Lease shall become effective only upon execution hereof by the parties hereto and delivery by Landlord to Tenant of an executed Lease.

(b)         This instrument contains the entire and only agreement between the parties with respect to the subject matter hereof. No oral statements or representations or prior written matter not contained herein shall have any force or effect.

(c)         This Lease shall not be modified, changed, or amended in any way or canceled, terminated or abridged or any provision hereof waived, except by a writing subscribed by the party to be charged.

(d)         If any term or provision of this Lease or the application thereof to any person or circumstances shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term or provision to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby and each term and provision of this Lease shall be valid and enforced to the fullest extent permitted by law.

(e)         This Lease shall be governed by and construed in accordance with the laws of the State of New York.

(f)          Neither this Lease nor any memorandum hereof shall be recorded without Landlord’s prior written consent.

(g)         In the event that Landlord defaults in any of its obligations hereunder, except in the case of emergencies, Landlord will have thirty (30) days from its receipt of written notice from Tenant specifying the nature of the default to cure such default (provided, however, in the event that such default is of a nature that it cannot be cured within such thirty (30) day period, and Landlord is diligently proceeding to cure such default, Landlord shall have such reasonable time to cure such default).

Page 26 of 28

(h)         This Lease may be executed in any number of counterparts, and any party hereto may execute any counterpart, each of which when executed and delivered will be deemed to be an original, and all of which counterparts of this Lease, as the case may be, when taken together will be deemed to be but one and the same instrument. Delivery of an executed counterpart signature page to this Lease by facsimile or in electronic (“pdf” or “tif”) format shall be equally as effective as delivery of a manually executed and delivered counterpart of this Lease.

(i)           The preamble set forth above is incorporated herein and made a part of this Lease.

SIGNATURE PAGE TO FOLLOW

Page 27 of 28

IN WITNESS WHEREOF, the parties hereto have executed this Lease the day and year first above written.

LANDLORD:		TENANT:
Long Island High Technology Incubator, Inc.		Applied DNA Sciences, Inc.
By:	/s/ Anilkumar Dhundale	By:	/s/ Kurt Jensen
Name:	Anilkumar Dhundale	Name:	Kurt Jensen
Title:	EXECUTIVE DIRECTOR	Title:	CFO
Date:	June 14, 2013	Date:	6/14/13

Page 28 of 28

AMENDMENT TO AGREEMENT OF LEASE

This Amendment to Agreement of Lease (this “Amendment”) is made as of this 14th day of June, 2013 between Long Island High Technology Incubator, Inc. (“Landlord”) and Applied DNA Sciences, Inc. (“Tenant”).

WHEREAS, the parties hereto previously entered into that certain Agreement of Lease (the “Original Lease”), dated as of November 1, 2005, as amended, relating to Suites 111, 112, 113, 114, 115, 117, 213, 215, 217 and 219 (collectively, the “Demised Premises”) located in the building known as 25 Health Sciences Drive, Stony Brook, New York; and

WHEREAS, Tenant currently leases the Demised Premises from Landlord on a month-to-month basis under the terms and conditions set forth in the Original Lease; and

WHEREAS, Landlord has constructed a building (the “Replacement Premises”) located at 50 Health Sciences Drive, Stony Brook, New York; and

WHEREAS, Landlord and Tenant intend to enter into that certain Agreement of Lease (the “New Lease”) under which Landlord will lease to Tenant, and Tenant will hire from Landlord, the Replacement Premises; and

WHEREAS, Landlord and Tenant agree that Tenant may remain in the Demised Premises until such time Tenant moves into the Replacement Premises (the “Occupancy Date”); and

WHEREAS, Landlord and Tenant agree that, so long as Tenant is paying rent under the New Lease, Tenant may remain in the Demised Premises, free of charge, until the Occupancy Date; and

WHEREAS, the parties hereto wish to amend the terms of the Original Lease as set forth below.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1.Recitals.All recitals set forth above are incorporated herein and made a part hereof.

2.Cessation of Rent Payments Under the Original Lease.The parties hereby agree that, as of the date Tenant begins paying rent under the New Lease, Tenant’s obligations to pay rent under the Original Lease shall cease.

3.Continued Occupancy.The parties hereby agree that, so long as Tenant is paying rent under the New Lease, Tenant may continue in occupancy of the Demised Premises at no charge until Tenant moves into the Replacement Premises.    Notwithstanding anything to the contrary herein, Tenant shall vacate and surrender the Demised Premises no later than August 15, 2013.  In the event that Tenant fails to vacate any suites by August 15, 2013 in accordance with the terms of the Original Lease, rent as provided for each suite in the Original Lease, as may have been amended, will be reinstated for such suite through the actual date of surrender on a month to month basis.

4.No Further Amendments.  Except as specifically set forth above, the Original Lease remains in full force and effect and unamended on a month to month basis.

5.Governing Law. This Amendment shall be construed in accordance with and governed by the laws of the State of New York, without reference to its principles of conflicts of laws.

6.Counterparts. This Amendment may be executed in counterparts by facsimile or PDF signature and by each party on separate counterparts, each of which when so executed and delivered shall be an original, and all of which when taken together shall constitute but one and the same instrument.

IN WITNESS WHEREOF, intending to be legally bound hereby, the parties hereto have duly executed this Amendment as of the date first written above.

LANDLORD:
LONG ISLAND HIGH TECHNOLOGY INCUBATOR, INC.
By:	/s/ Anilkumar Dhundale
	Name: Anilkumar Dhundale
	Title: EXEC. DIRECTOR
TENANT:
APPLIED DNA SCIENCES, INC.
By:	/s/ Kurt Jensen
	Name:
	Title:

- 2 -

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13A-14(a) OR 15D-14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, James A. Hayward, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c.	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d.	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
	Date:August 13, 2013

By:	/s/ JAMES A. HAYWARD
	James A. Hayward
	Chief Executive Officer
	Applied DNA Sciences, Inc.

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13A-14(a) OR 15D-14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Kurt H. Jensen, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Applied DNA Sciences, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	a.	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b.	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c.	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d.	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter  (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	a.	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b.	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
	Date: August 13, 2013

By:	/s/ KURT H. JENSEN
	Kurt H. Jensen
	Chief Financial Officer
	Applied DNA Sciences, Inc.

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

          The undersigned, James A. Hayward, Chief Executive Officer of Applied DNA Sciences, Inc. (the “Company”), in connection with the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2013 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

● the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and

● the information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

          This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.

By:	/s/ JAMES A. HAYWARD
	James A. Hayward
	Chief Executive Officer
	Applied DNA Sciences, Inc.
	August 13, 2013

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

           The undersigned, Kurt H. Jensen, Chief Financial Officer of Applied DNA Sciences, Inc. (the “Company”), in connection with the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2013 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, hereby certifies pursuant to the requirements of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that

● the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and

● the information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

          This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be “filed” for any purpose whatsoever.

By:	/s/ KURT H. JENSEN
	Kurt H. Jensen
	Chief Financial Officer
	Applied DNA Sciences, Inc.
	August 13, 2013

XML

SUMMARY OF ACCOUNTING POLICIES (Policies)

9 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures.  Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  The most complex and subjective estimates include:  recoverability of long-lived assets, including the value assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies and allowance for doubtful accounts.  Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the condensed consolidated interim financial statements in the period they are deemed to be necessary.  Accordingly, actual results could differ from those estimates.

Revenue Recognition

Revenue Recognition

Revenues are derived from research, development, qualification and production testing for certain commercial products. Revenue from fixed price testing contracts is generally recorded upon completion of the contracts, which are generally short-term, or upon completion of identifiable contractual tasks. At the time the Company enters into a contract that includes multiple tasks, the Company estimates the amount of actual labor and other costs that will be required to complete each task based on historical experience. Revenues are recognized which provide for a profit margin relative to the testing performed. Revenue relative to each task and from contracts which are time and materials based is recorded as effort is expended. Billings in excess of amounts earned are deferred. Any anticipated losses on contracts are charged to income when identified. To the extent management does not accurately forecast the level of effort required to complete a contract, or individual tasks within a contract, and the Company is unable to negotiate additional billings with a customer for cost over-runs, the Company may incur losses on individual contracts.

For revenue from product sales, the Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required. At June 30, 2013 and September 30, 2012, the Company did not record any deferred revenue for the respective periods.

Cash Equivalents

Cash Equivalents

For the purpose of the accompanying unaudited condensed consolidated interim financial statements, all highly liquid investments with a maturity of three months or less are considered to be cash equivalents.

Accounts receivable

Accounts Receivable

The Company provides an allowance for doubtful accounts equal to the estimated uncollectible amounts. The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable. It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change. At June 30, 2013 and September 30, 2012, the Company had an allowance for doubtful accounts of $70,000 and $0, respectively.  The Company writes-off receivables that are deemed uncollectible.

Income Taxes

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes include, but are not limited to, accounting for intangibles, warrants, equity based compensation and depreciation and amortization.

The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized.  During the three and nine months ended June 30, 2013 and 2012, the Company incurred losses from operations.  Based upon these results, and trends in the Company’s performance projected through 2013, it is more likely than not that the Company will not realize any benefit from the deferred tax assets recorded by the Company in previous periods.  Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability.  In management’s opinion, adequate provisions for income taxes have been made for all years.  If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.  The Company has identified its federal tax return and its state tax return in New York as “major” tax jurisdictions. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s condensed consolidated interim financial statements.  The Company’s evaluation was performed for tax years 2009 through 2012.  The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position.  It is the Company’s policy to accrue interest and penalties on unrecognized tax benefits as components of income tax provision.

Property Plant and Equipment

Property Plant and Equipment

Property plant and equipment are stated at cost and are depreciated using the straight line method over their estimated useful lives.  The estimated useful lives for computer equipment, lab equipment and furniture is 3 to 5 years and leasehold improvements are amortized over the shorter of their useful life or the lease term.  Property plant and equipment consist of:

	June 30, 2013 (unaudited)			September 30, 2012
Computer equipment	$	38,640		$	33,464
Lab equipment		589,737			296,904
Furniture		151,039			132,435
Leasehold improvements		222,283			—
Total		1,001,699			462,803
Accumulated depreciation		(337,593	)		(251,958	)
Property and equipment, net	$	664,106		$	210,845

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

The Company accounts for its long-lived assets in accordance with ASC 360, Property, Plant and Equipment (“ASC 360”) for purposes of determining and measuring impairment of its long-lived assets other than goodwill. ASC 360 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset.  ASC 360 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.

Comprehensive Income

Comprehensive Income

The Company does not have any items of comprehensive income in any of the periods presented.

Segment Information

Segment Information

The Company follows the provisions of ASC 280, Segment Reporting (“ASC 280”). ASC 280 establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders.  ASC 280 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision- making group, in making decisions how to allocate resources and assess performance.  The information disclosed herein, materially represents all of the financial information related to the Company’s single principal operating segment.

Loss Per Share

Loss per Share

The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share.  Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants. For the three and nine months ended June 30, 2013 and 2012, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

Fully diluted shares outstanding were 835,560,840 and 798,128,629 for the three and nine months ended June 30, 2013, respectively. Fully diluted shares outstanding were 646,110,663 and 641,715,691 for the three and nine months ended June 30, 2012, respectively.

Stock Based Compensation

Stock Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Stock Compensation.  ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.  Stock-based compensation expense recognized under ASC 718 for the three and nine months ended June 30, 2013 were $870,576 and $1,743,598 (including the stock option modification, see Note F), respectively, and for the three and nine months ended June 30, 2012 were $389,533 and $1,564,311, respectively.

As of June 30, 2013, 121,354,192 employee stock options were outstanding with 91,892,325 shares vested and exercisable.

Concentrations

Concentrations

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables.  The Company places its cash and temporary cash investments with high credit quality institutions.  At times, such investments may be in excess of the FDIC insurance limit.

The Company’s revenues earned from sale of products and services for the nine months ended June 30, 2013 included an aggregate of 14% from one customer of the Company’s total revenues.  No customers represented greater than 10% of the Company’s total revenues for the three months ended June 30, 2013.

Two and one customer(s) accounted for 59% and 46% of the Company’s revenues earned from sale of products and services for the three and nine months ended June 30, 2012, respectively.

One and two customer(s) accounted for 10% and 54% of the Company’s total accounts receivable at June 30, 2013 and September 30, 2012, respectively.

Research and Development

Research and Development

The Company accounts for research and development costs in accordance with the ASC 730, Research and Development (“ASC 730”).  Under ASC 730, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.  The Company incurred research and development expenses of $184,981 and $99,958 for the three month periods ended June 30, 2013 and 2012, respectively, and $509,132 and $274,528 for the nine month periods ended June 30, 2013 and 2012, respectively.

Advertising

Advertising

The Company follows the policy of charging the costs of advertising to expense as incurred.  The Company charged to operations $21,825 and $158,636 as advertising costs for the three and nine month periods ended June 30, 2013 and $13,244 and $68,148 for the three and nine month periods ended June 30, 2012, respectively.

Intangible Assets

Intangible Assets

The Company amortizes its intangible assets using the straight-line method over their estimated period of benefit.  The estimated useful life for patents is five years while other intellectual property uses a seven year useful life. The Company periodically evaluates the recoverability of intangible assets and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists.  All of the Company’s intangible assets are subject to amortization.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The Company’s financial instruments are primarily composed of cash, accounts receivable, accounts payable and accrued liabilities, and warrants. The fair value of cash, accounts receivable, accounts payable and accrued liabilities, as reflected in the condensed consolidated balance sheet, approximate its fair value due to the short-term maturity of these instruments.

The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.

The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.

For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.

As of June 30, 2013, there were no transfers in or out of Level 3 from other levels.

The fair value of each warrant is estimated using the Binomial Lattice option valuation model. Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility, in isolation, can significantly increase or decrease the fair value of the warrant. See Note I.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events

The Company has evaluated events that occurred subsequent to the balance sheet date and through the date the financial statements were available to be issued. Other than those events disclosed in the notes to these financial statements, management concluded that no additional subsequent events required disclosure in these financial statements.

XML

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Income Statement [Abstract]
Revenues	$ 644,842	$ 528,574	$ 1,307,117	$ 1,563,880
Operating expenses:
Selling, general and administrative	3,240,815	1,752,501	8,516,390	5,729,575
Research and development	184,981	99,958	509,132	274,528
Depreciation and amortization	62,280	103,338	105,105	300,419
Total operating expenses	3,488,076	1,955,797	9,130,627	6,304,522
LOSS FROM OPERATIONS	(2,843,234)	(1,427,223)	(7,823,510)	(4,740,642)
Other income (expense):
Interest, net	333	(2,422)	738	(642,790)
Gain (loss) on change in fair value of warrant liability	707,289		(6,145,229)
Net loss before provision for income taxes	(2,135,612)	(1,429,645)	(13,968,001)	(5,383,432)
Income taxes (benefit)
NET LOSS	$ (2,135,612)	$ (1,429,645)	$ (13,968,001)	$ (5,383,432)
Net loss per share-basic and diluted (in dollars per share)	$ 0.00	$ 0.00	$ (0.02)	$ (0.01)
Weighted average shares outstanding-
Basic and diluted (in shares)	721,142,161	594,931,878	683,709,950	556,036,906

XML

CAPITAL STOCK

9 Months Ended

Jun. 30, 2013

Stockholders' Equity Note [Abstract]

CAPITAL STOCK

NOTE E - CAPITAL STOCK

The Company is authorized to issue 1,350,000,000 shares of Common Stock with a par value of $0.001, as the result of a vote of stockholders conducted on January 27, 2012 which effected an increase in the authorized shares of Common Stock from 800,000,000 to 1,350,000,000.  In addition, the Company is authorized to issue 10,000,000 shares of preferred stock with a $0.001 par value per share. As of June 30, 2013 and September 30, 2012, there were 733,524,076 and 646,182,550 shares of Common Stock issued and outstanding, respectively, and no shares of Preferred Stock issued and outstanding.

During the three months ended June 30, 2013 and 2012, the Company expensed $15,018 and $0 related to stock based compensation, respectively. During the nine month periods ended June 30, 2013 and 2012, the Company has expensed $28,256 and $58,238 related to stock based compensation, respectively.

Preferred and Common Stock Transactions during the Nine Months Ended June 30, 2013:

On January 7, 2013, the Company completed the Second Closing of its transaction with Crede pursuant to the Purchase Agreement with Crede. The Company sold 5,500 shares of Series A Preferred Stock (“Series A Preferred”) to Crede at a price of $1,000 per share. The Company received gross proceeds of $5,500,000.   The Company exercised its option on January 8, 2013 and converted the Series A Preferred held by Crede into 25,462,963 shares of the Company’s Common Stock at a conversion price of $0.216 per share.

The Series A Preferred was convertible at the option of the holder thereof, in whole or in part, from time to time and at any time, at the lesser of (i) the Fixed Conversion Price and (ii) the Non-Fixed Conversion Price. The Fixed Conversion Price was equal to $0.186, which was the purchase price for the Common Stock at the Initial Closing. The Non-Fixed Conversion Price was equal to the consolidated closing bid price of the Company’s Common Stock for the most recently completed trading day as of the time of conversion. The Series A Preferred was convertible into Common Stock at the Company’s option, in whole or in part, from time to time during the ten trading day period beginning one trading day following the effectiveness of the registration statement (as described below) through the eleventh trading day following effectiveness of such registration statement, at the Non-Fixed Conversion Price, provided that certain equity conditions were met and the Company was not in breach of certain conditions. The Series A Preferred would have been automatically converted into Common Stock on the one year anniversary of the issuance of the Series A Preferred at the then applicable Non-Fixed Conversion Price, provided that certain equity conditions are met and the Company is not in breach of certain conditions. The Series A Preferred contained weighted average anti-dilution protection. The Series A Preferred did not accrue dividends except to the extent dividends are paid on the Common Stock. The Company’s Common Stock was junior in rank to the Series A Preferred with respect to preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company. The Series A Preferred generally had no voting rights except as required by law.

Pursuant to the Purchase Agreement, Crede agreed to purchase the Series A Preferred on the first business day following the date a registration statement covering the resale of all shares of Common Stock issuable pursuant to the Purchase Agreement, including those underlying the Series A Preferred and Series A, B and C Warrants, was declared effective by the SEC. The Company’s registration statement on Form S-3 was declared effective by the SEC on January 4, 2013.

Pursuant to the Purchase Agreement, Crede purchased at the Initial Closing, held on November 29, 2012, 10,752,688 shares of the Company’s Common Stock at a price of $0.186 per share, resulting in gross proceeds to the Company of $2,000,000. In addition, at the Initial Closing, Crede was issued (i) five year Series A Warrants allowing it to initially purchase 10,752,688 shares of Common Stock at a price of $0.2232 per share, (ii) five year Series B Warrants allowing it to initially purchase 29,569,892 shares of Common Stock at a price of $0.2232 per share which became exercisable at the Second Closing and (iii) Series C Warrants to initially purchase 26,881,720 shares of Common Stock which became exercisable for six months after the eleventh trading day following the Second Closing.  Crede may also exchange the Warrants for Common Stock pursuant to a Black-Scholes formula. The Series A, B and C Warrants each contain a 9.9% “blocker” so that in no event shall any of the Warrants be exercisable or exchangeable into or for Common Stock to the extent that such exercise or exchange would result in Crede having “beneficial ownership” (within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 9.9% of the Company’s Common Stock.

On January 22, 2013, the Company exercised its option to repurchase the Series C Warrants issued to Crede for $50,000.

Crede may exercise Series A and Series B Warrants by paying in cash or on a cashless basis by exchanging such Warrants for Common Stock using the Black-Scholes value. In the event that the Common Stock trades at a price 25% or more above the exercise price of the Series A and Series B Warrants for a period of 20 consecutive days (with average daily dollar volume of Common Stock on the OTC Bulletin Board at least equal to $300,000), the Company may obligate Crede to exercise such Warrants for cash.  On April 25, 2013, Crede effected the cashless exercise of 10,752,688 Series A Warrants and 29,569,892 Series B Warrants, and the Company thereupon issued to Crede an aggregate of 31,257,045 shares of its Common Stock.

Crede has the right to participate in other equity or equity-linked financings completed by the Company for a period of 180 days from the later of the Initial Closing or the date the registration statement went effective.

In addition, the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below $0.186 per share or the market price of the Common Stock on the date the registration statement was declared effective, for a period of 180 days from the effective date of the registration statement, except for issuances (i) pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar arrangements, (ii) to employees, consultants, directors and officers approved by the Board or pursuant to a plan approved by the Board, (iii) pursuant to one or more contracts entered into by the Company with third parties which would result in revenues to the Company during a three-month period equal to an annual run rate of $15 Million in revenues and (iv) pursuant to a contract entered into by the Company with a third party which would reasonably be expected to result in more than $3 Million in annual receivables.

Until one year after the Second Closing, the Company is prohibited from entering into any transaction to (i) sell any convertible securities at a conversion rate or other price that is generally based on and/or varies with the trading prices of the Company’s Common Stock at any time after the initial issuance of such convertible securities or (ii) sell securities at a future determined price, including, without limitation, an “equity line of credit” or an “at the market offering.”

On July 19, 2013, the Company entered into another securities purchase agreement (“Purchase Agreement”) with an affiliate of Crede; see Note K, Subsequent Events, for further details on the new financing.

XML

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals 1)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

Jun. 30, 2013

Total Revenues

Jun. 30, 2012

Total Revenues

Customer One

Jun. 30, 2013

Total Revenues

Customer One

Jun. 30, 2012

Total Revenues

Customer One

Jun. 30, 2012

Total Revenues

Customer Two

Jun. 30, 2012

Total Revenues

Customer Two

Jun. 30, 2013

Accounts Receivable

Customer One

Sep. 30, 2012

Accounts Receivable

Customer One

Jun. 30, 2013

Accounts Receivable

Customer Two

Sep. 30, 2012

Accounts Receivable

Customer Two

Concentration Risk [Line Items]

Percentage of total revenue and accounts receivable from various customers

46.00%

14.00%

46.00%

59.00%

59.00%

10.00%

10.00%

54.00%

54.00%

Total revenues, benchmark description

No customers represented greater than 10% of the Company’s total revenues

XML

SUMMARY OF ACCOUNTING POLICIES (Tables)

9 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Schedule of property and equipment

	June 30, 2013 (unaudited)			September 30, 2012
Computer equipment	$	38,640		$	33,464
Lab equipment		589,737			296,904
Furniture		151,039			132,435
Leasehold improvements		222,283			—
Total		1,001,699			462,803
Accumulated depreciation		(337,593	)		(251,958	)
Property and equipment, net	$	664,106		$	210,845

XML

STOCK OPTIONS AND WARRANTS -Employee Stock Options (Detail Textuals 3) (USD $)	0 Months Ended	1 Months Ended		3 Months Ended	9 Months Ended	3 Months Ended	9 Months Ended		0 Months Ended	9 Months Ended	12 Months Ended	1 Months Ended
	May 15, 2013	May 31, 2013	Apr. 30, 2013	Jun. 30, 2013	Jun. 30, 2013	Jun. 30, 2013 Employee Stock Options	Jun. 30, 2012 Employee Stock Options	May 12, 2013 Employee Stock Options	May 12, 2013 Employee Stock Options Incentive Stock Plan 2005	Jun. 30, 2013 Employee Stock Options Incentive Stock Plan 2005	Sep. 30, 2012 Employee Stock Options Incentive Stock Plan 2005	Nov. 30, 2012 Non-employee Stock Option Board of director members (except Mr. Catenacci)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options granted to purchase common stock (in shares)									100,000	7,599,367	6,558,825	2,099,367
Dividend yield assumed as per black scholes option pricing model									0.00%			0.00%
Volatility assumed as per black scholes option pricing model									117.57%			146.33%
Risk free interest rate									0.60%			0.82%
Method used to calculate fair value of warrants									Black Scholes Option Pricing Model			Black Scholes Option Pricing Model
Number of years for exercisable of options									5 years			5 years
Stock option vesting period from the date of issuance									4 years			1 year
Options, exercise prices								$ 0.20				$ 0.1799
Common stock issued in connection with the cashless exercise		2,418,971	11,285,376		4,639,483
Number of stock in connection with the cashless exercise of options (in shares)		2,975,956	15,438,337		5,954,000
Stock option exercise price (in dollars per share)		$ 0.042			$ 0.053
Number of common stock issued in connection with exercise of options					25,000
Number of stock options (in shares)					25,000					5,979,000	500,000
Stock option exercise price (in dollars per share)					$ 0.06					$ (0.042)	$ (0.080)
Number of options set to expire to June 16, 2018	5,400,000
Incremental stock compensation expense connection with modification				$ 870,576	$ 1,743,598	$ 408,605	$ 408,605

XML

CAPITAL STOCK (Detail Textuals) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Sep. 30, 2012	Jan. 27, 2012
Stockholders' Equity Note [Abstract]
Common stock, shares authorized	1,350,000,000		1,350,000,000		1,350,000,000	800,000,000
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001		$ 0.001
Preferred stock, shares authorized	10,000,000		10,000,000		10,000,000
Preferred stock, par value (in dollars per share)	$ 0.001		$ 0.001		$ 0.001
Common stock, shares issued	733,524,076		733,524,076		646,182,550
Common stock, shares outstanding	733,524,076		733,524,076		646,182,550
Stock-based compensation expense	$ 15,018	$ 0	$ 28,256	$ 58,238

XML

WARRANT LIABILITY (Detail Textuals) (USD $)	3 Months Ended	9 Months Ended	1 Months Ended	0 Months Ended								1 Months Ended
	Jun. 30, 2013	Jun. 30, 2013	Jan. 22, 2013 Series C Warrants	May 07, 2013 Warrants	Nov. 07, 2012 Warrants	Nov. 29, 2012 Warrants	Nov. 29, 2012 Securities Purchase Agreement With Crede CG II Ltd Series A Warrants	Nov. 28, 2012 Securities Purchase Agreement With Crede CG II Ltd Series A Warrants	Nov. 29, 2012 Securities Purchase Agreement With Crede CG II Ltd Series B Warrants	Nov. 28, 2012 Securities Purchase Agreement With Crede CG II Ltd Series B Warrants	Nov. 28, 2012 Securities Purchase Agreement With Crede CG II Ltd Series C Warrants	Apr. 25, 2013 Securities Purchase Agreement With Crede CG II Ltd Warrants	Nov. 28, 2012 Securities Purchase Agreement With Crede CG II Ltd Warrants
Agreement [Line Items]
Fair value of warrants				$ 15,018	$ 13,238							$ 7,326,553	$ 1,181,324
Number of common stock called by warrants								10,752,688		29,569,892	26,881,720
Payments for repurchase of warrants		50,000	50,000
Method used to calculate fair value of warrants				Black Scholes Option Pricing Model	Black Scholes Option Pricing Model							Binomial Lattice model	Binomial Lattice model
Fair value of company common stock (in dollars per share)												$ 0.221	$ 0.20
Dividend yield (in percent)				0.00%	0.00%							0.00%	0.00%
Number of expected term (in years)					3 years							4 years 6 months 14 days	5 years
Risk free interest rate (in percent)				0.35%	0.36%							0.71%	0.64%
Expected volatility (in percent)				119.72%	129.56%							125.97%	146.32%
Exercise price of warrants (in dollars per warrant)				0.214	0.179	0.2232	0.2232		0.2232			0.2232	0.2232
Change in fair value of warrant liability	$ (707,289)	$ 6,145,229

XML

SUBSEQUENT EVENTS (Detail Textuals 3) (USD $)	1 Months Ended		9 Months Ended		1 Months Ended
	May 31, 2013	Apr. 30, 2013	Jun. 30, 2013	Jun. 30, 2012	Jul. 31, 2013 Subsequent Event Initial Closing Crede CG II Ltd Securities Purchase Agreement	Jul. 31, 2013 Subsequent Event Second Closing Crede CG II Ltd Securities Purchase Agreement	Jul. 31, 2013 Subsequent Event Second Closing Crede CG II Ltd Securities Purchase Agreement Series B Preferred Stock
Subsequent Event [Line Items]
Investment Fee					$ 100,000	$ 265,000
Number of stock issued (in shares)	2,418,971	11,285,376		4,639,583			5,500
Share price							$ 1,000
Gross proceeds from issuance of preferred stock			$ 5,500,000				$ 5,500,000

XML

STOCK OPTIONS AND WARRANTS - Transactions involving stock options issued to employees (Details 3) (USD $)	0 Months Ended	9 Months Ended	12 Months Ended
	May 12, 2013	Jun. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Exercised		(25,000)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Exercised		$ 0.06
Employee Stock Options | Incentive Stock Plan 2005
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding Beginning balance, Number of Shares		125,208,825	120,650,000
Granted	100,000	7,599,367	6,558,825
Exercised		(5,979,000)	(500,000)
Cancelled or expired		(5,475,000)	(1,500,000)
Outstanding Ending Balance, Number of Shares		121,354,192	125,208,825
Vested at June 30, 2013		91,892,325
Non-vested at June 30, 2013		29,461,867
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding Beginning Balance, Weighted Average Exercise Price Per Share		$ 0.06	$ 0.06
Granted		$ 0.131	$ 0.07
Exercised		$ (0.042)	$ (0.080)
Cancelled or expired		$ (0.109)	$ (0.080)
Outstanding Ending Balance, Weighted Average Exercise Price Per Share		$ 0.063	$ 0.06
Vested at June 30, 2013		$ 0.061
Non-vested at June 30, 2013		$ 0.068
Share-Based Compensation Arrangement By Share-Based Payment Award Options Aggregate Intrinsic Value [Abstract]
Vested at June 30, 2013		$ 0.138
Non-vested at June 30, 2013		$ 0.131

XML

LIQUIDITY (Detail Textuals) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Liquidity [Abstract]
Net loss	$ (2,135,612)	$ (1,429,645)	$ (13,968,001)	$ (5,383,432)
Operating cash flow			(5,696,917)	(2,968,008)
Positive working capital	$ 1,027,531		$ 1,027,531

XML

STOCK OPTIONS AND WARRANTS - Changes in warrants outstanding and related prices (Details) (Warrants)	9 Months Ended
	Jun. 30, 2013	May 07, 2013	Nov. 29, 2012	Nov. 07, 2012	Sep. 30, 2012	Sep. 30, 2011
Class of Warrant or Right [Line Items]
Exercise price of warrants		0.214	0.2232	0.179
Number of warrants outstanding	19,226,354		67,204,300		45,840,647	58,205,280
Warrants Outstanding Remaining Contractual Life (Years)	2 years 9 months 29 days
Weighted Average Exercise Price	0.10331
Weighted Average Exercisable	19,126,354
Exercisable Weighted Average Exercise Price	0.10273
Exercise price $0.04000
Class of Warrant or Right [Line Items]
Exercise price of warrants	0.04000
Number of warrants outstanding	3,000,000
Warrants Outstanding Remaining Contractual Life (Years)	2 years 2 months 1 day
Weighted Average Exercise Price	0.04000
Weighted Average Exercisable	3,000,000
Exercisable Weighted Average Exercise Price	0.04000
Exercise price $0.04405
Class of Warrant or Right [Line Items]
Exercise price of warrants	0.04405
Number of warrants outstanding	510,784
Warrants Outstanding Remaining Contractual Life (Years)	4 years 15 days
Weighted Average Exercise Price	0.04405
Weighted Average Exercisable	510,784
Exercisable Weighted Average Exercise Price	0.04405
Exercise price $0.04750
Class of Warrant or Right [Line Items]
Exercise price of warrants	0.04750
Number of warrants outstanding	3,789,489
Warrants Outstanding Remaining Contractual Life (Years)	5 years 15 days
Weighted Average Exercise Price	0.04750
Weighted Average Exercisable	3,789,489
Exercisable Weighted Average Exercise Price	0.04750
Exercise price $0.05529
Class of Warrant or Right [Line Items]
Exercise price of warrants	0.05529
Number of warrants outstanding	226,081
Warrants Outstanding Remaining Contractual Life (Years)	4 years 6 months 11 days
Weighted Average Exercise Price	0.05529
Weighted Average Exercisable	226,081
Exercisable Weighted Average Exercise Price	0.05529
Exercise price $0.06000
Class of Warrant or Right [Line Items]
Exercise price of warrants	0.06000
Number of warrants outstanding	2,000,000
Warrants Outstanding Remaining Contractual Life (Years)	7 months 21 days
Weighted Average Exercise Price	0.06000
Weighted Average Exercisable	2,000,000
Exercisable Weighted Average Exercise Price	0.06000
Exercise price $0.07100
Class of Warrant or Right [Line Items]
Exercise price of warrants	0.07100
Number of warrants outstanding	1,000,000
Warrants Outstanding Remaining Contractual Life (Years)	1 year 6 months 26 days
Weighted Average Exercise Price	0.07100
Weighted Average Exercisable	1,000,000
Exercisable Weighted Average Exercise Price	0.07100
Exercise price $0.09000
Class of Warrant or Right [Line Items]
Exercise price of warrants	0.09000
Number of warrants outstanding	6,900,000
Warrants Outstanding Remaining Contractual Life (Years)	3 years 2 months 5 days
Weighted Average Exercise Price	0.09000
Weighted Average Exercisable	6,900,000
Exercisable Weighted Average Exercise Price	0.09000
Exercise price $0.17900
Class of Warrant or Right [Line Items]
Exercise price of warrants	0.17900
Number of warrants outstanding	100,000
Warrants Outstanding Remaining Contractual Life (Years)	2 years 4 months 6 days
Weighted Average Exercise Price	0.17900
Weighted Average Exercisable	100,000
Exercisable Weighted Average Exercise Price	0.17900
Exercise price $0.21400
Class of Warrant or Right [Line Items]
Exercise price of warrants	0.21400
Number of warrants outstanding	100,000
Warrants Outstanding Remaining Contractual Life (Years)	2 years 10 months 6 days
Weighted Average Exercise Price	0.21400
Weighted Average Exercisable
Exercisable Weighted Average Exercise Price
Exercise price $0.50000
Class of Warrant or Right [Line Items]
Exercise price of warrants	0.50000
Number of warrants outstanding	1,600,000
Warrants Outstanding Remaining Contractual Life (Years)	3 months 26 days
Weighted Average Exercise Price	0.50000
Weighted Average Exercisable	1,600,000
Exercisable Weighted Average Exercise Price	0.50000

XML

SUBSEQUENT EVENTS (Detail Textuals) (USD $)	1 Months Ended		9 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended			1 Months Ended
	May 31, 2013	Apr. 30, 2013	Jun. 30, 2013	Jun. 30, 2012	Jan. 22, 2013 Securities Purchase Agreement With Crede CG II Ltd	Jan. 08, 2013 Securities Purchase Agreement With Crede CG II Ltd Common Stock	Nov. 29, 2012 Securities Purchase Agreement With Crede CG II Ltd Common Stock	Jul. 19, 2013 Subsequent Event Securities Purchase Agreement With Crede CG II Ltd Common Stock Initial Closing	Jul. 19, 2013 Subsequent Event Securities Purchase Agreement With Crede CG II Ltd Series B Convertible Preferred Stock Initial Closing	Jul. 19, 2013 Subsequent Event Securities Purchase Agreement With Crede CG II Ltd Series B Convertible Preferred Stock Second Closing
Subsequent Event [Line Items]
Number of stock issued (in shares)	2,418,971	11,285,376		4,639,583		25,462,963	10,752,688	10,695,187		5,500,000
Gross proceeds from issuance of preferred stock			$ 5,500,000
Issuance price of stock issued (in dollars per share)					$ 0.186		$ 0.186	$ 0.187		$ 1,000
Gross proceeds from sale of common stock			$ 2,000,000	$ 1,542,600			$ 2,000,000	$ 2,000,000
Fixed conversion price (in dollars per share)						$ 0.216			$ 0.187

XML

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES - Summary of accounts payable and accrued liabilities (Details) (USD $)	Jun. 30, 2013	Sep. 30, 2012
Payables and Accruals [Abstract]
Accounts payable	$ 1,248,944	$ 473,060
Accrued consulting & legal fees	148,622	102,500
Accrued salaries payable	135,912	16,449
Total	$ 1,533,478	$ 592,009

XML

SUMMARY OF ACCOUNTING POLICIES

9 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

SUMMARY OF ACCOUNTING POLICIES

NOTE A — SUMMARY OF ACCOUNTING POLICIES

General

The accompanying unaudited condensed consolidated interim financial statements as of June 30, 2013 and for the three and nine months ended June 30, 2013 and 2012 are unaudited. These unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Rule S-X of the Securities and Exchange Commission (the “SEC”) and with the instructions to Form 10-Q. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine month periods ended June 30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2013. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended September 30, 2012 and footnotes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC.

The condensed consolidated balance sheet as of September 30, 2012 contained herein has been derived from the audited consolidated financial statements as of September 30, 2012, but do not include all disclosures required by GAAP.

Business and Basis of Presentation

On September 16, 2002, Applied DNA Sciences, Inc. (the “Company”) was incorporated under the laws of the State of Nevada. Effective December 17, 2008, the Company reincorporated from the State of Nevada to the State of Delaware.  The Company is principally devoted to developing DNA embedded biotechnology security solutions in the United States and Europe. To date, the Company has generated limited sales revenues from its services and products; it has incurred expenses and has sustained losses.  Consequently, its operations are subject to all the risks inherent in the establishment of an early stage operating company. For the period from inception through June 30, 2013, the Company has accumulated losses of $182,975,140.

The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Applied DNA Operations Management, Inc., APDN (B.V.I.) Inc. and Applied DNA Sciences Europe Limited. Significant inter-company transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures.  Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.  The most complex and subjective estimates include:  recoverability of long-lived assets, including the value assigned to intangible assets and property and equipment, fair value calculations for warrants, contingencies and allowance for doubtful accounts.  Management reviews its estimates on a regular basis and the effects of any material revisions are reflected in the condensed consolidated interim financial statements in the period they are deemed to be necessary.  Accordingly, actual results could differ from those estimates.

Revenue Recognition

Revenues are derived from research, development, qualification and production testing for certain commercial products. Revenue from fixed price testing contracts is generally recorded upon completion of the contracts, which are generally short-term, or upon completion of identifiable contractual tasks. At the time the Company enters into a contract that includes multiple tasks, the Company estimates the amount of actual labor and other costs that will be required to complete each task based on historical experience. Revenues are recognized which provide for a profit margin relative to the testing performed. Revenue relative to each task and from contracts which are time and materials based is recorded as effort is expended. Billings in excess of amounts earned are deferred. Any anticipated losses on contracts are charged to income when identified. To the extent management does not accurately forecast the level of effort required to complete a contract, or individual tasks within a contract, and the Company is unable to negotiate additional billings with a customer for cost over-runs, the Company may incur losses on individual contracts.

For revenue from product sales, the Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”) 605, Revenue Recognition (“ASC 605”). ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for allowances and other adjustments are provided for in the same period the related sales are recorded. The Company defers any revenue for which the product has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered or no refund will be required. At June 30, 2013 and September 30, 2012, the Company did not record any deferred revenue for the respective periods.

Cash Equivalents

For the purpose of the accompanying unaudited condensed consolidated interim financial statements, all highly liquid investments with a maturity of three months or less are considered to be cash equivalents.

Accounts Receivable

The Company provides an allowance for doubtful accounts equal to the estimated uncollectible amounts. The Company’s estimate is based on historical collection experience and a review of the current status of trade accounts receivable. It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change. At June 30, 2013 and September 30, 2012, the Company had an allowance for doubtful accounts of $70,000 and $0, respectively.  The Company writes-off receivables that are deemed uncollectible.

Income Taxes

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Temporary differences between taxable income reported for financial reporting purposes and income tax purposes include, but are not limited to, accounting for intangibles, warrants, equity based compensation and depreciation and amortization.

The Company evaluates the recoverability of deferred tax assets and establishes a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized.  During the three and nine months ended June 30, 2013 and 2012, the Company incurred losses from operations.  Based upon these results, and trends in the Company’s performance projected through 2013, it is more likely than not that the Company will not realize any benefit from the deferred tax assets recorded by the Company in previous periods.  Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability.  In management’s opinion, adequate provisions for income taxes have been made for all years.  If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.  The Company has identified its federal tax return and its state tax return in New York as “major” tax jurisdictions. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s condensed consolidated interim financial statements.  The Company’s evaluation was performed for tax years 2009 through 2012.  The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position.  It is the Company’s policy to accrue interest and penalties on unrecognized tax benefits as components of income tax provision.

Property Plant and Equipment

Property plant and equipment are stated at cost and are depreciated using the straight line method over their estimated useful lives.  The estimated useful lives for computer equipment, lab equipment and furniture is 3 to 5 years and leasehold improvements are amortized over the shorter of their useful life or the lease term.  Property plant and equipment consist of:

	June 30, 2013 (unaudited)			September 30, 2012
Computer equipment	$	38,640		$	33,464
Lab equipment		589,737			296,904
Furniture		151,039			132,435
Leasehold improvements		222,283			—
Total		1,001,699			462,803
Accumulated depreciation		(337,593	)		(251,958	)
Property and equipment, net	$	664,106		$	210,845

Impairment of Long-Lived Assets

The Company accounts for its long-lived assets in accordance with ASC 360, Property, Plant and Equipment (“ASC 360”) for purposes of determining and measuring impairment of its long-lived assets other than goodwill. ASC 360 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset.  ASC 360 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.

Comprehensive Income

The Company does not have any items of comprehensive income in any of the periods presented.

Segment Information

The Company follows the provisions of ASC 280, Segment Reporting (“ASC 280”). ASC 280 establishes standards for reporting information regarding operating segments in annual financial statements and requires selected information for those segments to be presented in interim financial reports issued to stockholders.  ASC 280 also establishes standards for related disclosures about products and services and geographic areas. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision- making group, in making decisions how to allocate resources and assess performance.  The information disclosed herein, materially represents all of the financial information related to the Company’s single principal operating segment.

Loss per Share

The Company presents loss per share utilizing a dual presentation of basic and diluted loss per share.  Basic loss per share includes no dilution and has been calculated based upon the weighted average number of common shares outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon the exercise of the Company’s stock options and warrants. For the three and nine months ended June 30, 2013 and 2012, common stock equivalent shares are excluded from the computation of the diluted loss per share as their effect would be anti-dilutive.

Fully diluted shares outstanding were 835,560,840 and 798,128,629 for the three and nine months ended June 30, 2013, respectively. Fully diluted shares outstanding were 646,110,663 and 641,715,691 for the three and nine months ended June 30, 2012, respectively.

Stock Based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Stock Compensation.  ASC 718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values. Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee’s requisite service period (generally the vesting period of the equity grant). The fair value of the Company’s common stock options are estimated using the Black Scholes option-pricing model with the following assumptions: expected volatility, dividend rate, risk free interest rate and the expected life. The Company expenses stock-based compensation by using the straight-line method. In accordance with ASC 718, excess tax benefits realized from the exercise of stock-based awards are classified in cash flows from financing activities. The future realization of the reserved deferred tax assets related to these tax benefits associated with the exercise of stock options will result in a credit to additional paid in capital if the related tax deduction reduces taxes payable. The Company has elected the “with and without approach” regarding ordering of windfall tax benefits to determine whether the windfall tax benefit did reduce taxes payable in the current year. Under this approach, the windfall tax benefit would be recognized in additional paid-in-capital only if an incremental tax benefit is realized after considering all other benefits presently available.  Stock-based compensation expense recognized under ASC 718 for the three and nine months ended June 30, 2013 were $870,576 and $1,743,598 (including the stock option modification, see Note F), respectively, and for the three and nine months ended June 30, 2012 were $389,533 and $1,564,311, respectively.

As of June 30, 2013, 121,354,192 employee stock options were outstanding with 91,892,325 shares vested and exercisable.

Concentrations

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables.  The Company places its cash and temporary cash investments with high credit quality institutions.  At times, such investments may be in excess of the FDIC insurance limit.

The Company’s revenues earned from sale of products and services for the nine months ended June 30, 2013 included an aggregate of 14% from one customer of the Company’s total revenues.  No customers represented greater than 10% of the Company’s total revenues for the three months ended June 30, 2013.

Two and one customer(s) accounted for 59% and 46% of the Company’s revenues earned from sale of products and services for the three and nine months ended June 30, 2012, respectively.

One and two customer(s) accounted for 10% and 54% of the Company’s total accounts receivable at June 30, 2013 and September 30, 2012, respectively.

Research and Development

The Company accounts for research and development costs in accordance with the ASC 730, Research and Development (“ASC 730”).  Under ASC 730, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred.  Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.  The Company incurred research and development expenses of $184,981 and $99,958 for the three month periods ended June 30, 2013 and 2012, respectively, and $509,132 and $274,528 for the nine month periods ended June 30, 2013 and 2012, respectively.

Advertising

The Company follows the policy of charging the costs of advertising to expense as incurred.  The Company charged to operations $21,825 and $158,636 as advertising costs for the three and nine month periods ended June 30, 2013 and $13,244 and $68,148 for the three and nine month periods ended June 30, 2012, respectively.

Intangible Assets

The Company amortizes its intangible assets using the straight-line method over their estimated period of benefit.  The estimated useful life for patents is five years while other intellectual property uses a seven year useful life. The Company periodically evaluates the recoverability of intangible assets and takes into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists.  All of the Company’s intangible assets are subject to amortization.

Fair Value of Financial Instruments

The Company’s financial instruments are primarily composed of cash, accounts receivable, accounts payable and accrued liabilities, and warrants. The fair value of cash, accounts receivable, accounts payable and accrued liabilities, as reflected in the condensed consolidated balance sheet, approximate its fair value due to the short-term maturity of these instruments.

The valuation techniques utilized are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect internal market assumptions. These two types of inputs create the following fair value hierarchy:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related asset or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities.

The Company utilizes observable market inputs (quoted market prices) when measuring fair value whenever possible.

For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, who report to the Chief Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department and are approved by the Chief Financial Officer.

As of June 30, 2013, there were no transfers in or out of Level 3 from other levels.

The fair value of each warrant is estimated using the Binomial Lattice option valuation model. Significant observable and unobservable inputs include stock price, exercise price, annual risk free rate, term, and expected volatility, and are classified within Level 3 of the valuation hierarchy. An increase or decrease in volatility, in isolation, can significantly increase or decrease the fair value of the warrant. See Note I.

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s unaudited condensed consolidated financial position, results of operations or cash flows.

Subsequent Events

The Company has evaluated events that occurred subsequent to the balance sheet date and through the date the financial statements were available to be issued. Other than those events disclosed in the notes to these financial statements, management concluded that no additional subsequent events required disclosure in these financial statements.

XML

WARRANT LIABILITY

9 Months Ended

Jun. 30, 2013

Warrant Liability [Abstract]

WARRANT LIABILITY

NOTE C – WARRANT LIABILITY

As more fully described in Note E below, on November 28, 2012, the Company entered into a securities purchase agreement (“Purchase Agreement”) with Crede CG II, Ltd. (“Crede”). In connection with the Purchase Agreement, the Company issued Series A, B and C Warrants allowing Crede to purchase 10,752,688, 29,569,892 and 26,881,720 shares of Common Stock, respectively.

The Company determined that the Series A and B Warrants described above should be classified as a liability due to transactions which may cause an adjustment to the conversion rate (reset provisions) contained in the warrant agreements and remeasured at each reporting date at their fair value with the changes reported in earnings (loss). Due to a callable provision of the Series C Warrants, the Company deemed such as an equity instrument. The Series C Warrants were repurchased by the Company for $50,000 on January 22, 2013.  Liability classification of the Series A and B Warrants will end upon expiration of reset provisions, at which time the Warrants will be reclassified to equity based on their then fair value. The Company determined the allocated fair value of the Warrants to be $1,181,324 on the issuance date using the Binomial Lattice model with the following assumptions: fair value of the Company’s Common Stock $0.20 per share; dividend yield 0%; expected terms 5 years; risk free interest rate: 0.64%; expected volatility of: 146.32%; and the expected price at which holders are likely to exercise their Warrants of $0.2232.

On April 25, 2013, Crede effected the cashless exercise of the Series A and Series B Warrants (see Note E).  At April 25, 2013 (date of exercise), the Company determined the fair value of the Warrants to be $7,326,553 using the Binomial Lattice model with the following assumptions: fair value of the Company’s Common Stock $0.221 per share; dividend yield 0%; expected term: 4.54 years; risk free interest rate: 0.71%; expected volatility of: 125.97%; and an exercise price of $0.2232. The change in fair value of the warrant liability amounted to a (gain) loss of $(707,289) and $6,145,229 for the three months and nine months ended June 30, 2013, respectively and was included in the results of operations.  Upon exercise, the fair value of the Series A and Series B Warrants were reclassified to equity.

XML

STOCK OPTIONS AND WARRANTS

9 Months Ended

Jun. 30, 2013

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

STOCK OPTIONS AND WARRANTS

NOTE F - STOCK OPTIONS AND WARRANTS

Warrants

The following table summarizes the changes in warrants outstanding and the related prices for the shares of Common Stock issued to non-employees of the Company.  These warrants were granted in lieu of cash compensation for services performed or financing expenses in connection with the sale of Common Stock.

			Warrants
			Outstanding	Weighted			Exercisable
			Remaining	Average		Weighted	Weighted
Exercise		Number	Contractual	Exercise		Average	Average
Prices		Outstanding	Life (Years)	Price		Exercisable	Exercise Price
$	0.04000	3,000,000	2.17	$	0.04000	3,000,000	$	0.04000
$	0.04405	510,784	4.04	$	0.04405	510,784	$	0.04405
$	0.04750	3,789,489	5.04	$	0.04750	3,789,489	$	0.04750
$	0.05529	226,081	4.53	$	0.05529	226,081	$	0.05529
$	0.06000	2,000,000	0.64	$	0.06000	2,000,000	$	0.06000
$	0.07100	1,000,000	1.57	$	0.07100	1,000,000	$	0.07100
$	0.09000	6,900,000	3.18	$	0.09000	6,900,000	$	0.09000
$	0.17900	100,000	2.35	$	0.17900	100,000	$	0.17900
$	0.21400	100,000	2.85	$	0.21400	—		—
$	0.50000	1,600,000	0.32	$	0.50000	1,600,000	$	0.50000
		19,226,354	2.83	$	0.10331	19,126,354	$	0.10273

Transactions involving warrants are summarized as follows:

	Number of Shares			Weighted Average Price Per Share
Balance, October 1, 2011		58,205,280		$	0.140
Granted		1,075,000			0.071
Exercised		(5,039,633	)		(0.045	)
Cancelled or expired		(8,400,000	)		(0.161	)
Balance at September 30, 2012		45,840,647		$	0.145
Granted		67,404,300			0.223
Exercised		(60,236,873	)		(0.170	)
Cancelled or expired		(33,781,720	)		(0.280	)
Balance, June 30, 2013		19,226,354		$	0.103

Transactions involving warrants are summarized as follows:

On November 7, 2012, 100,000 warrants were issued in connection with services. The warrants are exercisable on or after May 7, 2013 for three years at an exercise price of $0.179 per share. The fair value of the warrants of $13,238 was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 129.56% and risk free rate from 0.36% and were charged to current period operations.

On November 29, 2012, in connection with a securities purchase agreement as described in Note E above, the Company issued an aggregate of 67,204,300 warrants to purchase the Company’s common stock exercisable for one to five years after defined date or events, at an exercise price of $0.2232.

In March 2013, the Company issued an aggregate of 1,500,000 shares of its common stock in connection with the exercise of warrants at an exercise price of $0.10 per share; net proceeds of $150,000.

In April 2013, the Company issued 11,285,376 shares of its common stock in connection with the cashless exercise of 15,438,337 warrants to acquire the Company’s stock at a weighted average exercise price of $0.063 per share.

In May 2013, the Company issued 2,418,971 shares of its common stock in connection with the cashless exercise of 2,975,956 warrants to acquire the Company’s stock at a weighted average exercise price of $0.042 per share.

On May 7, 2013, 100,000 warrants were issued in connection with services. The warrants are exercisable on or after November 7, 2013 for three years at an exercise price of $0.214 per share.  The fair value of the warrants of $15,018 was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 119.72% and risk free rate from 0.35% and were charged to current period operations.

As described in Note E above, on January 22, 2013, the Company exercised its option to repurchase 26,881,720 Series C Warrants issued to Crede for $50,000.  On April 25, 2013, Crede effected the cashless exercise of 10,752,688 Series A Warrants and 29,569,892 Series B Warrants, and the Company thereupon issued to Crede an aggregate of 31,257,045 shares of its Common Stock.

Employee Stock Options

On January 26, 2005, the Board of Directors, and on February 15, 2005, the holders of a majority of the outstanding shares of Common Stock approved the 2005 Incentive Stock Plan and authorized the issuance of 16,000,000 shares of Common Stock as stock awards and stock options there under. On May 16, 2007, at the annual meeting of stockholders, the holders of a majority of the outstanding shares of Common Stock approved an increase in the number of shares subject to the 2005 Incentive Stock Plan to 20,000,000 shares of Common Stock.  On June 17, 2008, the Board of Directors unanimously adopted an amendment to the 2005 Incentive Stock Plan that increased the total number of shares of Common Stock issuable pursuant to the 2005 Incentive Stock Plan from a total of 20,000,000 shares to a total of 100,000,000 shares, which was approved by our stockholders at the 2008 annual meeting of stockholders held on December 16, 2008.  On November 30, 2011, the Board of Directors unanimously adopted an amendment to the 2005 Incentive Stock Plan that increased the total number of shares of Common Stock issuable there under to 350,000,000 and the number of shares of Common Stock that can be covered by awards made to any participant in any calendar year to 50,000,000, which was approved by our stockholders at the 2012 annual meeting of stockholders held on January 27, 2012.

The 2005 Incentive Stock Plan is designed to retain directors, executives, and selected employees and consultants by rewarding them for making contributions to the Company’s success with an award of options to purchase shares of Common Stock.  As of June 30, 2013, a total of 137,583,192 shares have been issued and options to purchase 121,354,192 shares are outstanding under the 2005 Incentive Stock Plan.

The following table summarizes the changes in options outstanding and the related prices for the shares of Common Stock issued to employees of the Company under the 2005 Incentive Stock Plan:

Options Outstanding				Options Exercisable
Exercise Prices		Number Outstanding	Weighted Average Remaining Contractual  Life (Years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
$	0.0500	24,000,000	1.91	$	0.0500	24,000,000	$	0.0500
$	0.0585	50,000,000	5.04	$	0.0585	31,250,000	$	0.0585
$	0.0600	30,000,000	2.00	$	0.0600	22,500,000	$	0.0600
$	0.0650	634,825	3.43	$	0.6500	634,825	$	0.0650
$	0.0680	4,770,000	3.42	$	0.0680	4,770,000	$	0.0680
$	0.0700	2,850,000	1.86	$	0.0700	1,837,500	$	0.0700
$	0.0900	1,500,000	3.17	$	0.0900	1,500,000	$	0.0900
$	0.1100	5,400,000	4.96	$	0.1100	5,400,000	$	0.1100
$	0.1799	2,099,367	4.42	$	0.1799	—	$	—
$	0.2000	100,000	4.88	$	0.2000	—	$	—
		121,354,192	3.49	$	0.0628	91,892,325	$	0.0610

Transactions involving stock options issued to employees are summarized as follows:

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value
Outstanding at October 1, 2011		120,650,000		$	0.060
Granted		6,558,825			0.070
Exercised		(500,000	)		(0.080	)
Cancelled or expired		(1,500,000	)		(0.080	)
Outstanding at September 30, 2012		125,208,825		$	0.060
Granted		7,599,367			0.131
Exercised		(5,979,000	)		(0.042	)
Canceled or expired		(5,475,000	)		(0.109	)
Outstanding at June 30, 2013		121,354,192		$	0.063
Vested at June 30, 2013		91,892,325		$	0.061		$	0.138
Non-vested at June 30, 2013		29,461,867		$	0.068		$	0.131

Transactions involving stock options granted to employees are summarized as follows:

On November 30, 2012, the Company granted an aggregate of 2,099,367 options to non-employee board of director members (except Mr. Catenacci) under the 2005 Incentive Stock Plan. The options are exercisable at $0.1799 per share for five years, vesting one year from the date of issuance. The fair value of options was determined using the Black Scholes Option Pricing Model with the following assumptions: dividend yield $-0-, volatility of 146.33% and risk free rate of 0.82%.

On May 12, 2013, the Company granted an aggregate of 100,000 options to an employee under the 2005 Incentive Stock Plan.  The options are exercisable at $0.20 per share for five years, vesting at 25% each anniversary for the next four years. The fair value of the options was determined using the Black Scholes Option Pricing Model with the following assumptions:  dividend yield $-0-, volatility of 117.57% and risk free rate of 0.60%.

During the nine months ended June 30, 2013, the Company issued 4,639,483 shares of its Common Stock in connection with the cashless exercise of 5,954,000 options to acquire the Company stock at weighted average $.053 per share. The Company also issued 25,000 shares of its Common Stock in connection with the exercise of 25,000 options at $0.06 per share.

On May 15, 2013 the Company extended the term of 5,400,000 options that were set to expire to June 16, 2018.  The Company recorded $408,605 of stock compensation expense for the three and nine months ended June 30, 2013 in connection with this modification as the incremental difference between the fair value of the stock options immediately before and after the modification.

The Company recorded $870,576 and $1,743,598 (including the stock option modification) as stock compensation expense for the three and nine month periods ended June 30, 2013, respectively, and $389,533 and $1,564,311 for the three and nine month periods ended June 30, 2012, respectively, for the vesting portion of all employee options outstanding. As of June 30, 2013, unrecorded compensation cost related to non-vested awards was $289,106, which is expected to be recognized through 2018.

XML

RELATED PARTY TRANSACTIONS

9 Months Ended

Jun. 30, 2013

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE D - RELATED PARTY TRANSACTIONS

The Company has consulting agreements with outside contractors, certain of whom are also Company stockholders. The agreements are generally month to month.

XML

FAIR VALUE - Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3) (Details) (Common Stock Warrants, USD $)	9 Months Ended
	Jun. 30, 2013		Jun. 30, 2012
Common Stock Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at October 1,
Issuance of Series A and B Warrants	1,181,324
Adjustment resulting from change in value recognized in earnings	6,145,229	[1]		[1]
Reclassification to equity upon exercise	(7,326,553)
Balance at June 30,

[1] Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to liabilities held at the reporting date. The unrealized gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

XML

CAPITAL STOCK (Detail Textuals 1) (USD $)	1 Months Ended		9 Months Ended		1 Months Ended	0 Months Ended	1 Months Ended	0 Months Ended
	May 31, 2013	Apr. 30, 2013	Jun. 30, 2013	Jun. 30, 2012	Jan. 22, 2013 Securities Purchase Agreement With Crede CG II Ltd	Jan. 08, 2013 Securities Purchase Agreement With Crede CG II Ltd Common Stock	Nov. 29, 2012 Securities Purchase Agreement With Crede CG II Ltd Common Stock	Jan. 07, 2013 Securities Purchase Agreement With Crede CG II Ltd Series A Convertible Preferred Stock
Agreement [Line Items]
Number of stock issued (in shares)	2,418,971	11,285,376		4,639,583		25,462,963	10,752,688	5,500
Issuance price of stock issued (in dollars per share)					$ 0.186		$ 0.186	$ 1,000
Gross proceeds from sale of common stock			$ 2,000,000	$ 1,542,600			$ 2,000,000	$ 5,500,000
Fixed conversion price (in dollars per share)						$ 0.216		$ 0.186

XML

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Details 1) (USD $)	1 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2013	Jun. 30, 2013 Warrants	Sep. 30, 2012 Warrants	Nov. 29, 2012 Warrants
Class Of Warrant Or Right, Number Of Shares [Roll Forward]
Beginning Balance, Number of Shares		45,840,647	58,205,280	67,204,300
Granted		67,404,300	1,075,000
Exercised		(60,236,873)	(5,039,633)
Cancelled or expired		(33,781,720)	(8,400,000)
Ending Balance, Number of Shares		19,226,354	45,840,647	67,204,300
Class Of Warrant Or Right, Weighted Average Price Per Share [Roll Forward]
Beginning Balance, Weighted Average Price Per Share		$ 0.145	$ 0.140
Granted		$ 0.223	$ 0.071
Exercised	$ 0.10	$ (0.170)	$ (0.045)
Cancelled or expired		$ (0.280)	$ (0.161)
Ending Balance, Weighted Average Price Per Share		$ 0.103	$ 0.145

XML

STOCK OPTIONS AND WARRANTS -Employee Stock Options (Detail Textuals 2) (USD $)	3 Months Ended	9 Months Ended		1 Months Ended
	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jan. 27, 2012 Employee Stock Options Incentive Stock Plan 2005	Jun. 30, 2013 Employee Stock Options Incentive Stock Plan 2005	Sep. 30, 2012 Employee Stock Options Incentive Stock Plan 2005	Nov. 30, 2011 Employee Stock Options Incentive Stock Plan 2005	Sep. 30, 2011 Employee Stock Options Incentive Stock Plan 2005	Jun. 17, 2008 Employee Stock Options Incentive Stock Plan 2005	May 16, 2007 Employee Stock Options Incentive Stock Plan 2005	Feb. 15, 2005 Employee Stock Options Incentive Stock Plan 2005	Jan. 26, 2005 Employee Stock Options Incentive Stock Plan 2005
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized to issue of common stock as stock awards and stock options							350,000,000		100,000,000	20,000,000	16,000,000	16,000,000
Issuance of additional common Stock as stock awards and stock options				50,000,000
Cumulative number of shares issued					137,583,192
Options outstanding under the 2005 Incentive Stock Plan					121,354,192	125,208,825		120,650,000
Equity based compensation	$ 389,533	$ 1,334,993	$ 1,564,311
Exercise price per share (in dollars per share)					$ 0.063	$ 0.06		$ 0.06
Unrecorded compensation cost related to non-vested awards		$ 289,106

XML

SUBSEQUENT EVENTS (Detail Textuals 2) (Subsequent Event, USD $)	1 Months Ended
	Jul. 19, 2013
Additional Condition [Abstract]
Condition of additional issuance of common stock, description	In addition, the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below $0.187 per share or the market price of the Common Stock on the date the registration statement is declared effective, for a period of 180 days from the effective date of the registration statement, except for issuances (i) pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar arrangements, (ii) to employees, consultants, directors and officers approved by the Board or pursuant to a plan approved by the Board, (iii) pursuant to one or more contracts entered into by the Company with third parties which would result in revenues to the Company during a three-month period equal to an annual run rate of $15 Million in revenues and (iv) pursuant to a contract entered into by the Company with a third party which would reasonably be expected to result in more than $3 Million in annual receivables.
Amount of annual run rate	$ 15,000,000
Amount of annual receivables	3,000,000
Crede CG II Ltd
Exercise Of Warrants For Cash [Abstract]
Exercise of warrants for cash, description	Crede may exercise Series A and Series B Warrants by paying in cash or on a cashless basis by exchanging such Warrants for Common Stock using a negotiated Black-Scholes value. In the event that the Common Stock trades at a price 25% or more above the exercise price of the Series A and Series B Warrants for a period of 20 consecutive days (with average daily dollar volume of Common Stock on the OTC Bulletin Board at least equal to $300,000), the Company may obligate Crede to exercise such Warrants for cash.
Number of average daily dollar volume of common stock	$ 300,000
Percentage of common stock trade	25.00%
Number of trading days	20 days
Beneficial Ownership Blocker [Abstract]
Beneficial Ownership Blocker Description	The Series B Preferred and the Series A, B and C Warrants each contain a 9.9% "blocker" so that in no event shall the Series B Preferred or any of the Series A, B and C Warrants be convertible or exercisable (including through the cashless exercise exchange provision) into or for Common Stock to the extent that such conversion or exercise would result in Crede having "beneficial ownership" (within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 9.9% of the Common Stock. Crede would, however, have the right from time to time to convert, exercise or exchange for shares of Common Stock, which over time would aggregate to greater than 9.9% beneficial ownership if all such shares of Common Stock so acquired had been held at one time by Crede.
Percentage Of Blocker	9.90%
Maximum Threshold For Beneficial Ownership	9.90%
Term for participation in other equity or equity linked financing's completed	180 days
Crede CG II Ltd | Registration rights agreement
Registration Rights Agreement [Abstract]
Number of days of initial closing to file registration statement	30 days
Number of days for registration statement to be effective	90 days
Number of days of registration statement fails to be declared effective subject to monthly penalties	90 days
Term of expiration of monthly penalties	6 months

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Jun. 30, 2013	Sep. 30, 2012
Allowance on accounts receivable (in dollars)	$ 70,000	$ 0
Accumulated depreciation on property, plant and equipment (in dollars)	337,593	251,958
Accumulated amortization on intellectual property (in dollars)	$ 19,470	$ 0
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	1,350,000,000	1,350,000,000
Common stock, shares issued	733,524,076	646,182,550
Common stock, shares outstanding	733,524,076	646,182,550
Series A Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,500	5,500
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

XML

FAIR VALUE

9 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

FAIR VALUE

NOTE I - FAIR VALUE

The carrying value of cash, accounts receivable, accounts payable and accrued expenses approximate estimated fair values because of their short maturities.

The carrying value of the warrant liability is determined using the Binomial Lattice model option pricing model as described in Note C. Certain assumptions used in the calculation of the warrants liability represent level-3 unobservable inputs. The Company did not have any assets or liabilities categorized as Level 1 or 2 as of June 30, 2013.

The following table summarizes the activity of Level 3 inputs measured on a recurring basis:

Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)	Nine Months Ended June 30,
	2013			2012
Balance at October 1,	$	—		$	—
Issuance of Series A and B Warrants		1,181,324			—
Adjustment resulting from change in value recognized in earnings (a)		6,145,229			—
Reclassification to equity upon exercise		(7,326,553	)		—
Balance at June 30,	$	—		$	—

(a) Adjustment resulting from change in fair value is the amount of total gains or losses for the period attributable to the change in unrealized gains or losses relating to liabilities held at the reporting date. The unrealized gain or loss is recorded in change in fair value of warrant liability in the accompanying condensed consolidated statements of operations.

XML

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (unaudited) (USD $)	9 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Cash flows from operating activities:
Net loss	$ (13,968,001)	$ (5,383,432)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	105,105	300,419
Fair value of vested options issued to officers, directors and employees	1,334,993	1,564,311
Change in fair value of warrant liability	6,145,229
Amortization of capitalized financing costs		85,975
Amortization of debt discount attributable to convertible debentures		541,120
Fair value change from employee option modification	408,605
Fair value of vested warrants issued for service	28,256	58,238
Common stock issued in settlement of interest		507,939
Bad debt expense	70,000
Change in operating assets and liabilities:
Accounts receivable	(360,661)	(234,180)
Prepaid expenses and deposits	(76,510)	(44,247)
Accounts payable and accrued liabilities	616,067	(389,151)
Deferred revenue		25,000
Net cash used in operating activities	(5,696,917)	(2,968,008)
Cash flows from investing activities:
Purchase of assets under RedWeb asset purchase agreement	(584,080)
Purchase of property and equipment	(213,494)	(65,792)
Net cash used in investing activities	(797,574)	(65,792)
Cash flows from financing activities:
Net proceeds from sale of common stock	2,000,000	1,542,600
Proceeds from sale of Series A preferred stock	5,500,000
Proceeds from exercise of warrants	150,000
Proceeds from exercise of options	1,500
Purchase and cancellation of previously issued warrants	(50,000)
Net cash provided by financing activities	7,601,500	1,542,600
Net increase (decrease) in cash and cash equivalents	1,107,009	(1,491,200)
Cash and cash equivalents at beginning of period	724,782	2,747,294
Cash and cash equivalents at end of period	1,831,791	1,256,094
Supplemental Disclosures of Cash Flow Information:
Cash paid during period for interest
Cash paid during period for taxes
Non-cash investing and financing activities:
Common stock issued in exchange for previously incurred debt		4,022,000
Property, plant and equipment acquired, included in accounts payable	$ 325,402

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2013	Sep. 30, 2012
Current assets:
Cash and cash equivalents	$ 1,831,791	$ 724,782
Accounts receivable, net of allowance of $70,000 and $0, respectively	587,655	296,994
Prepaid expenses	141,563	80,037
Total current assets	2,561,009	1,101,813
Property, plant and equipment-net of accumulated depreciation of $337,593 and $251,958 respectively	664,106	210,845
Other assets:
Deposits	51,260	36,276
Intangible assets:
Intellectual property, net of accumulated amortization of $19,470 and $0, respectively	564,610
Total Assets	3,840,985	1,348,934
Current liabilities:
Accounts payable and accrued liabilities	1,533,478	592,009
Total Liabilities	1,533,478	592,009
Commitments and Contingencies
Stockholders' Equity
Preferred stock, value
Common stock, par value $0.001 per share; 1,350,000,000 shares authorized; 733,524,076 and 646,182,550 shares issued and outstanding as of June 30, 2013 and September 30, 2012, respectively	733,524	646,183
Additional paid in capital	184,549,123	169,117,881
Accumulated deficit	(182,975,140)	(169,007,139)
Total stockholders' equity	2,307,507	756,925
Total Liabilities and Stockholders' Equity	3,840,985	1,348,934
Series A Preferred stock
Stockholders' Equity
Preferred stock, value

XML

CAPITAL STOCK (Detail Textuals 2) (USD $)	1 Months Ended			1 Months Ended		1 Months Ended				1 Months Ended
	Nov. 29, 2012 Securities Purchase Agreement With Crede CG II Ltd	Nov. 29, 2012 Securities Purchase Agreement With Crede CG II Ltd Series A Warrants	Nov. 28, 2012 Securities Purchase Agreement With Crede CG II Ltd Series A Warrants	Nov. 29, 2012 Securities Purchase Agreement With Crede CG II Ltd Series B Warrants	Nov. 28, 2012 Securities Purchase Agreement With Crede CG II Ltd Series B Warrants	Nov. 29, 2012 Securities Purchase Agreement With Crede CG II Ltd Series C Warrants	Jan. 22, 2013 Securities Purchase Agreement With Crede CG II Ltd Series C Warrants	Nov. 28, 2012 Securities Purchase Agreement With Crede CG II Ltd Series C Warrants	Apr. 25, 2013 Crede CG II Ltd	Apr. 25, 2013 Crede CG II Ltd Series A Warrants	Apr. 25, 2013 Crede CG II Ltd Series B Warrants
Agreement [Line Items]
Number cashless exercise of warrants										10,752,688	29,569,892
Number of common stock called by warrants			10,752,688		29,569,892			26,881,720	31,257,045
Term of warrants (in years)		5 years		5 years		6 months
Exercise price of warrants		0.2232		0.2232
Beneficial ownership blocker, description	The Series A, B and C Warrants each contain a 9.9% "blocker" so that in no event shall any of the Warrants be exercisable or exchangeable into or for Common Stock to the extent that such exercise or exchange would result in Crede having "beneficial ownership" (within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 9.9% of the Company's Common Stock.
Percentage of blocker		9.90%		9.90%		9.90%
Maximum threshold for beneficial ownership	9.90%
Repurchase price							$ 50,000

XML

SUMMARY OF ACCOUNTING POLICIES (Detail Textuals) (USD $)	3 Months Ended		9 Months Ended			3 Months Ended	9 Months Ended				9 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Sep. 30, 2012	Jun. 30, 2013 Employee Stock Options	Jun. 30, 2012 Employee Stock Options	Jun. 30, 2013 Employee Stock Options Incentive Stock Plan 2005	Sep. 30, 2012 Employee Stock Options Incentive Stock Plan 2005	Sep. 30, 2011 Employee Stock Options Incentive Stock Plan 2005	Jun. 30, 2013 Patents	Jun. 30, 2013 Intellectual property
Accounting Policies [Line Items]
Accumulated deficit	$ (182,975,140)		$ (182,975,140)		$ (169,007,139)
Allowance on accounts receivable (in dollars)	70,000		70,000		0
Estimated useful lives			3 to 5 years
Depreciation method			straight line method
Estimated useful life (in years)											5 years	7 years
Fully diluted shares outstanding (in shares)	835,560,840	646,110,663	798,128,629	641,715,691
Equity based compensation		389,533	1,334,993	1,564,311
Incremental stock compensation expense connection with modification	870,576		1,743,598			408,605	408,605
Employee stock options outstanding (in shares)								121,354,192	125,208,825	120,650,000
Number of shares vested and exercisable (in shares)								91,892,325
Research and development	184,981	99,958	509,132	274,528
Advertising expense	$ 21,825	$ 13,244	$ 158,636	$ 68,148

XML

SUBSEQUENT EVENTS (Detail Textuals 1) (Crede CG II Ltd, USD $)		1 Months Ended
	Apr. 25, 2013	Apr. 25, 2013 Series A Warrants	Apr. 25, 2013 Series B Warrants	Jul. 19, 2013 Subsequent Event Series A Warrants	Jul. 19, 2013 Subsequent Event Series B Warrants	Jul. 19, 2013 Subsequent Event Series C Warrants	Jul. 19, 2013 Subsequent Event Second Closing Series B Warrants	Jul. 19, 2013 Subsequent Event Second Closing Series C Warrants
Subsequent Event [Line Items]
Number cashless exercise of warrants		10,752,688	29,569,892
Number of common stock called by warrants	31,257,045			10,695,187	29,411,764	26,737,967
Term of warrants (in years)				5 years	5 years	6 months
Exercise price of warrants				0.2431	0.2431	0.2431
Percentage of premium				30.00%	30.00%	30.00%
Repurchase price						$ 10,000	$ 50,000	$ 50,000

XML

COMMITMENTS AND CONTINGENCIES (Detail Textuals) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended
	Jun. 14, 2013 sqft	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013 Claim	Jun. 30, 2012
Commitments and Contingencies Disclosure [Abstract]
Area of property under operating lease	30,000
Extended operating lease for two additional period	3 years
Base rent during initial lease term per annum	$ 449,142
Total lease rental expenses		$ 82,033	$ 63,200	$ 226,581	$ 173,502
Number of claims alleged in the amended complaint				17
Number of claims asserted against the company				5
Number of claims dismissed against asserted claims				4

XML

STOCK OPTIONS AND WARRANTS - Transactions involving warrants (Detail Textuals) (Warrants, USD $)	0 Months Ended						1 Months Ended
	May 07, 2013	Nov. 07, 2012	Jun. 30, 2013	Nov. 29, 2012	Sep. 30, 2012	Sep. 30, 2011	Nov. 29, 2012 Minimum	Nov. 29, 2012 Maximum
Class of Warrant or Right [Line Items]
Number of warrants issued in connection with service	100,000	100,000
Exercise price of warrants (in dollars per warrant)	0.214	0.179		0.2232
Fair value of warrants	$ 15,018	$ 13,238
Number of expected term (in years)		3 years
Dividend yield (in percent)	0.00%	0.00%
Expected volatility (in percent)	119.72%	129.56%
Risk free interest rate (in percent)	0.35%	0.36%
Method used to calculate fair value of warrants	Black Scholes Option Pricing Model	Black Scholes Option Pricing Model
Number of warrants outstanding			19,226,354	67,204,300	45,840,647	58,205,280
Number of years for exercisable of warrants							1 year	5 years

XML

STOCK OPTIONS AND WARRANTS (Detail Textuals 1) (USD $)	1 Months Ended	9 Months Ended	1 Months Ended		1 Months Ended
	Mar. 31, 2013	Jun. 30, 2013	Jan. 22, 2013 Series C Warrants	Apr. 25, 2013 Crede CG II Ltd	Apr. 25, 2013 Crede CG II Ltd Series A Warrants	Apr. 25, 2013 Crede CG II Ltd Series B Warrants
Class Of Warrant Or Right [Line Items]
Number cashless exercise of warrants					10,752,688	29,569,892
Number of common stock called by warrants				31,257,045
Common stock issued in connection with the exercise of warrants	1,500,000
Exercise price of warrants	$ 0.10
Net proceeds from exercise of warrants	$ 150,000	$ 150,000
Repurchase of Series C warrants			26,881,720
Payments for repurchase of warrants		$ 50,000	$ 50,000

XML

LIQUIDITY

9 Months Ended

Jun. 30, 2013

Liquidity [Abstract]

LIQUIDITY

NOTE H - LIQUIDITY

The Company incurred a net loss of $13,968,001 and generated negative operating cash flow of $5,696,917 for the nine months ended June 30, 2013. However, the Company has attained positive working capital of $1,027,531 as of June 30, 2013.  Management believes that the positive cash balance and working capital as of June 30, 2013 as well as the proceeds from the securities purchase agreement with Crede entered into on July 19, 2013 (see Note K) along with the current customer base, the projected cash flow and the minimum guaranteed revenues for the next fiscal year will allow the Company to continue to improve its working capital and to have sufficient capital resources to meet projected cash flow requirements.

XML

CAPITAL STOCK (Detail Textuals 3) (Securities Purchase Agreement With Crede CG II Ltd, USD $)	1 Months Ended
	Jan. 22, 2013
Securities Purchase Agreement With Crede CG II Ltd
Exercise Of Warrants For Cash [Abstract]
Exercise of warrants for cash, description	Crede may exercise Series A and Series B Warrants by paying in cash or on a cashless basis by exchanging such Warrants for Common Stock using the Black-Scholes value. In the event that the Common Stock trades at a price 25% or more above the exercise price of the Series A and Series B Warrants for a period of 20 consecutive days (with average daily dollar volume of Common Stock on the OTC Bulletin Board at least equal to $300,000), the Company may obligate Crede to exercise such Warrants for cash.
Number of average daily dollar volume of common stock	$ 300,000
Percentage of common stock trade	25.00%
Number of trading days	20 days
Additional Condition [Abstract]
Condition of additional issuance of common stock, description	In addition, the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below $0.186 per share or the market price of the Common Stock on the date the registration statement was declared effective, for a period of 180 days from the effective date of the registration statement, except for issuances (i) pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar arrangements, (ii) to employees, consultants, directors and officers approved by the Board or pursuant to a plan approved by the Board, (iii) pursuant to one or more contracts entered into by the Company with third parties which would result in revenues to the Company during a three-month period equal to an annual run rate of $15 Million in revenues and (iv) pursuant to a contract entered into by the Company with a third party which would reasonably be expected to result in more than $3 Million in annual receivables.
Issuance price of stock issued (in dollars per share)	$ 0.186
Term for participation in other equity or equity linked financing's completed	180 days
Amount of annual run rate	15,000,000
Amount of annual receivables	$ 3,000,000

XML

ASSET PURCHASE AGREEMENT (Detail Textuals) (Asset purchase agreement, Redweb Technologies Limited)	3 Months Ended
	Jun. 30, 2013 USD ($)	May 10, 2013 USD ($)	May 10, 2013 EUR (€)
Asset Purchase Agreement [Line Items]
Purchase price		$ 624,080	€ 400,000
Purchase price held in escrow		62,408
Purchase price held in escrow, term		1 year	1 year
Payments to acquire intellectual property	584,080
Remaining portion of purchase price allocated to supplies under asset acquisition	$ 40,000

XML

SUBSEQUENT EVENTS

9 Months Ended

Jun. 30, 2013

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE K – SUBSEQUENT EVENTS

Securities Purchase Agreement

On July 19, 2013, the Company entered into a securities purchase agreement (“Purchase Agreement”) with Crede CG III, Ltd. (“Crede”).  Pursuant to the Purchase Agreement, at the initial closing on July 19, 2013 (“Initial Closing”), Crede purchased 10,695,187 shares of the Company’s Common Stock at a price of $0.187 per share which was the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement.  The Company received gross proceeds of $2,000,000.  Pursuant to the Purchase Agreement, Crede agreed to purchase an additional $5,500,000 of the Company’s Series B Convertible Preferred Stock (“Series B Preferred”) at a purchase price of $1,000 per share on the date a registration statement (as described below) is declared effective by the SEC (“Second Closing”).

The Series B Preferred is convertible at the option of the holder thereof, in whole or in part, from time to time and at any time, at the lesser of (i) the Fixed Conversion Price and (ii) the Non-Fixed Conversion Price. The Fixed Conversion Price is equal to $0.187 per share which is the purchase price for the Common Stock at the Initial Closing.  The Non-Fixed Conversion Price is equal to the consolidated closing bid price of the Company’s Common Stock for the most recently completed trading day as of the time of conversion.  The Series B Preferred will be convertible into Common Stock at the Company’s option, in whole or in part, from time to time during the period beginning one trading day following the effectiveness of the registration statement (as described below) through the eleventh trading day following effectiveness of such registration statement, at the Non-Fixed Conversion Price, provided that certain equity conditions are met and the Company is not in breach of certain conditions.  The Series B Preferred will be automatically converted into Common Stock on the one year anniversary of the issuance of the Series B Preferred at the then applicable Non-Fixed Conversion Price, provided that certain equity conditions are met and the Company is not in breach of certain conditions.  The Series B Preferred contains weighted average anti-dilution protection.  The Series B Preferred will not accrue dividends except to the extent dividends are paid on the Common Stock.  The Company’s Common Stock will be junior in rank to the Series B Preferred with respect to preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Company.  The Series B Preferred will generally have no voting rights except as required by law.

The Company also issued Crede at the Initial Closing Warrants with a term of five years (though such term may be extended in certain instances) (“Series A Warrants”) allowing it to purchase 10,695,187 shares of Common Stock at a price of $0.2431 per share which is equal to a 30% premium to the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement.  At the Initial Closing, the Company also issued Crede a second set of Warrants (“Series B Warrants”) allowing it to purchase 29,411,764 shares of Common Stock, which is equal to one share of Common Stock for every share of Common Stock which would be issuable to it if it fully converted the Series B Preferred into Common Stock at the Fixed Conversion Price.  The exercise price of the Series B Warrants is $0.2431 per share, which is equal to a 30% premium to the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement.  The Series B Warrants are not exercisable until the earlier of (i) November 7, 2013 and (ii) the Second Closing, and have a term of five years (though such term may be extended in certain instances).

 In addition, at the Initial Closing, the Company issued to Crede a third set of Warrants (“Series C Warrants”) which is only exercisable for six months from the earlier of (i) November 7, 2013 and (ii) after the eleventh trading day following the Second Closing.  The Series C Warrants will allow Crede to purchase, at a price of $0.2431 per share (equal to a 30% premium to the consolidated closing bid price of the Common Stock on the day prior to the signing of the Purchase Agreement), 26,737,967 shares of Common Stock, which is equal to one-third the sum of (i) the number of shares of Common Stock issued at the Initial Closing, (ii) the number of shares of Common Stock which would be issuable to it if it fully converted the Series B Preferred into Common Stock at the Fixed Conversion Price, (iii) the number of shares of Common Stock subject to the Series A Warrants and (iv) the number of shares of Common Stock subject to the Series B Warrants.

The Series B and Series C Warrants provide the Company with an option to repurchase any remaining unexercised portion of such Warrants for a repurchase price equal to $50,000, if the Second Closing is terminated pursuant to the Purchase Agreement. The Company also has the option to repurchase the Series C Warrants at an aggregate repurchase price equal to $10,000 at the close of trading on the tenth trading day immediately following the Second Closing but only if the registration statement (described below) is effective and covers and is available for use for the resale of (i) all shares of Common Stock issued at the First Closing, (ii) all shares of Common Stock issued upon conversion of the Series B Preferred, (iii) all shares of Common Stock which would then be issuable if the full then unconverted portion of the Series B Preferred were then fully converted into Common Stock at the then applicable conversion price, (iv) all shares of Common Stock subject to the Series A Warrants and (v) all shares of Common Stock subject to the Series B Warrants.

Crede may exercise Series A and Series B Warrants by paying in cash or on a cashless basis by exchanging such Warrants for Common Stock using a negotiated Black-Scholes value.  In the event that the Common Stock trades at a price 25% or more above the exercise price of the Series A and Series B Warrants for a period of 20 consecutive days (with average daily dollar volume of Common Stock on the OTC Bulletin Board at least equal to $300,000), the Company may obligate Crede to exercise such Warrants for cash.

Pursuant to a registration rights agreement between the Company and Crede, the Company agreed to file a registration statement within 30 days of the Initial Closing and to use its best efforts to get such registration statement effective within 90 days.  The registration statement will cover the resale of all shares of Common Stock issuable pursuant to the Purchase Agreement, including the shares of Common Stock underlying the Series B Preferred and Series A, B and C Warrants.  The registration statement was declared effective by the SEC on July 31, 2013.  The Company has also agreed to prepare and file amendments and supplements to the registration statement to the extent necessary to keep the registration statement effective for the period of time required under the Purchase Agreement.  In the event the registration statement failed to be declared effective within the 90 day period, the Company would have been subject to monthly penalties which would expire six months after the Initial Closing.

The Company agreed to pay Crede an investment fee equal to $100,000 at the Initial Closing and $265,000 at the Second Closing.

The Series B Preferred and the Series A, B and C Warrants each contain a 9.9% “blocker” so that in no event shall the Series B Preferred or any of the Series A, B and C Warrants be convertible or exercisable (including through the cashless exercise exchange provision) into or for Common Stock to the extent that such conversion or exercise would result in Crede having “beneficial ownership” (within the meaning of Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 9.9% of the Common Stock. Crede would, however, have the right from time to time to convert, exercise or exchange for shares of Common Stock, which over time would aggregate to greater than 9.9% beneficial ownership if all such shares of Common Stock so acquired had been held at one time by Crede.

Crede has the right to participate in other equity or equity-linked financings completed by the Company for a period of 180 days from the later of the Initial Closing or the date the registration statement goes effective.

In addition, the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below $0.187 per share or the market price of the Common Stock on the date the registration statement is declared effective, for a period of 180 days from the effective date of the registration statement, except for issuances (i) pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar arrangements, (ii) to employees, consultants, directors and officers approved by the Board or pursuant to a plan approved by the Board, (iii) pursuant to one or more contracts entered into by the Company with third parties which would result in revenues to the Company during a three-month period equal to an annual run rate of $15 Million in revenues and (iv) pursuant to a contract entered into by the Company with a third party which would reasonably be expected to result in more than $3 Million in annual receivables.

Until one year after the Second Closing, the Company is prohibited from entering into any transaction to (i) sell any convertible securities at a conversion rate or other price that is generally based on and/or varies with the trading prices of the Company’s Common Stock at any time after the initial issuance of such convertible securities or (ii) sell securities at a future determined price, including, without limitation, an “equity line of credit” or an “at the market offering.”

On July 31, 2013, the Company completed the Second Closing of its transaction with Crede and sold 5,500 shares of Series B Preferred to Crede at a price of $1,000 per share.  The Company received gross proceeds of $5,500,000 less an investment fee of $265,000.

XML

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Jun. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE G - COMMITMENTS AND CONTINGENCIES

On June 14, 2013, the Company entered into an operating lease agreement for its new corporate headquarters located in Stony Brook, New York.  The lease is for a 30,000 square foot building.  The term of the lease commenced on June 15, 2013 and expires on May 31, 2016, with the option to extend the lease for two additional three-year periods.  The base rent during the initial lease term is $449,142 per annum.  This new location replaces a lesser amount of space leased by the Company in an adjacent building, which was for corporate use.   Total lease rental expenses for the three and nine month periods ended June 30, 2013 were $82,033 and $226,581, respectively.  Total lease rental expenses for the three and nine month periods ended on June 30, 2012 were $63,200 and $173,502, respectively.

Employment and Consulting Agreements

The Company has employment agreements with the Chief Executive Officer and Chief Financial Officer as disclosed in the notes to audited consolidated financial statements included in its Annual Report on Form 10-K for the fiscal year ended September 30, 2012 filed with the SEC. Also, the Company has consulting agreements with outside contractors, certain of whom are also Company stockholders. The agreements are generally month to month.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.  When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business.

Demodulation, Inc. v. Applied DNA Sciences, Inc., et al. (Civil Action No. - 2:11-cv-00296-WJM-MF, District of New Jersey):

On May 18, 2011, the Company was served with a complaint in a lawsuit brought by Demodulation, Inc. against the Company, Corning Incorporated, Alfred University, and Alfred Technology Resources, Inc. On July 8, 2011, the Company filed a motion to dismiss the complaint. In response, on August 3, 2011, Demodulation, Inc. filed an amended complaint. Demodulation, Inc. alleged that it was unable to bring its microwire technology to market due to the wrongful acts of defendants, who allegedly conspired to steal Demodulation, Inc.’s trade secrets and other intellectual property and to interfere in its business opportunities. Of the 17 claims alleged in the amended complaint, five were asserted against the Company, including alleged misappropriation of trade secrets, antitrust violations, civil RICO, and patent infringement. Demodulation, Inc. sought damages and injunctive relief against the Company. The Company believes these claims were without merit.  On January 27, 2012, the Company filed a motion to dismiss the amended complaint for failure to state a claim and on other grounds. On December 12, 2012, the Court entered an order on the Company’s motion to dismiss the amended complaint. The Court granted in part and denied in part the Company’s motion to dismiss. The Court dismissed four out of the five claims asserted against the Company without prejudice, leaving only the patent infringement claim.  Subsequently, the parties stipulated to sever the patent infringement claim against the Company from the claims against the other defendants.  The Court entered an order severing the patent claim on February 20, 2013, and terminated the main lawsuit against the Company.  Demodulation, Inc. may seek to re-file its patent claim as a separate action, but to date has not done so. If Demodulation re-files its action, the Company intends to vigorously defend the action.

Smartwater, Ltd. v. Applied DNA Sciences, Inc. (No. 12-CV-05731-JS-AKT (E.D.N.Y.))

On June 6, 2012, a complaint for patent infringement was filed against the Company by Smartwater, Ltd. in the United States District Court for the District of Massachusetts in an action entitled Smartwater, Ltd. v. Applied DNA Sciences, Inc., No. 1:12-cv-11009-PBS. The complaint alleged that the Company infringed one or more claims under two of plaintiff’s patents by selling or offering for sale, manufacturing and using certain of the Company’s products, by inducing others to infringe and by contributing to infringement by others. The plaintiff sought injunctive relief with respect to the patents as well as awards of damages and attorneys’ fees. The Company had not been served with the complaint and on August 24, 2012 the plaintiff voluntarily dismissed the complaint and refiled a similar complaint in the United States District Court for the Southern District of Florida, No. 12-61660-DMM (S.D. Fla.). On August 30, 2012, plaintiff served the Company with the complaint. The refiled complaint seeks injunctive relief with respect to one of the patents as well as awards of damages and attorneys’ fees. The Company filed a motion to dismiss and a motion to transfer the action to the Eastern District of New York. On November 19, 2012, the Court granted the Company’s motion to transfer the action to the Eastern District of New York. The Company’s motion to dismiss is pending before the Court in the Eastern District of New York.  An initial conference with the Court was held on February 21, 2013, at which time the Court directed the conduct of limited document discovery pending the Court’s decision on the motion to dismiss. On June 21, 2013, plaintiff filed a motion seeking leave from the Court to file an amended complaint asserting additional allegations in support of its claims.  The Company filed its opposition to the motion on July 29, 2013.  The Company believes that none of its products infringe any claims under either of plaintiff’s patents, and moreover notes that one of plaintiff’s patents has expiredand the other is due to expire on February 25, 2014.  The Company believes the allegations in the complaint are without merit and intends to defend the action vigorously. The ultimate outcome of this claim cannot be determined at the date of this report.

XML

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

9 Months Ended

Jun. 30, 2013

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE B – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities at June 30, 2013 and September 30, 2012 are as follows:

	June 30,
	2013			September 30,
	(unaudited)			2012
Accounts payable		$	1,248,944		$	473,060
Accrued consulting & legal fees			148,622			102,500
Accrued salaries payable			135,912			16,449
Total		$	1,533,478		$	592,009

XML

STOCK OPTIONS AND WARRANTS - Changes in options outstanding and related prices (Details 2) (Employee Stock Options, USD $)		9 Months Ended			9 Months Ended
	May 12, 2013	Jun. 30, 2013 Incentive Stock Plan 2005	Sep. 30, 2012 Incentive Stock Plan 2005	Sep. 30, 2011 Incentive Stock Plan 2005	Jun. 30, 2013 Incentive Stock Plan 2005 Exercise price $0.0500	Jun. 30, 2013 Incentive Stock Plan 2005 Exercise price $0.0585	Jun. 30, 2013 Incentive Stock Plan 2005 Exercise price $0.0600	Jun. 30, 2013 Incentive Stock Plan 2005 Exercise price $0.0650	Jun. 30, 2013 Incentive Stock Plan 2005 Exercise price $0.0680	Jun. 30, 2013 Incentive Stock Plan 2005 Exercise price $0.0700	Jun. 30, 2013 Incentive Stock Plan 2005 Exercise price $0.0900	Jun. 30, 2013 Incentive Stock Plan 2005 Exercise price $0.1100	Jun. 30, 2013 Incentive Stock Plan 2005 Exercise price $0.1799	Jun. 30, 2013 Incentive Stock Plan 2005 Exercise price $0.2000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, exercise prices	$ 0.20				$ 0.0500	$ 0.0585	$ 0.0600	$ 0.0650	$ 0.0680	$ 0.0700	$ 0.0900	$ 0.1100	$ 0.1799	$ 0.2000
Options outstanding under the 2005 Incentive Stock Plan		121,354,192	125,208,825	120,650,000	24,000,000	50,000,000	30,000,000	634,825	4,770,000	2,850,000	1,500,000	5,400,000	2,099,367	100,000
Weighted Average Remaining Contractual Life of Options Outstanding (Years)		3 years 5 months 26 days			1 year 10 months 28 days	5 years 14 days	2 years	3 years 5 months 5 days	3 years 5 months 1 day	1 year 10 months 10 days	3 years 2 months 1 day	4 years 11 months 16 days	4 years 5 months 1 day	4 years 10 months 17 days
Weighted Average Exercise Price of Options Outstanding		$ 0.063	$ 0.06	$ 0.06	$ 0.0500	$ 0.0585	$ 0.0600	$ 0.6500	$ 0.0680	$ 0.0700	$ 0.0900	$ 0.1100	$ 0.1799	$ 0.2000
Number of Options Exercisable		91,892,325			24,000,000	31,250,000	22,500,000	634,825	4,770,000	1,837,500	1,500,000	5,400,000
Weighted Average Exercise Price of Options		$ 0.061			$ 0.0500	$ 0.0585	$ 0.0600	$ 0.0650	$ 0.0680	$ 0.0700	$ 0.0900	$ 0.1100

XML

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

9 Months Ended

Jun. 30, 2013

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued liabilities

	June 30,
	2013			September 30,
	(unaudited)			2012
Accounts payable		$	1,248,944		$	473,060
Accrued consulting & legal fees			148,622			102,500
Accrued salaries payable			135,912			16,449
Total		$	1,533,478		$	592,009

XML

ASSET PURCHASE AGREEMENT

9 Months Ended

Jun. 30, 2013

Asset Purchase Agreement [Abstract]

ASSET PURCHASE AGREEMENT

NOTE J – ASSET PURCHASE AGREEMENT

On May 10, 2013, the Company entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with RedWeb Technologies Limited (“RedWeb”), a corporation incorporated and registered under the laws of England & Wales, to purchase certain assets of RedWeb (“Purchased Assets”) relating to its forensic tagging security system for a purchase price of £400,000 ($624,080). The Company completed the acquisition of the Purchased Assets on the same day. The Purchased Assets include RedWeb’s Sentry 500 Intruder Spray System, RedWeb’s Advanced Molecular Taggent Technology and all products relating thereto, certain intellectual property and supplies relating to the foregoing. £40,000 ($62,408) of the purchase price shall be held in escrow for up to one year to be applied against the indemnification obligations of RedWeb pursuant to the Asset Purchase Agreement. This transaction was accounted for as an asset acquisition in accordance with ASC 805.  The Company assigned $584,080 of the purchase price to intellectual property and the remaining $40,000 was for supplies, which were expensed during the three months ended June 30, 2013.

XML

SUMMARY OF ACCOUNTING POLICIES - Summary of property and equipment (Details) (USD $)	Jun. 30, 2013	Sep. 30, 2012
Property, Plant and Equipment [Line Items]
Total	$ 1,001,699	$ 462,803
Accumulated depreciation	(337,593)	(251,958)
Property and equipment, net	664,106	210,845
Computer equipment
Property, Plant and Equipment [Line Items]
Total	38,640	33,464
Lab equipment
Property, Plant and Equipment [Line Items]
Total	589,737	296,904
Furniture
Property, Plant and Equipment [Line Items]
Total	151,039	132,435
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total	$ 222,283

XML

STOCK OPTIONS AND WARRANTS (Tables)

9 Months Ended

Jun. 30, 2013

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of summary of the changes in warrants outstanding and the related prices for the shares of common Stock issued to non-employees of the company

			Warrants
			Outstanding	Weighted			Exercisable
			Remaining	Average		Weighted	Weighted
Exercise		Number	Contractual	Exercise		Average	Average
Prices		Outstanding	Life (Years)	Price		Exercisable	Exercise Price
$	0.04000	3,000,000	2.17	$	0.04000	3,000,000	$	0.04000
$	0.04405	510,784	4.04	$	0.04405	510,784	$	0.04405
$	0.04750	3,789,489	5.04	$	0.04750	3,789,489	$	0.04750
$	0.05529	226,081	4.53	$	0.05529	226,081	$	0.05529
$	0.06000	2,000,000	0.64	$	0.06000	2,000,000	$	0.06000
$	0.07100	1,000,000	1.57	$	0.07100	1,000,000	$	0.07100
$	0.09000	6,900,000	3.18	$	0.09000	6,900,000	$	0.09000
$	0.17900	100,000	2.35	$	0.17900	100,000	$	0.17900
$	0.21400	100,000	2.85	$	0.21400	—		—
$	0.50000	1,600,000	0.32	$	0.50000	1,600,000	$	0.50000
		19,226,354	2.83	$	0.10331	19,126,354	$	0.10273

Schedule of transactions involving warrants

	Number of Shares			Weighted Average Price Per Share
Balance, October 1, 2011		58,205,280		$	0.140
Granted		1,075,000			0.071
Exercised		(5,039,633	)		(0.045	)
Cancelled or expired		(8,400,000	)		(0.161	)
Balance at September 30, 2012		45,840,647		$	0.145
Granted		67,404,300			0.223
Exercised		(60,236,873	)		(0.170	)
Cancelled or expired		(33,781,720	)		(0.280	)
Balance, June 30, 2013		19,226,354		$	0.103

Schedule of summary of changes in options outstanding and the related prices for the shares of common Stock issued to employees of company

Options Outstanding				Options Exercisable
Exercise Prices		Number Outstanding	Weighted Average Remaining Contractual  Life (Years)	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
$	0.0500	24,000,000	1.91	$	0.0500	24,000,000	$	0.0500
$	0.0585	50,000,000	5.04	$	0.0585	31,250,000	$	0.0585
$	0.0600	30,000,000	2.00	$	0.0600	22,500,000	$	0.0600
$	0.0650	634,825	3.43	$	0.6500	634,825	$	0.0650
$	0.0680	4,770,000	3.42	$	0.0680	4,770,000	$	0.0680
$	0.0700	2,850,000	1.86	$	0.0700	1,837,500	$	0.0700
$	0.0900	1,500,000	3.17	$	0.0900	1,500,000	$	0.0900
$	0.1100	5,400,000	4.96	$	0.1100	5,400,000	$	0.1100
$	0.1799	2,099,367	4.42	$	0.1799	—	$	—
$	0.2000	100,000	4.88	$	0.2000	—	$	—
		121,354,192	3.49	$	0.0628	91,892,325	$	0.0610

Schedule of summary of transactions involving stock options issued to employees

	Number of Shares			Weighted Average Exercise Price Per Share			Aggregate Intrinsic Value
Outstanding at October 1, 2011		120,650,000		$	0.060
Granted		6,558,825			0.070
Exercised		(500,000	)		(0.080	)
Cancelled or expired		(1,500,000	)		(0.080	)
Outstanding at September 30, 2012		125,208,825		$	0.060
Granted		7,599,367			0.131
Exercised		(5,979,000	)		(0.042	)
Canceled or expired		(5,475,000	)		(0.109	)
Outstanding at June 30, 2013		121,354,192		$	0.063
Vested at June 30, 2013		91,892,325		$	0.061		$	0.138
Non-vested at June 30, 2013		29,461,867		$	0.068		$	0.131

XML

Document and Entity Information	9 Months Ended
	Jun. 30, 2013	Aug. 08, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	APPLIED DNA SCIENCES INC
Entity Central Index Key	0000744452
Trading Symbol	apdn
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		744,219,263
Document Type	10-Q
Document Period End Date	Jun. 30, 2013
Amendment Flag	false
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3

XML

FAIR VALUE (Tables)

9 Months Ended

Jun. 30, 2013

Fair Value Disclosures [Abstract]

Schedule of fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

	Nine Months Ended June 30,
	2013			2012
Balance at October 1,	$	—		$	—
Issuance of Series A and B Warrants		1,181,324			—
Adjustment resulting from change in value recognized in earnings (a)		6,145,229			—
Reclassification to equity upon exercise		(7,326,553	)		—
Balance at June 30,	$	—		$	—